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CHAPTER 1 
INTRODUCTION 

Sulphasalazine (salicylazosulphapyridine) and corticosteroids have been used 
extensively in the treatment of ulcerative colitis and Crohn's disease. Many 
therapeutical trials have been performed, showing effectivity of both drugs in 
active ulcerative colitis and active Crohn's disease, and relapse preventing 
properties of sulphasalazine in quiescent ulcerative colitis. 
Still, some questions as to the optimal use of both drugs, single or combined, 
remain unanswered. To date, the additive effect of prednisone to sulphasalazine 
in patients with active Crohn's disease has not been defined. 
The appreciation of the fact that 5-aminosalicylic acid (5-ASA) is the active 
moiety of sulphasalazine, whereas sulphapyridine is responsible for the majority of 
the side effects, has led to the development of new, merely 5-ASA containing 
drugs. As all these drugs have different mechanisms for the release of 5-ASA, 
comparative pharmacokinetic studies are necessary to define their possible role in 
the treatment of chronic inflammatory bowel diseases in different locations and 
under different circumstances, for instance normal and accelerated intestinal 
transit. 
Moreover, clinical trials are needed to demonstrate the efficacy and safety of the 
new 5-ASA containing drugs in comparison with placebo and of course 
sulphasalazine, the mainstay of treatment up till now. 
The yardstick for measuring disease activity, and, consequently, therapeutic effect 
in the two inflammatory bowel diseases is still subject to debate. In Crohn's 
disease, several clinical activity indices, composed of a number of objective and 
sometimes subjective data are available. Apart from the fact that no agreement 
exists about the optimal activity index, they are too complicated to be used in 
daily practice. Several studies have shown that the serum levels of some acute 
phase reactants reflect the severity of inflammation of the bowel, and this might 
provide a simple and easily obtainable substitute for the more cumbersome 
clinical activity indices. 
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Aim of this study 
The aim of this study was to investigate some unexplored areas in the medical 
treatment of chronic inflammatory bowel disease. A general survey of our 
knowledge of epidemiology, etiology, measurement of disease activity, medical 
treatment and prognosis of ulcerative colitis and Crohn's disease is given in 
Chapter 2. In Chapter 3 a clinical trial comparing the therapeutic effect of 
sulphasalazine plus prednisone with sulphasalazine plus placebo in patients with 
active Crohn's disease is described. In Chapter 4 the value of the determination 
of the acute phase reactants orosomucoid and C-reactive protein in the 
measurement of the disease activity of Crohn's disease is investigated.In Chapters 
5, 6 and 7 the disposition of sulphasalazine and the sulphapyridine-free, 5-ASA 
containing drugs olsalazine (DipentumR), PentasaR, AsacolR and SalofalkR is 
investigated in normal volunteers without diarrhoea, healthy volunteers with drug 
induced diarrhoea and patients with inflammatory bowel disease, with and without 
diarrhoea. 
In Chapter 8 the efficacy and safety of sulphasalazine and olsalazine are 
compared in patients with active ulcerative colitis, and in Chapter 9 a 
comparative study of the relapse-preventing properties and safety of these two 
drugs in patients with quiescent ulcerative colitis is described. 
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CHAPTER 2 
INTRODUCTORY REMARKS ABOUT THE EPIDEMIOLOGY, 
AETIOLOGY, MEASUREMENT OF DISEASE ACTIVITY, 
MEDICAL TREATMENT AND PROGNOSIS OF 
ULCERATIVE COLITIS AND CROHN'S DISEASE 
An expanded version of this paper has been accepted for publication in 
Chirurgische Gastroenterologie - Interdisziplinäre Gespräche 

INTRODUCTION 
Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases of 
unknown origin, which can be active for many years. Often a distinction between 
them can be made on the basis of certain features, but sometimes it is not 
possible to classify a patient immediately as having either disease. In these cases 
the nature of the disease becomes evident only after a course of time, and 
sometimes not at all. A common feature of both diseases is their tendency to 
chronicity with fluctuating disease activity, hampering daily life in varying degrees. 
Although this regularly leads to severe somatic and psycho-social disability, both 
diseases run a rather mild course in most patients, allowing a more or less normal 
life (1,2). 
EPIDEMIOLOGY 
Crohn's disease and ulcerative colitis are prone to occur at early adult age 
(between 15 and 40 years). In patients attending the Nijmegen University Hospital 
the incidence is low above the age of 40 (3), but in other studies a second 
incidence peak is detected around the age of 70, both for ulcerative colitis and 
for Crohn's disease (4,5). There is no clear sex predisposition. 
The incidence rates of ulcerative colitis vary in several studies from the western 
world from 3 to more than 10 per 100,000, without a change in the last few 
decades. Prevalences range from 40 to 120 per 100,000 (6). In contrast to 
ulcerative colitis the incidence rates of Crohn's disease show a clear tendency to 
increase, probably only partly attributable to improved diagnostic tools (see Figure 
1). The prevalence varies from 26 to 75 per 100,000 (22). The incidence rates of 
both diseases are said to be higher for Jews than for other populations, but the 
figures reported from Israel are lower than from other western countries (23). 
AETIOLOGY 
In spite of numerous hypotheses about possible causative factors and mechanisms 
the aetiology of Crohn's disease and ulcerative colitis remains unclear. 
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Figure 1. Incidence rates of Crohn's disease since 1960 in different locations: 1 = Basel, Switzerland 
(7); 2 = North Tees, UK (8); 3 = Faroe Islands, DK (9); 4 = Stockholm, Sweden (10); 5 = Cardiff, 
UK (11); 6 = Clydesdale, UK (12); 7 = Beer Sheva, Israel (13); 8 = Tel Aviv, Israel (14); 9 = 
Malmö, Sweden (15); 10 = Uppsala, Sweden (16); 11 = Scotland, UK (17); 12 = Nottingham, UK 
(18); 13 = Blackpool, UK (19); 14 = Copenhagen, DK (20), 15 = Scotland, UK (21). Modified 
figure from Binder V, Schweiz Med Wschr 1988; 118: 738-42, copied with permission of the 
editor. 
Genetic factors 
Chronic inflammatory bowel diseases occur more often among relatives of 
patients than in the general population: 10-15% in case of ulcerative colitis and 0-
30% in case of Crohn's disease (24-26). Sometimes a relative of a patient with 
Crohn's disease has ulcerative colitis, and vice versa. The genetic relationships do 
not follow simple mendelian rules. Possibly genes on multiple loci play a role. No 
consistent relationship has been found between blood groups or HLA-types and 
the occurrence of both diseases (27). 
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Infectious factors. 
Both ulcerative colitis and Crohn's disease show a close resemblance with certain 
bowel inflammations with a known infectious cause. Therefore, great efforts has 
been made to find such a cause for both diseases. Several bacteria, fungi and 
chlamydia have been suggested as the causative agent for ulcerative colitis (28), 
but reproducible results have never been obtained. It was reported possible to 
isolate a cytopathogenic factor, possibly a virus, from bowel tissue of patients with 
ulcerative colitis and to pass it serially in tissue cultures (29). This finding, 
however, has never been confirmed. 
Because Crohn's disease closely resembles infections that are caused by 
mycobacteria (tuberculosis in humans and Johne's disease in sheep) the possible 
role of these microorganisms has been investigated intensively. In an open study, 
quadruple anti-mycobacterial chemotherapy was effective in half of patients with 
refractory Crohn's disease (29a). Recent attention has specifically been paid to M. 
paratuberculosis (30), but the positive results of one group still await confirmation 
by others. Moreover, it was not possible to detect serum antibodies directed 
against mycobacteria in patients with Crohn's disease (31), or to demonstrate 
mycobacterial DNA in diseased tissue with immunohistochemical (32) or modem 
molecular-biological (33,34) techniques. The T-cell mediated immune response to 
sonicates of M. paratuberculosis, M. kansasii, M. tuberculosis and M. avium is in 
patients with Crohn's disease as frequently positive as in controls (34a). 
Although, until now, no microorganism has met the Koch's postulates, it is not 
excluded that an infectious agent initiates a chronic bowel inflammation that 
subsequently leads its own life. 
Nutritional and toxicologic factors 
No clear relationship has been demonstrated between intake of certain foods and 
development of ulcerative colitis or Crohn's disease (35,36). In some studies it 
was found that the intake of refined carbohydrates was higher in patients with 
Crohn's disease than in controls; the importance of this finding remains unclear 
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(37). 
In recent years considerable attention has been paid to the relationship between 
smoking habits and inflammatory bowel diseases. Patients with Crohn's disease 
would more often be smokers, whereas a negative correlation has been found 
between ulcerative colitis and smoking (38,39). Ex-smokers would particularly be 
at risk. Some authors report an increased risk for Crohn's disease amongst 
contraceptive pill users (40,41). 
Psychosocial factors 
Although some patients feel that stressful or traumatic events initiated or 
aggravated their disease, evidence for this hypothesis is lacking (42). Neither can 
specific pre-morbid personality characteristics consistently be found in patients 
with ulcerative colitis or Crohn's disease (43). Nevertheless, patients can be 
severely mentally distressed by problems related to their illness, and in addition 
some therapeutical agents, especially corticosteroids, may cause mental adverse 
effects. Of course the attending physician should be mindful of this and pay 
ample attention to these aspects of disease. Often the mental problems disappear 
when the bowel disease goes into remission. 
Immunological factors 
The chronic bowel inflammation with ongoing destruction of intestinal mucosa 
may be interpreted as an inadequate immunological reaction. Therefore, great 
efforts has been made to investigate the immunological apparatus in patients with 
inflammatory bowel diseases. There is no firm evidence that a primary 
immunological defect is involved in the aetiology of one of the two diseases. The 
humoral immune response is normal, and the levels of circulating and mucosal 
immunoglobulins are not decreased as a rule (44). The cell-mediated immunity 
may be impaired in active disease (the cutaneous anergia in severe Crohn's 
disease is well-known), but restoration occurs after resection of the diseased 
bowel or achievement of a remission. However, although no primary 
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immunological defect can be demonstrated, an immune reaction, once started, 
causes the tissue damage characteristic for these diseases. In inflamed bowel 
tissue the number of lymphocytes, both immunoglobulin producing and T-lym-
phocytes, is increased (45). This is not specific to inflammatory bowel disease; it is 
also found in bacterial enteritis (46). Indications exist for both antibody-induced 
and cell-mediated tissue damage. Many patients with chronic inflammatory bowel 
disease have antibodies directed against colon epithelium (47). Some investigators 
found these antibodies to cross-react with E. Coli lipopolysaccharides (48). It may 
be conjectured that an immunological response, initiated as a defence against E. 
Coli, is directed by cross-antigenicity against own intestinal tissue, but this does 
not tally with the finding that such antibodies can also be demonstrated in 
patients with bowel diseases not characterized by chronic inflammation (49). 
Moreover, high antibody titres against various colonic bacteria (50,51) and cow's 
milk (52) are often found in serum and mucosa. These antibodies might form 
immune complexes in the mucosa with the corresponding antigens, thus starting a 
type III (Arthus) inflammatory reaction, leading to tissue damage. Probably the 
high antibody titres are not a primary event but a consequence of epithelial 
damage. There are also indications of T-cell mediated cytotoxicity in patients with 
inflammatory bowel disease. The existence of T-cells sensitized for autologous 
colon epithelial cells has been demonstrated (53). Recently, serum anticolon 
antibody and in vitro anticolon antibody production by peripheral blood and 
mucosal lymphocytes was found increased in a majority of patients with ulcerative 
colitis, as opposed to healthy controls and patients with Crohn's disease (53a). 
This gives support to the conception that ulcerative colitis is, at least partially, an 
autoimmune disorder. Ulcerative colitis is also more often than Crohn's disease 
associated with HLA class II related autoimmune diseases, such as primary 
sclerosing cholangitis (53b). 
None of the above-mentioned immunological phenomena is made acceptable as a 
primary cause of the inflammatory process, nor are they specific of Crohn's 
disease or ulcerative colitis. They are probably epiphenomena of an existing 
inflammation, which nevertheless can amplify the inflammatory process by means 
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of production of inflammatory mediators such as complement, prostaglandins, 
leucotrienes and oxygen radicals, thereby worsening the tissue damage. This also 
explains the favourable effect of aspecific inhibitors of inflammation such as corti-
costeroids, and the effect of 5-aminisalicylic acid which, among other things, 
influences leucotriene production (54) and scavenges oxygen radicals (55). 
The question as to the primary event that starts the inflammation is still open. Do 
ulcerative colitis and Crohn's disease have different causes or are they the ends of 
a spectrum of one disease? The fact that sometimes features of both diseases can 
be found in one patient, and the occurrence of both diseases in one family 
support this hypothesis. On the other hand it is imaginable that various aetiologic 
factors can result in the same clinical picture, since the gut has only limited 
possibilities to respond to an inflammatory stimulus. The clinical and histological 
picture of a Yersinia infection can often not be distinguished from Crohn's 
disease, as shigellosis cannot be distinguished from ulcerative colitis. Possibly the 
individual immunological characteristics of a patient are also important for the 
appearance of the inflammation. 
THE MEASUREMENT OF DISEASE ACTIVITY 
There is a great need for a uniform yardstick to measure the disease activity of 
inflammatory bowel disease. Such an instrument is necessary to define the 
characteristics of patients taking part in therapeutic trials, and to compare the 
results of treatment. It might also be useful in decision-making in the 
management of an individual patient. 
A workable activity index should meet several requirements. An ideal activity 
index consists of as few factors as possible, factors easily obtainable in any 
hospital, is reproducible, independent of the subjectivity of patient and observer, 
and truly reflects the severity of inflammation. 
Both for ulcerative colitis and Crohn's disease numerous measures of disease 
activity have been proposed and actually used in clinical trials. A classification can 
be made in clinical activity indices, composed of several factors that relate to 
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physical status, signs, symptoms and laboratory data, further endoscopic indices, 
other imaging techniques, and single or multiple laboratory indices. Indices can be 
based on the intuition of the authors (e.g. Truelove-Witts classification for 
ulcerative colitis) or be derived from multiple variables by means of stepwise 
multiple regression analysis (e.g. the CDAI and AI for Crohn's disease), and may 
exist of discrete classes or a continuous numerical scale. It is generally accepted 
that, because of the different clinical presentation of ulcerative colitis and Crohn's 
disease, no single measure of disease activity can be applied to both diseases. 
Measures of disease activity in ulcerative colitis 
In 1955, Truelove and Witts proposed a three-grade scale of absent, mild, 
moderate and severe disease (56), shown in Table 1. 
Although this provides an easily obtainable and reproducible scale of disease 
activity, it has certain disadvantages. It is not stated how a patient with features 
from different catagories should be classified. Several factors, such as pulse rate, 
fever and anaemia, are interrelated. In a three-grade scale less pronounced 
changes of disease activity can be overlooked; patients answering the minimal 
requirements for the 'severe' scale are not severely ill in our opinion, so this scale 
can accommodate a large variation 
τ,,κι ι τ , nr~ - г , of disease activities. 
Table 1. Truelove-Witts severity catagones of ulcerative 
c o /
'
f
" Another activity index with 15 
Mild: Dianhoea <4 motions/day, non-bloody constituent factors was proposed 
No fever by Talstad et al (57) but to our 
Pulse rate < 90/min 
No severe anaemia 
ESR <30 rnrn/hr 
Severe: Diarrhoea >6 motions/day, bloody feasibility. The same disadvantage 
Evening temperature > Ъ1.5°С applies to the numerical index of 
Pulse rate >90/min Powell-Tuck et al. (58) which 
Haemoglobin 75% or below ^ ^
 o f n ¡ ^ § о ^ ^ 
ESR >30 mm/hr 
Truelove-Witts classification 
knowledge has never been used in 
practice, probably because of low 
Moderate: Intermediate between mild and severe 
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remains the most frequently used clinical index for ulcerative colitis. 
As the inflamed bowel is easily accessible by sigmoidoscope or colonoscope, 
endoscopic judgement is at least as important in ulcerative colitis. The gradings of 
Dick et al. who distinguished five degrees of severity (59), has also be used in 
other studies, but in many therapeutic trials of ulcerative colitis a modified 
endoscopic index is proposed. Recently, Rachmilewitz presented a numerical 
endoscopic index, in which granularity, vascular pattern, vulnerability and mucosal 
damage can be scored at several levels (60). The added score is than a measure 
of the endoscopically assessed severity of inflammation. The endoscopic index 
described by van der Heide et al, composed of eight items with three levels each 
starts from the same principle (61). Although granularity, vascular pattern, 
erythema, friability, bleeding and ulceration are invariably parts of any endosopic 
score, no general agreement exist as to how these factors should constitute an 
index. 
Segal et al were the first to demonstrate that the faecal excretion of reinjected 
'"In-labelled homologous leucocytes correlated with the presence of inflammatory 
bowel disease (62). Leddin et al found that the amount of " 'In in stools 
correlated significantly with their own activity index for ulcerative colitis, based 
upon clinical picture, colonoscopic and histological findings, and less well with the 
Truelove-Witts classification (63). 
After the publication of Dearing et al (64), indicating that serum levels of the 
acute phase reactant orosomucoid were elevated in patients with ulcerative colitis, 
serum levels of many serum proteins such as albumin, pre-albumin, 
immunoglobulins, opantichymotrypsin, orosomucoid, ο,-antitrypsin, and C-reactive 
protein were studied in their relation to disease activity and response to treatment 
(65,66). Orosomucoid and C-reactive protein are most consistently found to be 
elevated in active ulcerative colitis, and to correlate with disease activity (66,67). 
In one study, the level of C-reactive protein at admission was found to correlate 
well with the outcome of the attack (68), but this finding awaits confirmation. 
At present, the best way to judge the extent and severity of inflammation of 
ulcerative colitis remains endoscopy, while a clinical index is useful to measure the 
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impact of the inflammation on the health status. Because of the above-mentioned 
disadvantages of the Truelove-Witts classification, a more accurate index is 
desirable. In chapter 8 such an index is proposed, and actually used in a 
therapeutic trial. 
Measures of disease activity in Crohn's disease 
Measuring disease activity in Crohn's disease is much more complicated than in 
ulcerative colitis. Whereas in ulcerative colitis the extent of inflammation and 
development of mucosal damage is rather uniform, Crohn's disease can present 
with many patterns of anatomic distribution and intestinal injuries, from shallow 
aphthous ulcers to perforation, fistulas and stenoses. Therefore it is very difficult, 
if not impossible, to compare all conceivable appearances of Crohn's disease in 
one activity scale. Meanwhile, several activity indices have been developed, 
composed of the factors listed in Table 2. 
For the American National Cooperative Crohn's Disease Study the need for an 
appropriate activity index was felt, resulting in the Crohn's Disease Activity Index 
(CDAI) (69). Harvey and Bradshaw developed a simplified version of this index, 
necessitating the assessment for only one day instead of one week (70). Lloyd-Still 
devised a clinical score for inflammatory bowel disease in children, taking into 
account important paediatric factors such as growth and school activity (71). 
Because it was felt that the CDAI was too dependent on subjective data as well-
being and pain, a Dutch group developed the so-called van Hees Activity Index 
(AI), consisting merely of objective parameters (72). Others found the equations, 
necessary for the calculation of the CDAI and AI, too cumbersome and proposed 
a binary 10-item index, the so-called Oxford Index, scoring for the presence or 
absence of each parameter (73). The "Cape Town Index", published by South-
African investigators, is a complicated version of this index, allowing four degrees 
of severity for each of ten almost identical items (74). Recently, Pinchbeck et al 
devised a Crohn's Activity Group Scale by performing a discriminant function 
analysis on several demographic, anthropomorphic, clinical and laboratory data 
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Table 2. Factors assessed in various activity indices 
Harvey & 
Bradshaw van Hees Oxford Cape Town 
Factor assessed 
Abdominal pain 
Bowel habits 
Perianal complications 
Other complications 
Palpable mass 
Body weight/build 
Haemoglobin/haematocrit 
Well-being 
Use of anti-diarrhoeal drugs 
Quetelet index* 
Temperature 
Senim albumin 
ESR 
Sex 
Previous resection 
Tenderness 
Fistula 
CDAI 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
CDAI 
χ 
χ 
χ 
χ 
χ 
ΑΙ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
Index 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
Index 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
χ 
Quetelet index: weight/length2 (kg/m2) 
that was found to have predictive value as to the future course of disease (75), 
but the 15-item equation appears too complicated to gain much popularity. 
Members of the International Organization for the Study of Inflammatory Bowel 
Disease, all clinicians with a wide experience in the field, conducted an important 
exercise by calculating all the activity indices available at that time for a number 
of paper cases and real patients. In a report by De Dombal only the CDAI and 
AI are discussed thoroughly (76). The AI appeared less subject to interobserver 
variation than the CDAI. The correlation between AI and CDAI is rather poor 
(72). 
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The divergence between the outcomes of the activity indices is easy to understand 
as each index measures a different aspect of disease. The AI, consisting of 
objective factors, reflects the severity of inflammation, whereas the CDAI is more 
a general measure of illness. 
In contrast to ulcerative colitis, endoscopy is less feasible to assess the extent and 
severity of inflammation in Crohn's disease. Still, a standardized endoscopic 
evaluation, providing the opportunity to calculate a Crohn's disease endoscopic 
index, as proposed by Mary and Modigliani (77), can be useful in the judgement 
of medical or surgical intervention. The correlation between colonoscopic findings 
and the CDAI is reported to be poor (78). 
As in ulcerative colitis, the loss of inIn-labelled leucocytes in faeces has been used 
to quantify the degree in Crohn's disease (62), with different results in various 
studies. In the study of Leddin, loss of '"In-labelled leucocytes correlated well 
with the AI, but not with the CDAI (63), which is explained by the nature of the 
two indices. In the experience of the Leiden group, faecal '"Indium loss 
correlates of all indices only with the AI, and only if the disease is localized in 
the colon (79). On the basis of these results the authors conclude that activity 
indices are poor indicators of intestinal inflammation. As they found even poorer 
correlations between faecal loss of '"In-labelled leucocytes with serum 
orosomucoid and C-reactive protein levels, it may be questioned whether faecal 
'"Indium loss is much better. 
Of the acute phase reactants, orosomucoid and C-reactive protein are those most 
intensively studied in Crohn's disease after André and co-workers found that these 
proteins correlated best with the disease activity (66). The course of C-reactive 
protein levels corresponds closely to relapse, remission and response to therapy 
(80), and the levels of C-reactive protein and orosomucoid in periods of quiescent 
disease correlate with the probability of a future relapse (81,82). Orosomucoid 
and C-reactive protein may rise some months before a relapse of Crohn's disease 
becomes apparent (83). In chapter 4 of this thesis a study of the predictive value 
of orosomucoid and C-reactive protein in active Crohn's disease is described. 
Because of the many divergent clinical pictures the gold standard for Crohn's 
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disease is even more difficult to define than that for ulcerative colitis. For clinical 
trials an overall estimation of the severity of disease, as measured with clinical 
activity indices, is the most useful. The choice of one of the indices remains more 
or less a matter of philosophy. In our opinion the AI, which avoids subjective 
feelings of the patients and has the least interobserver variation, deserves 
preference. 
Possibly measurement of acute phase reactants will prove useful in the 
management of an individual patient. In one study it was possible to select a 
group of patients with quiescent Crohn's disease for prophylactic treatment with 
corticosteroids on the basis of high serum levels of orosomucoid and C-reactive 
protein (84). 
THERAPY 
General measures 
Both for patients with ulcerative colitis and with Crohn's disaese it is important to 
aim for a good general condition. In case of severe anaemia blood transfusions 
should be given, deficiencies of fluid and electrolytes should be supplemented; 
especially hypokalaemia should be corrected as this may bring about a toxic 
megacolon. 
Nutritional measures 
The nutritional status is often poor, as a consequence of the inflammation and of 
the - sometimes bizarre - dietary measures imposed on the patient by himself or 
by the attending physician. For ulcerative colitis it has never been demonstrated 
in controlled trials that any diet has a favourable effect on the course. Care 
should be taken that the patient, who is often in a catabolic state, has a sufficient 
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oral intake of calories in a palatable form. Only poorly tolerated foods should be 
left out of the diet. A small proportion of the patients have lactose intolerance 
and profit from lactose restriction. This may also apply to patients who have only 
a short length of functional bowel after resections. The possibility should be kept 
in mind of the occurrence of deficiencies of vitamin B12 and folic acid, and of 
iron, calcium, magnesium and zinc, and these should be supplemented whenever 
necessary. Withholding oral foods and administration of parenteral nutrition do 
not influence the course of ulcerative colitis (85,86). 
In Crohn's disease long-term administration of parenteral nutrition or an 
elementary diet may lead to an improvement of the inflammation, and sometimes 
to closure of fistulas, but it is questionable whether these effect persists in the 
long run (86,87). In one study the disease remained quiescent for some time after 
reinstitution of oral feeding (88). Generally, however, an operation cannot be 
avoided by these dietary measures. In our opinion it is not proper to try to 
improve the general and nutritional state by means of parenteral nutrition in the 
hope of diminishing the risk of operation. The fastest way to improve the general 
condition is a resection of the diseased bowel segment. The improvements 
induced by parenteral nutrition do not outweigh the long time necessary to 
achieve a substantial effect and the complications inherent in parenteral nutrition. 
Medical therapy 
As the causes of both chronic inflammatory bowel diseases are unknown, medical 
therapy has necessarily an empirical character. In mild or moderate disease 
salicylazosulphapyridine (Salazopyrine) and drugs containing 5-aminosalicylic acid 
are effective. In more severe cases administration of corticosteroids is necessary. 
The various drugs are discussed in more detail in the paragraphs below. 
Salazopyrine and other 5-aminosalicylic acid containing drugs 
Salicylazosulphapyridine (SASP) consists of sulphapyridine and 5-aminosalicylic 
acid (5-ASA), linked together with an azo bond. It has been used for almost 50 
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years in the treatment of patients with ulcerative colitis. Over the years it has 
become apparent that 5-ASA is the active part of SASP (89,90), and that 
sulphapyridine is responsible for the majority of adverse effects caused by SASP. 
Both parts are released in the bowel lumen after splitting of the azo bond by 
bacterial enzymes (91). 5-ASA constitutes almost 40% of the molecular weight of 
SASP, so equivalent doses of 5-ASA and SASP relate to each other as 1 : 2.5. A 
number of new drugs have been developed that contain only 5-ASA and no 
sulphapyridine. Plain 5-ASA cannot be given by mouth because it is largely 
absorbed in the proximal parts of the small bowel and reaches the distal small 
bowel and colon in insufficient amounts (92). In the new drugs sustained or 
delayed release of 5-ASA is achieved by the application of a acrylic resin coating 
that dissolves at a certain pH (AsacolR and SalofalkR), by packing 5-ASA in 
ethylcellulose vesicles that permit slow diffusion of 5-ASA (PentasaR), or by the 
coupling of two 5-ASA molecules via an azo bond that is, like SASP, split by 
intestinal bacteria (olsalazine, DipentumR). Last but not least enemas and 
suppositories are important application forms of 5-ASA resulting in high 
concentrations in the distal colon, with excellent therapeutic results (93-95). 
SASP and 5-ASA in ulcerative colitis 
Several studies demonstrated that SASP is more effective than placebo for the 
achievement of remission in patients with mildly or moderately active ulcerative 
colitis (96,97), and that it diminishes the risk of recurrence in patients with 
ulcerative colitis in remission (98,99). With the exception of PentasaR all new 5-
ASA containing drugs have been investigated in patients with active ulcerative 
colitis and they appeared to be more effective than placebo (100-102) or as 
effective as SASP (60,103,104). Efficacy equal to SASP in maintaining remission 
has been demonstrated for DipentumR (105), AsacolR (106), PentasaR (107) and 
ClaversalR (108), which is identical to Salofalk". 
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SASP and 5-ASA in Crohn's disease 
SASP is effective in the treatment of active Crohn's disease, especially if localized 
in the colon, according to the American National Cooperative Crohn's Disease 
Study and the European Cooperative Crohn's Disease Study (109,110). 
Effectiveness in patients with terminal ileitis also has been described (111). Until 
recently no studies were available that showed effectiveness of SASP in 
maintaining remission of Crohn's disease, or in reducing the risk of recurrence 
after resection. It has to be kept in mind, however, that the compliance to 
therapy of patients without symptoms is often poor, which might explain the lack 
of effect in the prevention of relapses. Recently it could be demonstrated in one 
study that SASP in a dosage of three grams per day reduced the risk of 
recurrence after resection (112). Data on the effectiveness of the new 5-ASA 
containing drugs in Crohn's disease are still scarce. In a placebo-controlled trial in 
patients with small bowel Crohn's disease the course of disease was more 
favourable in patients treated with PentasaR, but this effect was not statistically 
significant (113). 
Dosages of 5-ASA and adverse effects 
The effect of 5-ASA drugs is the result of the locally achieved concentrations and 
not of serum concentrations, which are at least a 1000 times lower (114). 
Therefore the highest possible concentration at the site of inflammation has to be 
aimed for. 
In most studies SASP is given in a dosage of 3 to 4 grams in active disease, and 
1 to 2 grams during remission. In our experience a considerable proportion of 
patients with active disease tolerate a daily dose of 6 gram well, although some 
patients will experience adverse effects. These adverse effects are the most 
important restriction on the use of SASP. Most adverse effects such as headache, 
nausea and abdominal discomfort, anorexia and myalgia are not severe and dose-
dependent (96,97,99,115). Skin rash, often on parts exposed to sunlight, and fever 
are probably dose-independent (115). Severe adverse effects such as hepatitis, 
pancreatitis, interstitial pneumonitis, bone marrow suppression and the Stevens-
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Johnson syndrome are rare. SASP interferes with the intestinal absorption of folic 
acid, sometimes resulting in folic acid deficiency and anaemia (116). Another 
frequent cause of SASP-related anaemia is haemolysis (117). Finally the 
frequently occurring male infertility, which is reversible after discontinuation of 
SASP, should be mentioned (118). 
With the new 5-ASA containing drugs, adverse effects, although less frequent, are 
not completely absent. In patients intolerant of SASP who are treated with 
olsalazine or slow-release 5-ASA adverse effects occur in 13 to 25% of cases 
(119). Especially skinrash appears to be caused sometimes by the 5-ASA 
component (120). 5-ASA is also reported to provoke an exacerbation of the 
disease (121,122). Olsalazine causes diarrhoea in some patients (123), as a result 
of impaired absorption of water, sodium and chloride in the small intestine (124-
126). Incidentally, diarrhoea has also been mentioned as an adverse effect of 
slow-release 5-ASA (120). Meanwhile, pancreatitis also is reported as an adverse 
effect of olsalazine (127), AsacolR (128) and Claversal* (129). 
Finally, the possibly 5-ASA-related renal damage should be discussed. In the rat 
5-ASA has nephrotoxic properties (130). Case reports on occurrence of a 
nephrotic syndrome (131) and interstitial nephritis (132) during 5-ASA therapy 
have been published, and in one trial a rise of serum creatinine was observed in 
some patients during treatment with Asacol (102). In the absence of 
sulphapyridine-related adverse effects high doses of 5-ASA (more than 3 grams 
per day) for longer periods look tempting, but in the light of these reports, 
caution is indicated. 
Because of the short time for which the new 5-ASA containing drugs have been 
available, their relative efficacies have not been compared so far. Therefore it is 
not possible to give a firmly based preference to any one of these drugs in 
specific clinical situations. Choices can only be made on the basis of 
pharmacokinetic studies. Of some drugs, the proportions recovered in ileostomy 
effluent after oral intake have been measured, permitting calculation of the 
proportions absorbed in the small intestines. After intake of PentasaR, 35% of 5-
ASA appeared to be released in the small bowel (133), as against less than 1% 
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after intake of olsalazine (134). Another approach to investigate the site of 
release of 5-ASA is measurement of the amount of (acetyl)-5-ASA in urine in 
relation to time after ingestion, and of the amount of acetylated 5-ASA in faeces. 
A considerable proportion of 5-ASA excreted into the urine shortly after intake 
indicates that it has been released and absorbed in the proximal parts of the 
digestive tract (92,135). 5-ASA is acetylated by bowel mucosa and by intestinal 
bacteria (136,137). Therefore, large amounts of acetyl-5-ASA in faeces indicate 
early release of 5-ASA, whereas little or no acetyl-5-ASA indicates (too) late 
release from the drug concerned. In the chapters 5, 6 and 7 of this thesis these 
principles are applied to investigate the disposition of 5-ASA from several 5-ASA 
delivering drugs in healthy volunteers without diarrhoea, in healthy volunteers with 
diarrhoea induced by bisacodyl, and in patients with inflammatory bowel diseases, 
with and without diarrhoea. The results of these studies inspired some recommen-
dations concerning the treatment of patients with inflammatory bowel disease, 
which are discussed in the summary. 
Corticosteroids 
Corticosteroids are very effective in patients with active ulcerative colitis (56) or 
Crohn's disease (109,110). Corticosteroids appeared generally ineffective in the 
prevention of relapses (109,110,138), but it should be kept in mind that the 
compliance to therapy is always a problem in patients on long-term therapy, the 
more so when they are free of complaints. In a small study the risk of relapse of 
Crohn's disease was smaller during corticosteroid maintenance therapy in patients 
with elevated serum levels of acute phase proteins (139). The most frequently 
prescribed drugs are prednisone and prednisolone. Prednisone is not active by 
itself, but is, after absorption, rapidly transformed in the liver into the active 
metabolite prednisolone. Orally administered prednisone is as effective as 
prednisolone, except in patients with severe liver failure. For rectal administration 
only prednisolone is appropriate. 
Prednisone or prednisolone are indicated in ulcerative colitis in patients with 
moderately or severely active disease, where insufficient efficacy of 5-ASA drugs is 
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to be expected. If the inflammation is limited to the rectum or rectosigmoid 
region, corticosteroids, like 5-ASA, can successfully be applied locally as enemas 
or suppositories (140). 
In Crohn's disease, also corticosteroids are prescribed in moderate and severe 
cases, the more so if fever or considerable weight loss is present. Initial dosages 
and tapering-off schedules vary widely in literature. 
It has never been investigated whether the combination of SASP and prednisone 
is better than SASP alone. In chapter 3 a comparative study of these treatment 
modalities in patients with active Crohn's disease is described. 
In a small proportion of patients it is not possible, even in the long run, to lower 
the dosage of prednisone to less than 10 or 15 mg per day. When these dosages 
of corticosteroids have to be continued for longer than one or two years, 
resection of the diseased bowel segment, or, if that is not feasible (e.g. because of 
the risk of a short bowel syndrome), institution of treatment with azathioprine has 
to be considered. 
All physicians and most patients are well aware of the many possible adverse 
effects of corticosteroids. However, when the duration of administration is limited 
to a few months, the side effects are well surveyable in our experience and their 
importance is certainly outweighed by the efficacy of corticosteroids, which is not 
equaled by any other form of medical therapy (141). 
At this moment some corticosteroids are being investigated which presumably 
have the same local efficacy as prednisolone, but fewer systemic adverse effects 
because of low intestinal absorption or considerable first-pass inactivation in the 
liver (142). If the first promising results are confirmed they will be an appreciated 
adjunct to the therapeutic arsenal. 
Immunosuppressive drugs 
In a chronic inflammation with destruction of tissue immunosuppressive drugs may 
be expected to be useful. In inflammatory bowel diseases experience has been 
gathered with azathioprine, its metabolite 6-mercaptopurine, and with 
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cyclosporine, which interferes with the T-cell mediated immune response. 
Data on the effectiveness of azathioprine in patients with ulcerative colitis are 
scarce. In two controlled trials azathioprine appeared to decrease the need for 
corticosteroids (143) or the disease activity (144). In another study, however, no 
effect was observed (145). Reports on a favourable effect of cyclosporine in 
ulcerative colitis remain sporadic (146). 
More data are available on the efficacy of immunosuppressives in Crohn's disease. 
In several studies a prednisone-sparing effect of azathioprine and 6-
mercaptopurine was found (147,148). However, the long period (two months or 
more) sometimes elapsing before an effect can be observed, and the considerable 
frequency of adverse effects such as bone marrow suppression, pancreatitis, fever 
and nausea are drawbacks of this therapy (149). Therefore these immunosup-
pressive drugs should be reserved for cases refractory to protracted treatment 
with corticosteroids, or immediately relapsing after lowering the dosage, if 
resection of the diseased bowel is not feasible for whatever reason. 
Cyclosporine has appeared to be effective in patients with Crohn's disease with 
insufficient response to or intolerance of corticosteroids (150). In a considerable 
proportion of patients a deterioration occurred after lowering the dose. 
Metronidazole 
Metronidazole in a dosage of 800 mg per day is more effective than placebo 
(151) or as effective as SASP (152) in patients with Crohn's disease, especially 
with locations in the colon. Perianal fistules in particular may sometimes respond 
well to local or systemic application of metronidazole. Unfortunately, the 
inflammation often flares up immediately after discontinuation of therapy, and 
prolonged administration is not rarely complicated by severe polyneuropathy 
which is not always reversible. Metronidazole does not seem to be effective in 
ulcerative colitis (153). 
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PROGNOSIS 
Ulcerative colitis 
The course of ulcerative colitis is veiy variable and unpredictable. In the majority 
of patients the disease activity is intermittent, with alternating exacerbations and 
remissions. Less than 5% have only one attack without a relapse in the next 15 
years, and in approximately 10% the disease is more or less continuously active 
(154). At a random moment in the course of disease about half the patients are 
free of symptoms (155). 
The mortality of a first attack of ulcerative colitis has decreased with time and is 
now less than 2% (154,155,156). The vast majority of deaths occur in severe 
colitis, mostly corresponding with colitis of the entire colon. Other factors that 
might be associated with increased mortality are a short history before the onset 
of a severe attack and advanced age at presentation (157-159). The mortality of 
toxic megacolon ranges from 13 to 30%. 
In our own patients no clear correlation between the severity and extension of the 
first attack on the one hand and the probability of a prolonged remission and 
mortality on the other could be found (3). In other studies the long-term 
prognosis is related to the severity of the first attack: increasing severity is 
connected with an increased risk of relapses later on and increased 5-year 
mortality. 
Crohn's disease 
The course of Crohn's disease is highly unpredictable in the individual patient. 
Usually the disease has a continuously fluctuating nature (160,161). 
In the National Cooperative Crohn's Disease Study the cumulative probability of 
an operation was about 50% after 5 years and about 75% after 10 years. The risk 
was greatest for patients with ileocolitis (162). The figures for second operations 
are of the same order. In unselected populations from defined geographic areas 
the figures are lower. In the Leiden region (Netherlands) the cumulative risk of a 
reoperation was 25% after 10 years and 60% after 20 years (163). In this study, 
the risk of a second resection was greater if the patient was over 30 years of age 
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at the time of the first operation. In the Copenhagen region (Denmark) 55% of 
the patients had undergone at least one operation after 10 years (161). 
The mortality in patients with Crohn's disease in unselected populations was 
higher than in the normal population, especially in the first three years of illness 
in one study (164), but in another study it was not clearly increased (161). 
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CHAPTER 3 
EFFECT OF SULPHASALAZINE AND PREDNISONE COMPARED WITH 
SULPHASALAZINE AND PLACEBO IN TREATING 
ACTIVE CROHN DISEASE 
A double-blind, randomized, multicenter trial 
Marno C.M. Rijk MD, Ruud A. van Hogezand MD, PhD, Henk J.J. van Lier 
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ABSTRACT 
Objective: To determine whether sulphasalazine plus prednisone is more effective 
than sulphasalazine alone in treating active Crohn's disease. 
Design: Randomized, double-blind, placebo-controlled trial. 
Setting: Multicenter trial in one university hospital and nine general hospitals. 
Patients: Patients with active Crohn's disease and a Van Hees Activity Index of 
140 or more. Of 71 patients who were randomly assigned 60 completed treatment 
and were analyzed. 
Interventions: For 16 weeks, 30 patients received sulphasalazine 6 g/d (or 4 g/d if 
adverse effects occurred) and prednisone 30 mg/d initially. Prednisone therapy 
was tapered in steps of 5 mg/2wk to 10 mg/d after 8 weeks. Thirty other patients 
received sulphasalazine and a placebo. 
Measurements and Main Results: In the first 6 weeks of treatment, the Van Hees 
Activity Index decreased to a median of 70% (interquartile range 57 to 81%) of 
the initial value in patients treated with sulphasalazine and prednisone and to a 
median of 87% (interquartile range 70 to 94%) in patients treated with sulphasal-
azine alone (P = 0.001). In the last 4 weeks of treatment, the corresponding 
figures were 63% (interquartile range 40 to 75%) and 70% (interquartile range 54 
to 90%) (P = 0.10). The Crohn's Disease Activity Index decreased in the first 6 
weeks to a median of 65% (interquartile range 57 to 86%) in patients receiving 
sulphasalazine and prednisone and to a median of 75% (interquartile range 58 to 
101%) in patients receiving sulphasalazine alone (P = 0.13). In the last 4 weeks 
of treatment, the corresponding figures were 65% (interquartile range 42 to 90%) 
and 76% (49 to 110%) (P = 0.19). 
Conclusions: The use of prednisone in addition to sulphasalazine in patients with 
active Crohn's disease results in a significantly faster initial improvement, but not 
in a significantly better result after 16 weeks of treatment, when disease activity is 
measured by the Van Hees Activity Index. 
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INTRODUCTION 
Both sulphasalazine and prednisone are widely used in the treatment of patients 
with Crohn's disease. Sulphasalazine is generally used for patients with mildly or 
moderately active Crohn's disease, and corticosteroids are used as well when the 
disease is severe or the condition worsens during treatment. The superiority of 
sulphasalazine to placebo has been proved in several studies (1-3). In the Natio-
nal Cooperative Crohn's Disease Study sulphasalazine was shown to be effective 
in treating Crohn's colitis and ileocolitis (1), whereas, in the European Cooperati-
ve Crohn's Disease Study, it was effective only for treatment of colonic involve-
ment (2). The study of Van Hees and colleagues (3) showed the effectiveness of 
sulphasalazine in treating both small- and large-bowel disease. In both studies, the 
effectiveness of corticosteroids in treating patients with active disease in different 
locations was shown. In the National Cooperative Crohn's Disease Study, 
corticosteroids alone were not effective in treating colonic disease (1). 
An additive effect from combination therapy with corticosteroids and 
sulphasalazine in patients with active Crohn's disease might be expected, but so 
far has not been investigated. Nor has it become clear whether severely ill 
patients will benefit more from addition of corticosteroids than do mildly or 
moderately ill patients. We therefore compared the effect of therapy with 
sulphasalazine and prednisone with the effect of therapy with sulphasalazine and 
placebo in 60 patients with active Crohn's disease in a double-blind, randomized, 
multicenter trial designed to answer three questions: Does combination therapy 
with sulphasalazine and prednisone induce more rapid improvement in active 
Crohn's disease than does sulphasalazine alone? Does such therapy result in a 
better improvement at the end of treatment than does therapy with 
sulphasalazine alone? Is combination therapy with prednisone and sulphasalazine 
especially effective in treating Crohn's disease that manifests in certain locations 
or in treating severe Crohn's disease? 
49 
METHODS 
Patient selection and diagnostic criteria for Crohn's disease 
Ten Dutch hospitals participated in the study. The reference committee of the 
University Hospital Nijmegen determined whether diagnoses of Crohn's disease 
were correct and approved the application of criteria for inclusion, exclusion 
(Table 1), and premature withdrawals. From February 1982 to May 1986, 175 
patients with active Crohn's disease were examined for eligibility for the trial. 
Patients were diagnosed as having Crohn's disease if they had a chronic 
inflammatory bowel disease (for at least 3 months) and their radiographs showed 
typical features of Crohn's disease (4). In several patients, the diagnosis was 
confirmed by endoscopy; however, only radiologic criteria were used for patient 
selection because this procedure allowed central and uniform judgment. Only 
patients with a Van Hees Activity Index of 140 or more (see next section) were 
included. Patients with a first attack as well as patients with a relapse who had 
been medically or surgically treated in the past were eligible. For patients 
receiving maintenance treatment with sulphasalazine, corticosteroids, or both, a 
washout period of 14 days was instituted. Patients who met one or more of the 
criteria listed in Table 1 were excluded from the study. 
The study protocol was reviewed and approved by the ethics committee of 
the University Hospital Nijmegen. Patients were fully informed, and their written 
consent was obtained in accordance with the declarations of Helsinki and Tokyo. 
Assessment of inflammatory activity 
The activity index developed by Van Hees and colleagues (5) was used to assess 
inflammatory activity and to evaluate the effects of therapy. In addition, all 
variables included in the Crohn's Disease Activity Index were collected to permit 
computation this index according to Best and colleagues (6). The variables in the 
Van Hees Activity Index are stool consistency, the presence of extra-intestinal 
lesions, the presence of an abdominal mass, temperature, the Quetelet index 
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(weight divided by height squared), sex, previous resections, erythrocyte 
sedimentation rate, and serum albumin level. Values of less than 100 indicate 
quiescent disease, of 100 to 150 indicate mild disease, of 150 to 210 indicate 
moderately severe disease and values of more than 210 indicate severe or very 
severe disease. The variables in the Crohn's Disease Activity Index are the 
number of liquid or soft stools, the number of perianal and extra-intestinal 
lesions, the presence of an abdominal mass, the percentage of body weight that is 
below standard weight, hematocrit results, abdominal pain, well-being, and use of 
opiates. A Crohn's Disease Activity Index of less than 150 denotes quiescent 
disease, of 150 to 450 indicates active disease, and of more than 450 indicates 
very severe disease. 
Study design and randomization 
Patients who satisfied the diagnostic and study criteria and had given their 
written informed consent were assigned to receive either sulphasalazine and 
prednisone or sulphasalazine and placebo. Patients were allocated to treatment 
groups using a modification of the standardized range method presented by Begg 
(7) to ensure equal distribution of prognostic factors between both treatment 
groups. The modification consisted of standardization of the variance method. The 
balancing variables were the Van Hees Activity Index, the location of disease, first 
attack or recurrence, the duration of symptoms, previous medical or surgical 
therapy, and attending physician. 
The duration of treatment was 16 weeks. The dose of sulphasalazine was 
initially 6 g/d in four doses and was reduced to 4 g/d when side effects attribu-
table to sulphasalazine occurred. Prednisone and placebo were given as externally 
indistinguishable capsules, each containing 5 mg. Double-blindness appeared to be 
maintained throughout the study in all patients. The dose of prednisone was 30 
mg/d during the first 2 weeks. Prednisone therapy was tapered in steps of 5 mg/2 
wk to 10 mg/d after 8 weeks and remained at that level until the end of the 
study. 
All patients were interviewed and examined at inclusion and every 2 weeks 
51 
Table 1 Cntena for exclusion 
Criteria 
Severe illness 
presence of abscesses or large infíltrales 
very poor general condition (inclusion in the trial would entail an unacceptable risk) 
Surgery is likely to be needed soon (for example, severe stenosis, extensive fistulae) 
Presence of a blind loop, ileostomy, proximal colostomy, or ileorcctal anastomosis 
Location of Crohn's discase in the proximal small or entire small bowel 
Reinstitution of treatment within the 4 weeks before study entry 
Van Hees Activity Index of 140 or less 
Elevation of at least two out of four liver function variable (bilirubin, alkaline phosphatase, 
alanine aminotransferase and aspartate aminotransferase levels) to more than twice the 
upper margin of the normal range, or evidence of liver cirrhosis 
Creatinine clearance of less than 30 mL/mm 
Diabetes mellitus 
Conditions influencing Van Hecs Activity Index variables (for example the nephrotic 
syndrome, hyperthyroidism, malabsorption not caused by Crohn's disease and diseases 
associated with raised erythrocyte sedimentation rate such as rheumatoid arthritis) 
Need for antibiotics or corticosteroids (for any reason) 
Proved allergy to sulphadrugs, salicylates, or sulphasalazine 
Pregnancy 
Uncooperattveness 
during the study period: At each visit, a medical history was taken, patients were 
questioned about the intake of the capsules; a physical examination was done, 
with an emphasis on the findings needed to estabhsh the Van Hees Activity Index 
and the Crohn's Disease Activity Index, and blood was drawn for determining all 
of the laboratory variables included in the two indices and for measuring serum 
levels of sulphapyridine. All patients recorded their complaints on a diary chart 
during the week before each visit. 
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Criteria for premature discontinuation of treatment 
Therapy was considered to be no longer justified and was discontinued when a 
patient's temperature was persistently over 38.СРС, the Van Hees Activity Index 
value increased by more than 25% to more than 200, or when this index was 
more than 200 for more than 8 weeks. When therapy was stopped for one of 
these reasons, the patient was included in the evaluation as a treatment failure. 
Patients who were withdrawn for reasons other than the three above were not 
included in the analysis. 
Assessment of the response to therapy and statistical analysis 
The response to treatment was examined and tested by comparing the relative 
changes in the activity indices of both treatment groups in the early phase and at 
the end of the treatment period. In Van Hees and colleagues study (3), the most 
substantial decrease in activity in patients receiving sulphasalazine was reached 
after 6 weeks of treatment. In our study, the means of the data obtained at 
weeks 2, 4 and 6 were considered to represent the initial response, and the 
means of the data obtained at weeks 12, 14 and 16 were considered to represent 
the final response. Comparisons were made between the two treatment groups as 
a whole and after subdivision according to the location of disease (in the small 
bowel only, in the small bowel and colon, and in the colon only) and according to 
the initial Van Hees Activity Index value (< 175 or > 175). 
In cases of premature withdrawal due to treatment failure the values of the 
activity indices at all later times were set at the values they had been at the time 
of withdrawal. The test of Shapiro-Wilk was used to assess normality. Because of 
the non-normal distribution of the responses, the Wilcoxon two-sample test was 
used. 
Differences in sulphasalazine intake and serum sulphapyridine levels were also 
examined with the Wilcoxon two-sample test. Correlations between stool 
frequency and the activity index were examined with the Spearman correlation 
coefficient (r,). The chi-square test was used to test the dependance of the 
disease activity on the location of disease. Only two-sided test results were used. 
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P-values of less than 0.05 were considered significant. Data were analyzed with 
the Statistical Analysis System (SAS Institute, Сагу, North Carolina). 
RESULTS 
Composition of treatment groups 
During the entire study period, 175 patients were examined for eligibility. One 
hundred and four of them were excluded because of too low an Activity Index 
value (67 patients), recent start of drug treatment (12), need for surgery (11), 
severe illness (5), refusal to provide informed consent (3), previous adverse 
reactions to test drugs (2) and other reasons (4 patients). Seventy-one patients 
were randomly assigned. Eleven of them dropped out before the end of the study 
for reasons that made them not évaluable: adverse effects of sulphasalazine (3 
patients), uncooperativeness (2 patients), false diagnosis of Crohn's disease (2 
patients), need for surgery within 14 days (2 patients), break in drug use (1 
patient) and cerebrovascular accident (1 patient). Sixty patients remained for 
analysis. Thirty were assigned to receive sulphasalazine and prednisone and 30 to 
receive sulphasalazine and placebo. The main characteristics of both treatment 
groups are shown in Table 2. The distribution of the initial values for the Van 
Hees Activity Index did not differ significantly according to the location of disease 
in either treatment group. The number of patients per center ranged from 4 to 
17. 
The mean intake of sulphasalazine, as judged by the biweekly questionnaire, 
was 5.4 ± 0.7 g/d (mean ± SD) in the group assigned to receive sulphasalazine 
and prednisone and 5.0 ± 1.1 g/d in the group assigned to receive sulphasalazine 
and placebo. No significant difference in serum levels of sulphapyridine was found 
between the two treatment groups, indicating similar compliance to therapy. 
Response to therapy 
Four patients had a premature treatment failure. One was treated with 
sulphasalazine and prednisone and was excluded from the study after 8 weeks 
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Table 2. Comparability of treatment groups 
Patient 
characteristics 
Men : women 
Mean age ± SD, y 
Bowel involvement, η 
Small bowel only 
Small bowel and colon 
Colon only 
First attack : relapse 
Maintenance treatment with 
Prednisone 
Sulphasalazine 
Mean Van Hees Activity Index 
Initial Van Hees Activity Index 
Mean Crohn's Disease Activity 
Number of liquid or very 
soft stools per week ± SD 
¿ 
> 
SD 
175 
Index ± SD 
Treatment group 
sulphasalazine 
plus prednisone 
(n = 30) 
8:22 
29.4 ± 14.0 
10 
10 
10 
26:4 
0 
3 
178.4 ± 30.2 
13 
304.9 ±105.0 
31.6 ± 27.1 
sulphasalazine 
plus placebo 
(n = 30) 
7:23 
27.9 ± 11.0 
11 
9 
10 
24:6 
1 
4 
173.2 ± 27.3 
11 
254.8 ± 79.1 
20.1 ± 15.7 
There was no significant difference between the two groups 
because the Van Hees Activity Index remained above 200 for that time. The 
other three patients, treated with sulphasalazine and placebo, were excluded after 
2 and 4 weeks (because of persistent high fever), and 8 weeks (because of a Van 
Hees Activity Index that remained above 200), respectively. The course of the 
relative Van Hees Activity Index, as compared with the initial value, in both 
treatment groups is shown in Figure 1. 
1. Initial response 
The mean relative changes in activity indices in the first 6 weeks of treatment 
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Figure 1. The Van Hees Activity Index value as a proportion of the inilinl value in patients 
treated with sulphasalazine and prednisone (0) or sulphasalazine and placebo (O). 
The daily dose of prednisone in the patients treated with sulphasalazine and prednisone is 
shown in the bottom panel Data are presented as medians and quartiles. The median and 
the first and third quartiles of a sample are the values which include 50%, 25%, and 75% of 
the observations, respectively. 
are presented in Table 3. In the initial phase of treatment a significantly faster 
decrease in the Van Hees Activity Index was seen in all of the patients who 
were treated with sulphasalazine and prednisone, in the subgroups of patients 
whose Crohn's disease was located in the small bowel and the colon and in 
the colon only, and in the subgroup with a high and the subgroup with a low 
initial Van Hees Activity Index value. When the Crohn's Disease Activity 
Index was used as an indicator of the degree of illness, the conditions of pa-
tients who were treated with sulphasalazine and prednisone also showed more 
improvement during the first 6 weeks than did the conditions of those who 
Table 3. Relative values of the Van Hees Activity Index and the Crohn's Disease Activity Index in the first 6 
weeks of treatment'. 
mean Van Hees Activity Index mean Crohn's Disease Activity Index 
Disease location 
Small bowel only 73 (64-86) 
N = 10 
sulphasalazine sulphasalazine P- sulphasalazine sulphasalazine P-
plus prednisone plus placebo value plus prednisone plus placebo value 
87 (72- 89) 0.27 72 (52-86) 93 (55-121) 0.17 
N = 11 N = 9 N = 11 
Small bowel and colon 68 (54-81) 
N = 10 
86 (70-100) 0.04 58 (56-88) 
N = 9 N = 9 
72 (50- 98) 0.79 
N = 9 
Colon only 64 (47-79) 88 (59- 93) 0.03 65 (61-87) 71 (66-110) 0.38 
N = 10 N = 10 N = 10 N = 10 
Initial activity index 
<175 75 (64-84) 
N = 17 
86 (74- 89) 0.04 
N = 19 
> 175 63 (51-72) 
N = 13 
88 (60-103) 0.02 
N = 11 
All 70 (57-80) 87 (70- 94) 0.001 65 (57-86) 
N = 30 N = 30 N = 28 
75 (58-100) 0.13 
N = 30 
The relative values are expressed as percentages of the initial values. The data are the medians of the 
mean values obtained at week 2, 4 and 6, with quamle ranges m parentheses. N = number of patients. 
were treated with sulphasalazine and placebo; however, this difference was not 
significant. This finding applied to the whole group of patients and to all 
subgroups according to disease location. 
2. Final response 
The values of the relative activity indices in the last 4 weeks of treatment (the 
mean of the values obtained at weeks 12, 14 and 16) are presented in Table 
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4. Although the improvement at the end of the treatment period, as measured 
with both activity indices, was larger in patients treated with sulphasalazine 
and prednisone, this benefit was not significant when all patients were taken 
together. When subgroups were considered separately, significant benefit from 
the additional use of prednisone was seen only in patients with a high initial 
Van Hees Activity Index value. 
The proportion of patients in each treatment group that showed improvement 
in the components of the two indices in the initial and final phases is shown in 
Table 5. Of the components of the Van Hees Activity Index, serum albumin, 
erythrocyte sedimentation rate, and Quetelet score improved most often in both 
treatment groups in the last 4 weeks. These components also improved in the 
first 6 weeks in patients who were treated with sulphasalazine and prednisone. In 
the first 6 weeks of treatment with sulphasalazine and placebo, improvement in 
the erythrocyte sedimentation rate and in Quetelet score was far less frequent. 
The number of liquid and very loose stools, scores for abdominal pain and well-
being, and body weight were the components of the Crohn's Disease Activity 
Index that improved most frequently in both treatment groups in the initial and 
final phases of treatment. 
Before the start of treatment, the number of liquid or very soft stools per week 
was almost significantly higher in patients assigned to receive sulphasalazine and 
prednisone (Table 2). In this group, there was no significant correlation between 
the mean relative change in the Van Hees Activity Index in the first 6 weeks and 
the number of liquid or very soft stools at the start of treatment. In the group 
assigned to receive sulphasalazine and placebo, however, the mean relative 
decrease in the Van Hees Activity Index in the first 6 weeks correlated negatively 
with the number of liquid or very soft stools at the start of treatment (r, = -0.47; 
Ρ = 0.009; η = 30). In other words, the higher the frequency of diarrhea was, the 
less improvement there was in the initial phase. In this group, some correlation 
remained between the mean decrease in the Van Hees Activity Index in the last 
4 weeks and the number of liquid or very soft stools at the start of treatment (r
s 
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Table 4. Relative values of the Van Hees Activity Index and the Crohn's Disease Activity Index in the lust • 
weeks of treatment'. 
mean Van Hees Activity Index mean Crohn's Disease Activity Index 
Disease location 
Small bowel only 
sulphasalazme sulphasalazme P- sulphasalazme sulphasalazme P-
plus prednisone plus placebo value plus prednisone plus placebo value 
73 (63-80) 71 (53- 80) 0.81 69 (55-90) 71 (50-100) 0.70 
N = 10 N = 11 N = 10 N = 11 
Small bowel and colon 62 (38-75) 
N = 10 
70 (52- 98) 0.21 42 (33-92) 70 (53- 90) 0.33 
N = 9 N = 10 N = 9 
Colon only 52 (35-68) 
N = 10 
Initial activity index 
< 175 71 (62-76) 
N = 17 
71 (53- 92) 0.09 73 (44-92) 
N = 10 N = 10 
71 (54- 80) 0.94 
N = 19 
98 (42-129) 0.47 
N = 10 
> 175 42(36-68) 
N = 13 
70 (49-101) 0.02 
N = 11 
All 63 (40-75) 70 (54- 90) 0.10 65 (42-90) 76 (49-110) 0.19 
N = 30 N = 30 N = 30 N = 30 
* The relative values are expressed as percentages of the initial values. The data are the medians of the 
mean values obtained at week 12, 14 and 16, with quartile ranges in parentheses. N = number of patients. 
= -0.36; Ρ = 0.05; η = 30). 
DISCUSSION 
Our results show that the use of prednisone, in the dose prescribed, in addition 
to sulphasalazme in the treatment of patients with active Crohn's disease results 
in markedly faster initial improvement, as measured with the Van Hees Activity 
Index. This advantage remains at the end of the 16-week treatment period. 
However, is then far smaller and insignificant. This pattern can be seen in all 
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Table 5. Improvement in the components of the Van Hees Activity Index and the Crohn's 
Disease Activity Index during treatment with sulphasalazine plus prednisone and during treatment 
with sulphasalazine plus placebo' 
Components 
Van Hees Activity Index 
Serum albumin level 
Erythrocyte sedimentation rate 
Quetelet score 
Abdominal mass 
Temperature 
Stool consistency 
Extra-intestinal lesions 
Crohn's Disease Activity Index 
Loose stools 
Abdominal pain 
Well-being 
Perianal and 
Extra-intestinal lesions 
Abdominal mass 
Haematocrit result 
Weight 
sulphasalazine 
plus 
prednisone 
first 6 
weeks 
^ 
100 
70 
87 
30 
40 
46 
3 
90 
90 
66 
43 
30 
43 
87 
last 4 
weeks 
% 
75 
97 
34 
38 
52 
0 
86 
89 
68 
43 
35 
45 
93 
sulphasalazine 
plus 
placebo 
first 6 
weeks 
/w 
ΎΟ 
89 
33 
40 
20 
24 
48 
7 
57 
63 
57 
40 
20 
57 
47 
I 
last 4 
weeks 
92 
65 
74 
26 
27 
58 
7 
58 
73 
65 
40 
27 
42 
69 
* percentage of patients with improvement 
patient subgroups made according to the location of disease, and for patients with 
ileocolonic and colonic disease the difference in initial improvement was sig­
nificant. A real difference may have remained undiscovered as a result of the 
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small numbers in each subgroup. Prednisone therapy may have produced a better 
result at 16 weeks had it been tapered off more slowly. 
When patients were subdivided according to the severity of disease at the start of 
treatment, both those with a high (> 175) and those with a low (< 175) initial 
Van Hees Activity Index value benefited significantly from use of prednisone in 
addition to sulphasalazine in the first 6 weeks of treatment. In the last 4 weeks, 
however, this advantage remained significant only for patients with a high initial 
value. When the initial Van Hees Activity Index value was low, the use of 
prednisone in addition to sulphasalazine made no difference at all at the end of 
the treatment period. In other words, the conditions of all of the patients 
improved faster when sulphasalazine was combined with prednisone, but the end 
result was only better in cases of severe disease. The location of disease and the 
initial value of the Van Hees Activity Index did not appear to be related to each 
other. 
The course of the Van Hees Activity Index in this study is consistent with that 
noted in the study of van Hees and colleagues (3), in which the mean initial value 
in patients treated with sulphasalazine was 185 ± 30 and the median proportional 
decrease after 16 weeks of treatment with sulphasalazine was approximately 30%. 
In our study, the mean initial value of patients treated with sulphasalazine and 
placebo was 173 ± 27 and the median proportional decrease after 16 weeks 29% 
(95% CI 17% to 39%). 
Although the Crohn's Disease Activity Index did not show a significant difference 
between the two treatment groups, the trends were in the same direction as those 
obtained with the Van Hees Activity Index. The course of the Crohn's Disease 
Activity Index during treatment with sulphasalazine alone in our study was less 
favorable than in the National Cooperative Crohn's Disease Study. The mean 
initial value was 255 ± 79 in our study and 256 ± 71 in the National Cooperative 
Crohn's Disease Study. After 15 weeks of treatment in that study, the mean value 
of the Crohn's Disease Activity Index had maximally decreased to approximately 
60% of its initial value. After 16 weeks of treatment in our study, this figure was 
about 78%. Comparison of our findings with the results of the National and the 
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European Cooperative Crohn's Disease Study should be made cautiously, 
however, because the duration of treatment and the dosages used in that studies 
were different from those used in our study (1,2). 
When patients have diarrhea with an accelerated intestinal transit time, the time 
of mucosal contact is shortened and, moreover, the splitting of sulphasalazine is 
less complete (8,9), resulting in decreased availability of 5-aminosalicylic acid to 
the diseased intestine. We found a negative correlation between the number of 
liquid or very soft stools and a decrease in the Van Hees Activity Index in the 
first 6 weeks and even in the last 4 weeks of treatment in the patients who 
received sulphasalazine and placebo. Patients who do not respond to therapy may 
continue to have accelerated intestinal transit times, causing incomplete splitting 
of sulphasalazine and resulting in a diminished therapeutic effect. These 
correlations were not found in patients treated with sulphasalazine and 
prednisone, thus warranting the conclusion that sulphasalazine alone, compared 
with prednisone, which has an uptake largely independent of intestinal transit 
time, is not effective in patients with severe diarrhea. 
The value of the Crohn's Disease Activity Index at the start of the treatment, 
which was not a balancing variable at the time of assignment, was higher in the 
group of patients treated with sulphasalazine and prednisone (P = 0.057, the 
Wilcoxon test). On one hand, a high initial disease activity may be attended by a 
higher probability of treatment failure, thus implying a disadvantage for treatment 
with sulphasalazine and prednisone. On the other hand, patients with a high 
initial Crohn's Disease Activity Index value may react better than patients with a 
lower initial value to administration of prednisone. We tried to correct for the 
difference between the initial values by using relative instead of absolute values. 
The finding that the Crohn's Disease Activity Index, as compared with the Van 
Hees Activity Index, showed less pronounced differences between the treatment 
groups might be caused in part by the large variability of the data and the 
relatively small number of patients. This finding does not indicate that the first 
index is better than the latter; however, it shows how important the choice of the 
yardstick of disease activity is for measuring the effectiveness of treatment. The 
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existence of many activity indices for Crohn's disease indicates that none of them 
is perfect. The Van Hees Activity Index is composed of some readily accessible 
laboratory variables and other objective items that mostly indicate inflammatory 
activity (5), whereas the Crohn's Disease Activity Index contains more subjective 
variables, like general well-being and abdominal pain (6), that do not necessarily 
relate to inflammation. In our study, serum albumin, erythrocyte sedimentation 
rate, and weight were the most frequently improving components of the Van 
Hees Activity Index. In the Crohn's Disease Activity Index, abdominal pain and 
well-being were also among the components most frequently improving. So, 
although the two indices measure different aspects of disease, changes in 
inflammatory parameters and subjective parameters appear to parallel each other 
quite well in practice. 
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CHAPTER 4 
DETERMINATION OF SERUM LEVELS OF OROSOMUCOID AND 
C-REACTIVE PROTEIN IN PATIENTS WITH ACTIVE CROHN'S DISEASE 
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SUMMARY 
In 103 patients with Crohn's disease the van Hees Activity Index, the Crohn's 
Disease Activity Index and serum levels of the acute phase reactants orosomucoid 
and C-reactive protein were measured and their mutual correlations calculated. 
The predictive power of the initial value of the acute phase reactants and of their 
change early in treatment was investigated in 30 patients treated with 
sulphasalazine and prednisone and 30 patients treated with sulphasalazine alone. 
Coefficients of correlation between the clinical activity indices and the acute 
phase reactants did not exceed 0.56. In patients with high initial orosomucoid 
levels (>175mg/100 ml) the response of the van Hees Activity Index was better in 
the last 4 weeks of treatment with sulphasalazine and prednisone (median 40.8% 
of initial value, interquartile range 34.9-66.2%) as compared with sulphasalazine 
alone (median 62.6%, interquartile range 47.1-85.7%; p=0.07). The changes of 
the acute phase reactants after 2 and 4 weeks of treatment did not distinguish 
patients with a good and a poor response. We conclude that the acute phase 
reactants cannot be put in place of clinical activity indices and are of limited 
predictive value as to the response to therapy. 
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INTRODUCTION 
Many methods are available for the measurement of the activity of Crohn's 
disease. Clinical activity indices are composed of factors that are considered 
important for the judgement of the severity of the disease. Factors can be related 
to the patient's physical status, such as weight and previous resections, to 
symptoms of inflammation such as stool frequency, extra-intestinal manifestations 
and fever, to subjective complaints such as abdominal pain and well-being, and to 
objective laboratory data as ESR, haemoglobin, haematocrit or serum albumin. 
The Crohn's Disease Activity Index (CDAI) and the Van Hees Activity Index 
(AI), presented in Table 1, are examples of such composite indices (1, 2). 
In several studies it was found that the serum concentrations of some acute phase 
reactants such as orosomucoid, C-reactive protein and alpha-1-antitrypsin 
correlated well with disease Table 1. Composition of the Van Hees Index (AI) 
and the Crohn's Disease Activity Index (CDAI) 
Factor assessed 
Stool habits 
Extra-intestinal lesions 
Abdominal mass 
Temperature 
Quetelet score (lenght/height2) 
Weight related to ideal weight 
Sex 
Previous resections 
ESR 
Serum albumin 
Haemoglobin/haematocrit 
Pain 
General well-being 
Anti-diarrhocal drugs 
AI 
X 
X 
X 
X 
X 
X 
X 
X 
X 
CDAI 
X 
X 
X 
X 
X 
X 
X 
X 
AI < 100: quiescent disease, 
AI 100-150: mild disease, 
AI 150-210: moderately severe disease. 
AI > 210: (very) severe disease. 
CDAI < 150: quiescent disease, 
CDAI 150-450: active disease, 
CDAI > 450: veiy severe disease. 
For formulas of AI and CDAI see ref. 1 and 2. 
activity, and therefore might serve 
as a substitute for or as an 
adjunct to other indices (3-7). 
Moreover, the level of one or 
more of the acute phase 
reactants, and the value of an 
index composed of these, were 
closely related to a future relapse 
of Crohn's disease in patients in a 
quiescent phase (7-9). 
We investigated the course of the 
AI, CDAI, and serum levels of 
orosomucoid and C-reactive 
protein in patients with active 
Crohn's disease, their mutual 
correlations and the value of the 
measurement of the serum 
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concentrations of these acute phase reactants to predict the response to two 
defined treatment schemes. 
METHODS 
Patients and treatment 
As described Chapter 3 (10), 175 patients with active Crohn's disease were 
examined as to their eligibility for a clinical trial, designed to compare the 
therapeutic effect of salazosulphapyridine (SASP) and prednisone with SASP and 
placebo. One-hundred-and-four patients were not admitted to the trial, most of 
them because of an AI lower than 140 points. Of the 71 patients entering the 
trial eleven were withdrawn for reasons other than treatment failure. Of the 
remaining 60 patients 30 were assigned to SASP and prednisone, and 30 to SASP 
and placebo. The dosage of SASP was 4 to 6 g per day. Prednisone was given in 
an initial dose of 30 mg daily and tapered down to 10 mg after 8 weeks. The 
total duration of the study was 16 weeks. Control visits took place every two 
weeks. At each control visit data were collected to calculate the CDAI and AI, 
and blood was drawn for the determination of orosomucoid and C-reactive 
protein. The effect of treatment was assessed by the value of the AI and CDAI 
at the end of the study, expressed as a proportion of the initial value. The mean 
of available data of week 12, 14 and 16 was considered representative for the end 
of the treatment period, and was called "final response". 
In the group of patients treated with SASP and prednisone the median final 
response of AI was 63.2% and the median final response of CDAI 65.2%. In 
patients assigned to SASP and placebo the median final response of AI was 
70.4% and of CDAI 75.9% (10). 
In 48 of the 104 patients excluded from the trial values of AI, orosomucoid and 
C-reactive protein were available, and in only 22 of them (mostly seen at the 
University Hospital Nijmegen) also all data needed for the calculation of the 
CDAI. In seven out of the 60 patients treated according to the trial protocol data 
of orosomucoid and C-reactive protein at entry, and in two patients the initial 
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CDAI were missing. In two out of the eleven patients who were withdrawn 
prematurely not because of a treatment failure, all data at entry were available. 
Data from included and excluded patients were combined to establish correlations 
between the levels of acute phase reactants and activity indices. In the group 
examined the AI ranged from 50 to 243 (median 153) and the CDAI from 10 to 
470 (median 195). 
Determination of orosomucoid and C-reactive protein 
Serum of patients was stored at -20oC until analysis. Orosomucoid and C-reactive 
protein levels were measured by means of a radial immunodiffusion method (LC-
PartigenR for C-reactive protein, NOR-PartigenR for orosomucoid, both from 
Behringwerke AG, Marburg, W. Germany). The normal range of orosomucoid is 
55-140 mg/100 ml, and of C-reactive protein 6-10 mg/1. 
Assessment of the value of orosomucoid and C-reactive protein 
The measurement of the serum levels of orosomucoid and C-reactive protein was 
presumed to be of clinical importance if they could replace the clinical activity 
indices or if their value at the start, or their change in the initial phase of 
treatment (after 2 or 4 weeks) would have predictive value with regard to the 
final response to treatment. 
To determine the correlations between orosomucoid and C-reactive protein on 
the one side and AI and CDAI on the other side data from all patients 
participating in the trial before the start of treatment were taken, and moreover 
from patients excluded from the trial, as far as all data needed were available. 
Also, mutual correlation coefficients during the course of treatment were calcu-
lated. 
The possible predictive value of C-reactive protein and orosomucoid in both treat-
ment groups was examined in two ways. Firstly, we examined whether patients 
with a high initial level of orosomucoid or C-reactive protein were more likely to 
profit from the addition of prednisone to SASP than those with a low initial level. 
Secondly, we studied the correlations between the proportional decrease of the 
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acute phase reactants in the initial phase of treatment (after two and four weeks) 
and the final response. 
Statistical analysis 
Correlations between concentrations of orosomucoid and C-reactive protein and 
activity indices were examined with Spearman's rank correlation coefficient. 
Wilcoxon's two-sample test was used to examine differences in proportional 
changes of the activity indices in both treatment groups. All tests were two-sided. 
A p-value of 0.05 or less was considered significant. 
If a patient was withdrawn from the study because of treatment failure the 
relative value of AI and CDAI at subsequent times was set at the value at the 
time of withdrawal. 
RESULTS 
The correlation coefficients between the acute 
indices in 103 patients with quiescent and active 
The correlation coefficients of the AI with 
somewhat higher than of the CDAI. 
Table 2. Spearman's rank correlations between serum 
orosomucoid, serum C-reactive protein and Van Hees 
Activity Index (AI) and Crohn's Disease Activity Index 
(CDAI) in patients with Crohn's disease. All values 
measured before the start of treatment 
orosomucoid 
C-reactive protein 
AI 
г = 0.56 
ρ < 0.001 
η = 103 
г = 0.56 
ρ <0.001 
η = 103 
CDAI 
г = 0.34 
ρ = 0.003 
η = 75 
г = 0.32 
ρ = 0.005 
η = 75 
phase reactants and the activity 
disease are presented in Table 2. 
the acute phase reactants are 
From Figures 1 and 2 it is 
obvious that the mean values of 
the activity indices run closely 
together with the mean values 
of the serum levels of oroso­
mucoid, and far less with C-
reactive protein. C-reactive 
protein responds much faster to 
treatment, especially in patients 
treated with SASP and 
prednisone, than the other 
parameters. In patients treated 
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TREATMENT WITH SASP PLUS PREDNISONE 
% of initial value 
TREATMENT WITH SASP PLUS PLACEBO 
1 of Ifllttel ν 
Figure 1 Course of the mean proportional value of AI, 
CDAI, orosomucoid and C-reacttve protein (CRP) in 
patients with active Crohn's disease, treated with 
sulphasalazine and prednisone 
Figure 2. Course of the mean proportional value of AI, 
CDAI, orosomucoid and C-reacttve protein (CRP) m 
patients wah active Crohn's disease, treated with 
sulphasalazine and placebo 
with sulphasalazine and prednisone the mean value of C-reactive protein had 
decreased after 2 weeks to 36 ± 31% of its initial value, whereas orosomucoid 
had decreased to only 77 ± 23%, the AI to 76 ± 15% and the CDAI to 74 ± 
18%. In patients treated with sulphasalazine and placebo the values of C-reactive 
protein, orosomucoid, AI and CDAI had decreased to 73 ± 66%, 99 ± 42%, 92 
± 28% and 93 ± 44%. 
In Table 3 correlation coefficients at the start of treatment and after 2 and 16 
weeks are presented. The coefficients of correlation with the CDAI were 
generally much lower. Although the Figures 1 and 2 suggest that the correlation 
between activity indices and orosomucoid is fairly good, the r-values never 
exceeded 0.71, due to a large spread of values. Furthermore, the r-values showed 
a considerable week-to-week fluctuation. 
In the group of patients with a high initial serum orosomucoid (higher than the 
median value of 175 mg/lOO ml) or a high initial C-reactive protein (higher than 
the median value of 50 mg/1) the final response of AI and CDAI was better in 
those treated with SASP and prednisone than in those treated with SASP and 
placebo, but this failed to reach statistical significance ( the lowest p-value was 
0.07 for the difference in response of AI in patients with high and low initial 
orosomucoid). In patients with a low initial orosomucoid or C-reactive protein the 
responses to SASP and prednisone and to SASP and placebo were similar (Table 
73 
Table 3. Spearman's rank correlations between serum orosomucoid, serum C-reacttve protein 
(CRP) and Van Hees Activity Index (AI) m patients with Crohn's disease, measured during 
treatment with sulphasalazme and prednisone or sulphasalazme alone. 
orosomucoid 
CRP 
At the start of 
treatment with 
SASP plus 
prednisone 
r = 0.59 
ρ = 001 
η = 28 
г = 048 
ρ = 001 
η = 27 
SASP plus 
placebo 
г = 041 
ρ = 004 
η = 26 
г = 031 
ρ = 0.11 
η = 27 
Correlation coefficients with AI 
After 2 weeks of 
treatment with 
SASP plus 
prednisone 
r = 029 
ρ = 013 
η = 29 
r = 034 
p = 008 
η = 28 
SASP plus 
placebo 
r = 050 
ρ = 001 
η = 23 
r = 0.14 
ρ = 054 
η = 23 
After 16 weeks of 
treatment with 
SASP plus 
prednisone 
r = 069 
ρ = 0003 
η = 16 
r = 0 45 
ρ = 007 
η = 16 
SASP plus 
placebo 
г = 070 
ρ = 0008 
η = 13 
r = 071 
ρ = 0007 
η = 13 
4). The choice of any other cut-off point for high and low values of the acute 
phase reactants did not result in a better prediction of the result of therapy. It is 
apparent however from the data in Table 4 that patients treated with SASP and 
prednisone who have high initial orosomucoid levels respond far better than those 
with low initial levels (no overlap in quartile ranges of final respons, ρ < 0.001). 
The correlations between the change of acute phase reactants in the first four 
weeks of treatment and the final response of the AI are shown in Table 5. As 
none of the r-values of the correlations with the CD AI exceeded 0.31, these 
correlation coefficients are not mentioned. With the exception of orosomucoid in 
patients treated with SASP and placebo, the relative value of orosomucoid and C-
reactive protein after four weeks correlated significantly with the final response of 
AI in the whole group of patients and in both treatment groups. However, the 
change of the acute phase reactants after four weeks in individual cases had little 
predictive power with regard to the final response. For, when patients were 
divided according to the height of the relative values after four weeks (more or 
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Table 4. Relative values of AI and CDAI (expressed as percentages of the initial value) in the last 
four weeks of treatment,m subgroups of patients according to initial height of the acute phase 
reactants. Figures are medians of the mean values of week 12, 14 and 16, with quartile ranges in 
parenteses. 
mean AI in the last four weeks mean CDAI in the last four weeks 
SASP SASP ρ SASP SASP ρ 
+ prednisone + placebo + prednisone + placebo 
orosomucoKJ <175 75.1 (67.3-82.2) 71.7 (55.0-88.3) 0.48 75.7 (59.0-96.7) 70.8 (51.9-107.3) 0.98 
η = 13 η = 16 η = 13 η = 16 
orosomucoid >175 40.8(34.9-66.2) 62.6(47.1-85.7)0.07 45.9(33.5-72.7) 87.0 (50.4-102J) 0.12 
η = 15 η = 10 η = 13 η = 9 
C-reactivc protein <50 71.9 (54.9-76.5) 66.3 (52.2-80.6) 0.84 70.5 (54.7-91.9) 69.8 (42.1- 90.5) 0.91 
η = 14 η = 14 π = 14 η = 14 
C-reactive protein >50 60.8(35.4-71.4) 72J (51.9-90.7) 0.095 59.6(31.0-85 0) 90.3(53.6-110.0)0.19 
η = 13 η = 13 η = 11 η = 12 
Units of orosomucoid: mg/100 ml; units of C-reactive protein: mg/ml. 
p. Ρ-values of the difference between the SASP plus prednisone treated and the SASP plus placebo treated 
group. 
less than the median value), the difference in final response of AI between these 
groups was not significant, neither when other cut-off points were chosen. This 
was due to a large overlap in final response of AI between both groups. The 
correlations between the relative changes of the acute phase reactants after two 
weeks and the final responses of the activity indices were even lower than after 
four weeks, so the relative change after two weeks does not provide any 
information as to the final outcome. 
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Table 5. Spearman 's rank correlations between the relative value of serum orosomucoid, C-reactive 
protein after four weeks of treatment, expressed as percentage of the initial value, and the final 
response of the Van Hees Activity Index (AI), expressed as the mean of available relative values of 
week 12, 14 and 16, in patients with Crohn's disease treated for 16 weeks with sulphasalazine 
(SASP) and prednisone or SASP and placebo. 
Proportional value 
after four weeks of 
orosomucoid 
C-reaaive protein 
Patients treated with 
SASP and prednisone 
r = 0.65 
ρ = 0.0003 
η = 26 
г = 0.51 
ρ = 0.02 
η = 22 
Final response of AI 
Patients treated with 
SASP and 
г = 0.31 
ρ = 0.13 
η = 25 
г = 0.54 
ρ = 0.007 
η = 24 
placebo 
All patients 
r = 0.53 
ρ = 0.0001 
η = 0.51 
г = 0.49 
ρ - 0.(1004 
η = 46 
DISCUSSION 
Serum levels of C-reactive protein and orosomucoid are considered to reflect the 
severity of acute inflammation. The question whether this holds for patients with 
active Crohn's disease cannot be answered in this study, as our "gold standards" 
were clinical activity indices, partly consisting of factors, e.g. haemoglobin and 
body weight, that certainly do not immediately respond to acute inflammation. 
But, even if acute phase reactants cannot be expected to correlate closely with 
the activity indices - what they actually did not in this study - they would be of 
value if they were good predictors of the outcome of therapy. 
We found significant correlations between the activity indices and the acute phase 
reactants, but indeed the correlation coefficients were too low to permit the 
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replacement of the first by the latter. Furthermore, the r-values changed 
considerably during the course of both treatments, being particularly low shortly 
after the start. This inconsistency makes acute phase reactants even less 
suitabable to substitute the clinical activity indices. 
In this study, the average course of the activity indices was well reflected by the 
average course of the serum levels of orosomucoid, and less by the course of C-
reactive protein, that responds much faster to treatment. Measurement of C-
reactive protein would be of importance if this early occurring change would be a 
good predictor of the final outcome of therapy. However, similar to orosomucoid, 
the initial value of C-reactive protein was not a good predictor of the response to 
treatment, neither did its relative value after four weeks correlate well with the 
final response of the activity indices in any treatment group. 
In the group of patients with a high orosomucoid level at the start of treatment 
patients assigned to SASP and prednisone tended to do better than those 
assigned to SASP and placebo, but the difference just failed to be significant (p 
= 0.07). Still, this might be considered an argument to add prednisone to SASP 
therapy in patients with high orosomucoid levels. 
The relative values of the acute phase reactants after four weeks of treatment 
correlate significantly with the final response of AI, but, due to a large overlap in 
final response between patients with a high and a low relative value after four 
weeks, these values cannot be safely used to predict the individual response to 
therapy. 
André et al found correlations between a simple, four-grade clinical index of 
disease activity and orosomucoid, C-reactive protein and ESR strong enough to 
advise addition of one or more of these parameters to a practical clinical index of 
Crohn's disease activity (3). We feel that the addition of an extra parameter to an 
activity index is of little use unless it possesses additional proporties, e.g. the 
power to predict the future course of disease. 
Starting from the results of our study, we believe that the determination of the 
acute phase reactants is of limited additional value in the assessment of disease 
activity and in the management of the individual patient. Only the initial serum 
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levels of orosomucoid show a trend to significance in predicting the outcome of 
treatment in active disease. This is in contrast with the situation of quiescent 
disease, where a high level of acute phase reactants correlates with an early flare-
up (7-9), and may even be helpful in selecting patient groups that could profit of 
relapse preventing use of corticosteroids (11). 
Of course, criticism can be raised against the fact that we judge the usefulness of 
the acute phase reactants by the AI and CDAI as the gold standards. The choice 
of the gold standard is less a matter of mathematics than of philosophy. Some 
authors consider endoscopical and histological findings as the ultimate criterion of 
disease activity and criticize clinical activity indices and laboratory indicators, 
including acute phase reactants, for their lack of correlation with endoscopy and 
histology (12). It can be argued, however, that endoscopy assesses only the 
internal surface of the gut, histology providing two or three millimeters deeper 
insight, with ample space for sampling error. 
Composite clinical indices as the AI and the CDAI provide more information 
about the effects of inflammation on metabolism and/or the patient as a whole. 
After all, activity indices are the quantification of the clinical judgement of its 
designers, who take decisions in patient management on the basis of its 
components, not on the basis of whatever single laboratory measurement. The 
results of this study indicate that clinical activity indices cannot be replaced by a 
single determination of serum orosomucoid or C-reactive protein, and that these 
acute phase proteins are of limited prognostic value during treatment of active 
disease. It should be emphasised, however, that these results apply only to 
situations where patients are treated according to the described medication 
scheme. 
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CHAPTER 5.1 
DISPOSITION OF 5-AMINOSALICYLIC ACID BY 5-AMINOSALICYLIC ACID 
DELIVERING COMPOUNDS IN HEALTHY VOLUNTEERS 
Scandinavian Journal of Gastroenterology 1988; 233: 107-112 

Disposition of 5-Aminosalicylic Acid by 
5-Aminosalicylic Acid-Delivering Compounds 
M С M RIJK, A VAN SCHAIK & J H M VAN TONGEREN 
Dept of Gastroenterology, University Hospital Nijmegen, Nijmegen, 
The Netherlands 
Rijk MCM, van Schaik A, van Tongeren JHM Disposition of S-aminosahcyhc acid 
by S aminosalicylic acid delivering compounds Scand J Gastroenterol 1988,23,107-
112 
The disposition of S-aminosalicylic acid (S-ASA) from S-ASA-delivenng drugs was 
studied in eight healthy volunteers Time-related unnary excretion and faecal 
excretion of S-ASA and acetyl-5-ASA were measured after a single oral dose of 
the azo compounds sulphasalazme and olsalazine, of the slow-release compounds 
Pentasa·, Asacol·, and Salofalk·, and of plain 5-ASA Plain 5-ASA was rapidly 
excreted into unne and had a low faecal recovery, indicating fast absorption proxi-
mally in the intestine and little availability to the colon After ingestion of both azo 
compounds and slow-release compounds, unnary excretion of 5-ASA was markedly 
delayed and reduced, and faecal excretion was enhanced At all points of time there 
was a significant but not very marked difference m unnary excretion of 5-ASA after 
ingestion of the azo compounds and the slow-release compounds, ш favour of the 
azo compounds A significantly larger proportion of the ingested 5-ASA, moreover, 
was excreted in faeces after intake of azo compounds as compared with slow-release 
compounds 
Key words 5 Aminosalicylic acid, azodisal sodium (olsalazine), metabolism, 
sahcylazosulphapyndinc 
MCM Rijk, M D , Dept of Gastroenterology, University Hospital Nijmegen, 
Ρ О Box 9101, 6500 HB Nijmegen, The Netherlands 
For many years salazosulphapyndine (sulpha­
salazme, Salazopynne·, Azulfidine* (SASP)) has 
been used in the treatment of inflammatory bowel 
disease (1-6) Unfortunately, adverse effects due 
to SASP occur not infrequently, necessitating 
dose reduction or even withdrawal of the drug 
After it had become clear that SASP is split by 
mtestinal bactena into 5-aminosaIicylic acid (5-
ASA) and sulphapyndine (SP) (7, 8), studies have 
been performed to identify the active moiety It 
has been demonstrated that 5-ASA is the active 
part (9,10) 
Since nearly all side effects are attributable to 
SP, the development of SP-free alternatives to 
SASP was a logical next step S-ASA in sup­
positories and enemas is now successfully used m 
the treatment of idiopathic proctitis and distal 
colitis For more extensive ulcerative colitis and 
Crohn's disease rectal application is insufficient, 
and in such situations 5-ASA has to be given by 
mouth Plain 5-ASA, however, is rapidly ab­
sorbed and excreted into unne (11), suggesting 
that it is largely taken up in the small bowel This 
is likely to reduce the luminal 5-ASA con­
centrations in the distal intestine to insufficient 
levels This problem has been dealt with in two 
ways 
First, 5-ASA has been given such a galemc 
formulation that it is released gradually or after 
a certain delay in an environment with a neutral 
pH Several of these slow-release or sustained-
release formulations are now bemg developed by 
vanous pharmaceutical companies, which all coat 
and buffer 5-ASA in a different manner Pentasa* 
(Ferring A/S Vanlose, Denmark, 5-ASA m 
microgranules with an ethyl cellulose membrane), 
Asacol· (Tillotts Laboratones, Henlow, UK, 5-
ASA coated with Eudragit-S, an acrylic-based 
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resin), and Salofalk* (Falk GmbH Freiburg, 
FRG, 5-ASA buffered with sodium carbonate 
and glyane in an enteric soluble film) are now 
available in some European countries 
Secondly, 5-ASA can be coupled with another 
earner instead of sulphapyndine via an azo bond 
Analogous to sulphasalazine, such a compound is 
also split by intestinal bactena, resulting in the 
release of 5-ASA at the proper site The camer 
can be an indifferent molecule, such as in ipsal-
azide or balsalazide (12), or another 5-ASA mol­
ecule, thus constituting azodisahcylate (ADS) or 
olsalazine (Dipentum·, Pharmacia) The latter 
molecule has the advantage that it does not con­
tain superfluous substances Both olsalazine and 
slow-release formulations have been tested in 
patients with active or quiescent ulcerative colitis 
or Crohn's disease These compounds were 
claimed to be as effective as sulphasalazine or 
more active than placebo and were generally tol­
erated well (13-17) 
We wondered whether all 5-ASA-delivenng 
drugs are equally capable of delivering 5-ASA to 
the distal bowel If one drug would release 5-
ASA more proximally in the gut than the others, 
it would be less appropnate for use in colonic 
inflammatory bowel disease Reports on the 
disposition of the new 5-ASA-delivenng drugs 
have been published They all suggest that the 
disposition is roughly comparable with that of 
sulphazalazine (18-22) Differences in study 
design, study subjects, and dosages make it 
impossible to compare the results We therefore 
compared the disposition of six 5-ASA-delivenng 
Table I Dosages and S-ASA contents of the drugs 
administered in this study 
Dose 5-ASA content 
Drugs administered (mg) (μπιοΙ) 
Azo compounds 
Salazopynne· 
Dipentum· 
ow-release compounds 
Pentasa· 
Asacol· 
Salofalk· 
lam S-ASA 
1500 
500 
500 
400 
500 
500 
3760 
2890 
3268 
2614 
3268 
3268 
drugs (SASP, ADS, Pentasa, Asacol, Salofalk, 
and plain 5-ASA) in the same subjects, adhenng 
to a fixed protocol A basic assumption was that 
5-ASA liberated early in the proximal small bowel 
would be absorbed promptly and excreted rapidly 
into the unne The more 5-ASA is excreted into 
unne at an early stage, therefore, the less becomes 
available to the colon We therefore measured 
the time-related unnary excretion of 5-ASA after 
a single oral dose of the drugs considered and, in 
addition, the faecal recovery Both 5-ASA and 
its major metabolite acetyl-5-ASA were deter­
mined 
Subjects and methods 
The study was approved by the hospital's ethi­
cal committee 
Eight healthy volunteers, six men and two 
women, took part after giving their informed 
consent Their age ranged from 20 to 38 years 
None had a history of gastrointestinal disorders 
Dosages and 5-ASA content of the drugs admin­
istered are listed in Table I The sequence of 
administration was random, and the washout 
penod after intake of one of the drugs was at least 
7 days On the day of administration of the drug 
the volunteers fasted from midnight until 1300 h 
Dnnking was not restneted At 0900 h the drug 
was taken by mouth Dunng the first 8 h there­
after, unne was collected in four 2-h portions 
The fifth portion covered the rest of the first 
day Dunng the next 3 days unne was collected 
every 24 h Faeces were collected per 4-day 
penod Unne was collected in plastic containers 
and immediately placed in dry ice Faeces were 
collected in plastic containers with HgCl2 and, 
after thorough shaking, also placed in dry ice 
Both unne and faeces were stored at -20oC until 
analysis These measures were taken to prevent 
(so far as possible) further acetylation and break­
down of 5-ASA and intact parent molecules by 
bactenal enzymes (23) 
Analysis for 5-ASA, ac-5-ASA, SASP, and 
ADS was done with a sensitive and specific high-
performance bquid chromatography (HPLC) 
method combined with fluorescence spectro­
photometry, as desenbed elsewhere (23) 
The two-sided Wilcoxon test was used in com-
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Fig. 1. Cumulative excretion of 5-ASA (acetylated + unacetylated) in urine after 
ingestion of a 5-ASA-delivenng drug, expressed as a percentage of the dose 
ingested. Azo compounds (SASP and ADS) and slow-release compounds are 
represented as groups. Bars represent means ± SEM of eight healthy volunteers. 
paring the results. Ρ values of <0.05 were con­
sidered to be significant. 
RESULTS 
Fig. 1 shows the cumulative excretion of total 
5-ASA (5-ASA plus ac-5-ASA) in urine, ex­
pressed as a percentage of the dose ingested. In 
this figure azo compounds (SASP and ADS) and 
slow-release compounds are presented as groups. 
Plain 5-ASA is excreted very rapidly. After 4 h 
58.9% is found in the urine, after 2 4 h 90.0%, 
and after 96 h 91.5%. After ingestion of both azo 
compounds and slow-release compounds, urinary 
excretion of 5-ASA is markedly delayed and 
reduced. After 8 h only 2.6% of the 5-ASA 
administered is recovered in the urine after inges­
tion of the azo compounds, and 7.3% after inges­
tion of slow-release tablets. After 24 h the 
percentages are 16.5 and 23.6, and at % h 24.2 
and 32.0%, respectively. At all points of time the 
difference in excretion between the two groups 
was significant. 
Fig. 2 shows the cumulative urinary excretion 
after 8, 24, and 96 h for all the drugs separately. 
No significant differences within one group were 
present. The faecal excretion of 5-ASA and ac-5-
A S A after ingestion of the test drugs is shown in 
Table 11. 
The faecal recovery of 5-ASA from azo com­
pounds was significantly higher than that from 
slow-release compounds (p < 0.05). Again, no 
significant differences within one group were 
found. The faecal excretion of the intact parent 
molecule was 6.4 ± 1.8% after ingestion of SASP 
and 4.1 ± 1.1% after ingestion of A D S . 
The total recovery rate of 5-ASA from the azo 
compounds and slow-release compounds ranged 
from 71.5% (Salofalk) to 81.8% (SASP). 
DISCUSSION 
The therapeutic effect of 5-ASA is probably 
related to its local concentration in the bowel 
lumen and not to serum levels, which are always 
very low owing to the very rapid excretion of 5-
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Table II Faecal excretion of 5 ASA and acetyl 5-ASA in 96 h after ingestion of 5-ASA delivenng drugs by eight 
healthy volunteers, expressed as a percentage (mean ± SEM) of the dose ingested 
SASP 
ADS 
Pentasa· 
Asacol· 
Salofalk· 
Plain-5 ASA 
Mean of azo 
compounds 
Mean of slow-
release compounds 
5-ASA 
12 8 ± 2 2 
8 2 ± 1 3 
9 0 + 1 5 
7 0 ± 1 4 
5 2 + 1 3 
Ol + O h 
10 5 ± 1 ς 
NS 
7 1 + 0 9 -
Acetyl 5-ASA 
45 4 ± 3 4 
39 1 ± 3 4 
38 4 ± 2 4 
33 2 + 2 3 
32 1 + 4 2 
15 7 ± 2 1η 
42 3 ± 2 T. 
* 
346 + 21-
Total 5-ASA 
58 3 ± 4 8 
47 4 £ 3 5 
47 3 i 2 5 
402 + 2 0 
37 3 ± 4 4 
15 8 ± 2 Г 
52 8 ± 3 5: 
* 
41 7 + 2 0-
Intact parent 
molecule 
6 6 ± 1 8 
4 1 + 11 
' P < 0 0 5 
" Ж 0 0 1 
inside the bowel could of course not be prevented 
Recently, Myers et al (25) published the results 
of a study in which they measured time-related 
unnary excretion after ingestion of 500 mg plain 
5-ASA and 2 4 g 5-ASA coated with Endragit-S 
(equivalent to the Asacol used in this study) The 
proportional unnary excretion of total 5-ASA 
after 4 h was closely comparable with our results, 
for plain 5-ASA, 48 2% (58 6% m our study), 
and for Asacol, 0% (0% in our study) 
They found a total unnary recovery from plain 
5-ASA of 78% and from Asacol of 21%, these 
are somewhat smaller percentages than we found 
m this study This may be partly due to a different 
method of analysis Unfortunately, they did not 
measure faecal excretion of 5-ASA Although it 
seems justified to favour azo compounds in the 
treatment of distal inflammatory bowel disease 
on the basis of the results of our study, some 
precautions should be taken 
In this study the total amount of 5-ASA admin­
istered was not exactly the same for all the drugs 
as a result of the different 5-ASA content of some 
of the tablets Giving equal amounts would mean 
that some tablets would have to be broken, thus 
destroying the slow-release mechanism It seems 
unlikely, however, that the small differences in 5-
ASA content have influenced the outcome of this 
study 
The study was performed m healthy volun­
teers who had a normal intestinal transit time 
In this respect they resemble patients with quies­
cent inflammatory bowel disease In active 
inflammatory bowel disease transit time is often 
accelerated This may have an unfavourable effect 
on the release of 5-ASA from the 5-ASA-de-
Uvenng drugs The release from slow-release tab­
lets takes place more distally m the bowel, and 
when transit time is very fast, the tablet could be 
excreted more or less intact We do not know 
whether this applies equally to each of these slow-
release drugs The start of the release of 5-ASA 
from azo compounds does not depend on the time 
since ingestion but on the presence of intestinal 
bactena The release of 5-ASA from azo com­
pounds starts in the distal small bowel and colon 
or in more proximal bowel loops when bacterial 
overgrowth is present, which might be the case 
in small-bowel segments affected with Crohn's 
disease (26) This might explain the beneficial 
effect of SASP in small-bowel Crohn's disease 
reported m one study (6) On the other hand, 
splitting of azo compounds will be less complete 
when intestinal transit time is accelerated, also 
resulting in impaired delivery of 5-ASA to the 
colon (27) 
Another difference between healthy persons 
and patients is the reduced capacity of the 
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inflamed colon mucosa to absorb 5-ASA (28) 
This results in a higher luminal 5-ASA con­
centration after ingestion of both slow-release and 
azo compounds 
Firm conclusions can therefore only be drawn 
when the comparison made in this study has also 
been made in patients with inflammatory bowel 
disease with increased transit time For the time 
being, we think that azo compounds are the most 
appropriate for distally localized inflammatory 
bowel disease Being much cheaper than all other 
5-ASA-delivenng drugs, salazosulphapyndine 
should be the first choice When salazosulpha-
pynne is not tolerated well, treatment with 
olsalazine should be considered 
This study shows once again that plain S-ASA 
is rapidly absorbed and excreted into unne It is 
not appropnate for the treatment of distal 
inflammatory bowel disease It may be suitable 
for Crohn's disease located in the stomach, duo­
denum, and jejunum 
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CHAPTER 5.2 
ADDENDUM TO CHAPTER 5.1 

Only after the publication of the paper presented in chapter 5 it was fully 
appreciated that considerable differences exist in disposition of the individual 5-
ASA delivering drugs, and that the results of the two azo compounds on the one 
side and of the slow-release compounds on the other cannot be simply lumped 
together. It is therefore considered appropriate to re-evaluate the data of the 
drugs separately and to subject them to additional statistical analysis. 
The urinary excretion of (acetyl)-5-ASA after eight hours, representing the early 
release of 5-ASA from the drugs, is shown on the left side of Figure 2. The 
figures for SalazopyrinR and DipentumR were significantly lower than for PentasaR 
and SalofalkR. The early release from AsacolR was intermediate, not differing 
significantly from any other drug. 
The total urinary excretion of (acetyl)-5-ASA after 96 hours is shown on the 
right side of Figure 2. At this point of time the figures for SalazopyrinR and 
DipentumR were still significantly lower than for SalofalkR, and moreover, the 
excretion from SalazopyrinR was significantly lower than from AsacolR. 
The proportions of 5-ASA, acetyl-5-ASA and unsplit parent molecule excreted in 
faeces are shown in Table 2. 
None of the differences in faecally excreted 5-ASA was significant. As for the 
faecal excretion of acetyl-5-ASA, only the differences between SalazopyrinR and 
SalofalkR and between SalazopyrinR and AsacolR were significant. 
The consideration of the individual drugs instead of azo and slow-release groups 
does not substantially alter the conclusions with regard to the early release in the 
first eight hours after ingestion. Eight hours represents quite well the transit 
through stomach and small bowel, as the median gastric emptying time in fasting 
subjects is aprroximately one hour, and the median small bowel transit time is 
four to eight hours (1,2). Both azo-compounds release significantly less 5-ASA at 
an early stage than the slow-release drugs PentasaR and SalofalkR. AsacolR takes 
an intermediate position. These results indicate that PentasaR and SalofalkR are 
probably more fit for the treatment of small bowel locations of Crohn's disease, 
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and that more 5-ASA is saved for the colon when given in the form of 
Salazopyrin" and DipentumR, and, to a lesser extent, AsacolR. That the azo-
compounds do not release 5-ASA too late can be derived from the high 
proportion of acetyl-5-ASA in the faeces, for SalazopyrinR even significantly higher 
than for AsacolR and SalofalkR. The proportion of unacetylated 5-ASA the 
therapeutically active substance (3), recovered in faeces is low for all drugs, the 
least low for SalazopyrinR. 
It is concluded that in healthy volunteers without diarrhoea, early release of 5-
ASA is largest after intake of Pentasa" and SalofalkR, and least after intake of 
SalazopyrinR and DipentumR. The latter two compounds have a disposition profile 
that is the most in agreement with good availability to the colon. It should be 
emphasised that for all drugs the ratio of acetyl-5-ASA to 5-ASA in faeces is high 
to such an extent, that the bulk of 5-ASA must have been released at con-
siderable time before defaecation, and only little unreleased or unacetylated 5-
ASA can have reached the rectum. This contrasts with the situation with an 
accelerated intestinal transit, either artificially generated, or present in patients 
with active disease, as will be pointed out in the chapters 6 and 7. 
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CHAPTER 6 
DISPOSITION OF 5-AMINOSALICYLIC ACID BY 5-AMINOSALICYLIC ACID 
DELIVERING DRUGS DURING ACCELERATED INTESTINAL 
TRANSIT IN HEALTHY VOLUNTEERS 
Scandinavian Journal of Gastroenterology 1989; 24: 1179-1185 

Disposition of 5-Aminosalicylic Acid from 
5-Aminosalicylic Acid-Delivering Drugs during 
Accelerated Intestinal Transit in Healthy Volunteers 
M. С M. RIJK, R A. VAN HOGEZAND, A. VAN SCHAIK & J. Η. M. 
VAN TONGEREN 
Dept. of Gastrointestinal and Liver Diseases. University Hospital Nijmegen. 
Nijmegen, The Netherlands 
Rijk MCM, van Hogezand RA. van Schaik A. van Tongeren JHM Disposition of 
5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs dunng accelerated 
intestinal transit in healthy volunteers. Scand J Gastroenterol 1989. 24. 1179-1185 
In eight healthy volunteers accelerated intestinal transit time was induced with 
bisacodyl, and urinary and faecal excretion of sulphasalazine. olsalazine. 5-amino-
salicylic acid Í5-ASA). and acetyl-5-ASA was studied after a single oral dose of 
3.3 mmol sulphasalazine. olsalazine, Pentasa*. and Salofalk* and 2 6 mmol of Asa-
col* The faecal and unnary excretion of aceiyl-5-ASA was lowest after intake of 
sulphasalazine and olsalazine and highes' after intake of Pentasa and Salofalk. The 
figures for Asacol were intermediate. This indicates insufficient release of 5-ASA 
from sulphasalazine and olsalazine When the results of this study are compared with 
those of a previous study without accelerated transit time, the disposition of 5-ASA 
from all the 5-ASA-delivering drugs is influenced unfavourably by an accelerated gut 
transit but most pronounced in the case of sulphasalazine. olsalazine. and Asacol 
The impaired release from the azo compounds sulphasalazine and olsalazine is a 
result of far less complete splitting of the diazo bond. 
Key words 5-Aminosalicylic acid; azodisal sodium (olsalazine); metabolism, sali-
cylazosulphapyndme 
MCM. Rijk, M D , Dept. of Gastrointestinal and Lwer Diseases. University 
Hospital Ni/megen, Ρ О Boi 9101, 6500 HB Ni/megen, The Netherlands 
In recent years several sulphapyridine-free, 5-
aminosalicylic acid (5-ASA)-containing alterna­
tives for sulphasalazine have been developed for 
the treatment of patients with inflammatory bowel 
disease. In olsalazine (Dipentum®) two 5-ASA 
molecules are linked together via an azo bond, 
which is split by intestinal bacteria, resulting in 
the delivery of only 5-ASA to the bowel and no 
superfluous substances (1, 2). 5-ASA can also be 
packed in a slow-release tablet that delivers 5-
ASA gradually after dwelling a certain time in an 
environment with a pH above 5.5 or 6.5 Penta­
s a · , Asacol®, and Salofalk® are such presently 
available slow-release formulations (3-5). 
Orally administered 5-ASA should not be 
released too early or too late, because in both 
instances insufficient concentrations and exposure 
times will be accomplished in the distal small 
bowel and in the colon. The time-related unnary 
excretion of 5-ASA and the amount of acetylated 
5-ASA in the faeces can serve as indicators of 
proper delivery. When 5-ASA is released too 
early, it is rapidly absorbed and excreted into the 
urine, resulting in a high urinary output of 5-ASA 
shortly after intake. When it is released too late, 
very little is absorbed, and the total unnary 
excretion is low. The longer 5-ASA resides in the 
bowel lumen, the more of it is acetylated So a 
considerable proportion of acetylated 5-ASA in 
the faeces indicates that release has not taken 
place too late. Thus, after ingestion of the 'ideal' 
5-ASA-containmg tablet little 5-ASA will be 
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excreted into the urine in the first hours after 
ingestion, and a considerable proportion of 5-
ASA in the faeces will be acetylated 
On the basis of these assumptions we compared 
in a previous study sulphasalazine, olsalazine, 
Pentasa, Asacol. and Salofalk in healthy vol­
unteers with normal intestinal transit (6) After 
ingestion of sulphasalazine and olsalazine the 
early urinary recovery was significantly less, and 
the proportion of acetylated 5-ASA in the faeces 
greater than after ingestion of the slow-release 
tablets, indicating that azo compounds are pref­
erable to slow-release tablets It may be assumed, 
however, that some patients with inflammatory 
bowel disease ha\e an accelerated intestinal tran­
sit, which influences the disposition of 5-ASA 
We therefore investigated the disposition of 5-
ASA from the above-mentioned 5-ASA-deli-
venng drugs in healthy volunteers with accel­
erated intestinal transit, induced by bisacodyl 
The results obtained per drug during accelerated 
transit were compared, and, moreover, the re­
sults from this study were compared with those 
from the previous study in volunteers, who were 
all different individuals, with normal intestinal 
transit 
MATERIALS AND METHODS 
The study protocol was approved by the ethics 
committee of the University Hospital Nijmegen. 
and the study was performed in accordance with 
the Declaration of Helsinki 
Eight healthy volunteers (three men and five 
women, aged 20 to 62 (median 27) years) without 
a history of gastrointestinal complaints par­
ticipated in the study after having given their 
written informed consent 
Diarrhoea was induced with bisacodyl in a dose 
of S to 10 mg three times daily Bisacodyl was 
started on the evening before intake of the study 
drug and maintained during the period that urine 
and faeces were collected The participants were 
instructed to adjust the dose in such a manner 
that a stool frequency between four and eight 
times per day was established On the 1st day of 
each investigation period a single dose of one 
of the study drugs was taken by mouth during 
breakfast together with 20 radiopaque rings The 
dosages of the study drugs were chosen to contain 
approximately equal amounts of 5-ASA (Table 
I) Urine was collected ever\ 2 h during the first 
8 h and thereafter in a 4-h portion, and the sixth 
portion covered the last 12 h of the first dav On 
the 2nd and 3rd day urine was collected per 24 h 
Each unne portion was placed on dr> ice immedi­
ately after voiding and later stored at -203C until 
analysis Faeces were collected in containers with 
1% HgCli and. after thorough shaking also 
immediately placed on dry ice and later stored at 
-20oC These measures were taken to pre\ent 
further acetvlation and breakdown of 5-ASA 
The time of each defaecation was noted 
Faeces were radiographed for the presence of 
the radiopaque rings Intestinal transit time was 
defined in accordance with Hmton et al (7) as 
the time at which 80% of the ingested rings were 
recovered in the faeces Transit time was 
measured during administration of each of the 5-
ASA-contammg drugs, together with Bisacodvl 
and also on one separate occasion without 
administration of bisacodyl Urine and faeces 
were analysed for 5-ASA. acet\l-5-ASA and in 
the case of sulphasalazine and olsalazine for the 
intact parent molecule with a sensim e and specific 
high-performance liquid chromatograph\ 
method, combined with fluorescence spectro­
photometry (8) 
In the previous study with normal transit time 
eight healthy volunteers, all different from the 
subjects in the present study, took part (6) They 
had all normal bowel habits, with a defaecation 
frequency of once or twice a da) Six were male, 
Table I Dose and 5-ASA content of the administered 
drugs 
Accelerated Normal transit 
transit time time 
Sulphasalazine 
Olsalazine 
Pentasa· 
Asacol* 
Salofalk· 
Dose 
(mg) 
1290 
560 
500 
400 
500 
5-ASA 
(μπιοΙ) 
3234 
3237 
3268 
2614 
3268 
Dose 
(mg) 
1500 
500 
500 
400 
500 
5-ASA 
(μπιοΙ) 
3760 
2890 
3268 
2614 
326S 
96 
Table II Intestinal transit times defined as the time at 
which 80% of ingested radiopaque markers are 
recovered in faeces during simultaneous intake of 5-
ASA delivering drugs and bisacodyl and under basal 
conditions without intake of bisacodyl (mean ± SD) 
Transit time 
(h) 
Bisacodyl together with 
Sulphasalazine 
Olsalazine 
Pentasa® 
Asacol® 
Salofalk» 
Without intake of bisacodvl 
21 6 ± 14 2 
20 2 ± 19 5 
1 7 2 i 7 9 
24 8 ± 15 4 
14 2 ± 6 5 
53 2 ± 13 8 
two female, and their age ranged from 20 to 38 
(median. 34) years Sex distribution (chi-square 
test) and age (rank sum two-sample test) did not 
differ significantly from those of the present study 
The protocol of the previous study was identical 
to that of the present study, except for the intake 
of bisacodyl, small differences in 5-ASA content 
of the study drugs, and the duration of the col­
lection period of urine and faeces The dosages 
used in the previous study are listed in Table I 
The collecting period in the previous study was 
96 h instead of 72 h However, data on urinary 
recovery after 72 h are available, and these figures 
are used for comparison with the present study 
Faeces of 96 h were mixed together, so no data on 
faecal recovery after 72 h during normal intestinal 
transit are available 
Data obtained during accelerated intestinal 
transit were compared by means of the two-tailed 
Wilcoxon test for paired observations Results 
during accelerated intestinal transit time were 
compared with results during normal intestinal 
transit by the rank sum two-sample test, which 
enables companson of unpaired observations Ρ 
values less than 0 05 were considered significant 
RESULTS 
Without bisacodyl the intestinal transit time in 
the group of volunteers also studied during intake 
of bisacodyl was 53 2 ± 13 8 h (mean * SD) The 
transit times during intake of bisacodyl are pre­
sented in Table II None of the differences in 
accelerated transit times were significant 
The amounts of 5-ASA, acetyl-5-ASA, and 
parent molecule recovered in urine and faeces 
and expressed as percentage of the ingested dose 
are presented in Table HI The 5-ASA recovered 
in urine is almost exclusively in the acetylated 
form The earlv unnary excretion of 5-ASA 
(excretion within the first 8 h) was 1 1 ± 0 4 % 
for sulphasalazine, 0 9 ± 0 4 for olsalazine, 
10 0 ± 1 7% for Pentasa. 1 2 ± 0 7 for Asacol, 
and 10 6 ± 3 37c for Salofalk It is clear that the 
early excretion of 5-ASA in urine is very small. 
indicating that no drug released too much 5-ASA 
at an early stage 
After 72 h significantly less 5-ASA in unne was 
recovered from sulphasalazine and olsalazine as 
compared with Pentasa and Salofalk The dif­
ference between Pentasa and Salofalk was also 
significant in this respect The urinary excretion 
after intake of Asacol was intermediate and did 
not differ significantly from any of the other drugs 
The urinary excretion of unspht parent azo mol­
ecules was very small 22 ±0 8% for sulpha-
Table III Urinary and faecal excretion of 5-ASA, acetyl-5-ASA and parent molecules in 72 h after ingestion of 
5-ASA-delivering drugs by eight healthy volunteers with drug-induced diarrhoea Figures are percentages of the 
ingested dose (mean ± SEM) 
Unne Faeces 
(Ac-)5-ASA Ac-5-ASA 5-ASA Parent molecule 
Sulphasalazine 
Olsalazine 
Pentasa® 
Asacol® 
Salofalk® 
4 5 ± 1 5 
4 9 ± 1 5 
14 5 ± 2 5 
10 1 ± 4 1 
26 7 ± 4 9 
6 6 ± 2 1 
8 4 ± 2 7 
21 2 ± 3 4 
9 5 ± 4 3 
18 6 ± 6 0 
15 9 ± 3 4 
17 6 ± 4 8 
30 4 ± 7 6 
38 6 ± 8 5 
22 3 ± 5 9 
41 5 ± 6 5 
52 2 ±11 5 
97 
salazine and 0.5 ± 0 1% for olsalazine (mean 
s SEM). 
The amount of acetylated 5-ASA in the faeces. 
to be regarded as an indicator of the release of 5-
ASA in proper time, was significantly smaller 
after intake of sulphasalazme and olsalazine, on 
the one hand, and Pentasa, on the other The 
difference between olsalazine and Salofalk was 
also significant, and the difference between sul-
phasalazinc and Salofalk was nearly significant 
(p = 0.06). From Table III it is apparent that a 
large proportion of the parent molecules sul-
phasalazine and olsalazine is excreted unsplit in 
the faeces. The total recovery of ingested 5-ASA 
was 70.6 ± 4.0% for sulphasalazme (mean ± 
SEM), 83.6 ± 5.3% for olsalazine. 66 1 ± 5.3% 
for Pentasa. 58.1 ± 7.6% for Asacol, and 67.6 ± 
4.8% for Salofalk. 
When the results of the present study are com-
pared with those from the previous study, in 
which the intestinal transit time was not accel-
erated, it i< clear that shortening of the transit 
time results in a marked reduction of the unnary 
5-ASA excretion and of the amount of acetylated 
5-ASA in the faeces (Table IV and Figs. 1 and 
2). This applies to all the drugs investigated, and 
the results for normal and accelerated intestinal 
transit are significant except for Salofalk. 
Shortening of the intestinal transit time also 
results in a significant increase of unsplit sul-
phasalazme and olsalazine. 
DISCUSSION 
The present study shows that acceleration of the 
intestinal transit causes an impairment of the de-
livery of 5-ASA from all investigated 5-ASA-
containing drugs. The impairment is most pro-
nounced for sulphasalazme. olsalazine. and 
Asacol. The impaired delivery of 5-ASA from 
the azo drugs is obviously the result of far less 
complete splitting of these drugs. During accel-
erated intestinal transit there is probably not 
enough time for intestinal bacteria to split the 
diazo bond. The azo reduction is not directly 
influenced by bisacodyl (9). The modes of action 
of bisacodyl include stimulation of peristaltic con-
tractions. stimulation of mucus production, and 
conversion of net water and sodium absorption 
into secretion. It is not known to what extent each 
of these mechanisms contributes to its effect, but 
it is certain that the end result is reduction of the 
intestinal transit time, which is the condition that 
we wanted to investigate in this study. 
It might be disputed whether it is permissible 
to compare the data of the present study with data 
from the previous study with normal intestinal 
transit, in volunteers who were all different from 
those in the present study. The subjects were not, 
however, significantly different with regard to 
age and sex distribution. Some minor inter-study 
differences in dosages of study drugs existed, as 
did minor intra-study differences in 5-ASA con-
tent of the drugs, inherent in the various amounts 
of 5-ASA packed in one tablet. This problem can 
be solved by comparing the proportions of the 
ingested 5-ASA recovered in faeces and urine, 
instead of using absolute figures. Seventy-two-
hour faecal excretion of (ac-)5-ASA during accel-
erated transit is compared with 96-h excretion 
during normal transit. The urinary excretion of 
ac-5-ASA from 72 to 96 h during normal intestinal 
Table IV. Urinary excretion of (ac-)5-ASA m 72 h and faecal excretion of 5-ASA. acetyl-5-ASA. and parent 
molecules in 96 h after ingestion of 5-ASA-delivenng drugs by eight healthy volunteers, all different from the 
subjects mentioned in Table HI. with normal intestinal transit time Figures are perceniages of the ¡neesied dose 
(mean ± SEM) 
Sulphasalazinc 
Olsalazine 
Pentasa* 
Asacol* 
Salofalk* 
Urine 
(Ac-)5-ASA 
23.3 ± 2 1 
24 5 ± 2 5 
28.0 ± 3.2 
31 1±2 .8 
36.1 ± 2 5 
Ac-5-ASA 
45 4 ± 3.4 
39 1 ± 3.4 
38 4 ± 2.4 
33 2 ± 2.3 
32 1 ± 4 2 
Faeces 
5-ASA 
12 8 ± 2 2 
8.2 ± 1 3 
9.0 ±1.5 
7 0 ± 1 . 4 
5 .2* 1.3 
Parent molecule 
6 6 ± 18 
4.1 ±1.1 
98 
% of ingested dose (mean + SEM) 
SALAZOPYRINE DIPENTUM 
I NORMAL TRANSIT I ACCELERATED TRANSIT 
Fig 1 Unnary excretion of (ücetyl-)5-ASA in 72 h after ingestion of a single dose 
of 5-ASA delivering drugs by eight healthy volunteers during accelerated intestinal 
transit time and eight different healthy volunteers during normal intestinal transit 
time Bars represent means ± SEM 
transit, however was very low, indicating that ferences existed in the gut transit times during 
only negligible amounts of 5 ASA could have administration of the various drugs A short tran-
remained in the bowel at that time sit time could indicate a disadvantage, but the 
Although not statistically significant some dif- shortest transit times (Pentasa and Salofalk) were 
% of ingested dose (mean * SEM) 
SALAZOPYRINE DIPENTUM PENTASA 
I NORMAL TRANSIT 
І ACCELERATED TRANSIT 
Fig 2 Faecal excretion of acetyl-5-ASA in 72 h after ingestion of a single dose 
of 5-ASA-delivenng drugs by eight healthy volunteers during accelerated intestinal 
transit time and faecal excretion in 96 h in eight different healthy volunteers during 
normal intestinal transit time Bars represent means ± SEM 
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associated with the most favourable disposition, 
which perhaps even blunted the real difference. 
The results are in accordance with two other 
studies on the influence of transit time on 5-ASA 
disposition. In a study by Van Hees et al. (9) 
the disposition of sulphasalazine was investigated 
under conditions of normal and accelerated intes­
tinal transit time during maintenance treatment. 
The proportion of unsplit sulphasalazine in faeces 
increased from 0 5% to 45.4%, the proportion of 
5-ASA excreted in urine decreased from 18.5% 
to 5.9%, and the proportion of total 5-ASA in 
faeces decreased from 74.5% to 45.5%. Unfor­
tunately, figures for acetylated and unacetylated 
5-ASA were not mentioned separately. Chns-
tensen et al. (10) studied the disposition of Pen-
tasa and found that a fivefold speeding up of the 
gut transit resulted in a decrease of the proportion 
of urinary excreted 5-ASA from 3 4 % to 2 3 % and 
a decrease of faecal acetyl-5-ASA from 3 8 % to 
3 0 % . 
The cruciar question is to which patients the 
results of the present study are applicable. Not 
every patient with active inflammatory bowel 
disease has clearly accelerated intestinal transit 
In a study of patients with ulcerative colitis Rao 
et al. (11) did not And an accelerated intestinal 
transit but rather proximal colonic stasis. Fre­
quent stools were not attributable to rapid bowel 
transit but to mucus secretion and impaired com­
pliance of the rectum. Other authors, however. 
found no evidence of colonic stasis in patients with 
active ulcerative colitis and even demonstrated a 
shortened transit time (12). The observation that 
serum sulphapyridine levels during sulphasalazine 
therapy are lower in the active phase of inflam­
matory bowel disease than in the quiescent phase 
supports the assumption that splitting of sulpha­
salazine is impaired during active disease, most 
likely due to accelerated intestinal transit (9). 
The shortening of transit time induced with 
bisacodyl was considerable in this study: from a 
mean of 53.2 h to a mean of 19.6 h Probably few 
patients will have such a short transit time, but it 
is conceivable that the same trends in 5-ASA 
disposition will be found at less accelerated transit 
times, albeit less pronounced. 
The total recovery of ingested 5-ASA did not 
reach 100% for any of the study drugs. This 
problem is encountered in all studies dealing with 
disposition of 5-ASA-delivering compounds and 
is probably caused by breakdown of 5-ASA and 
100 
acetyl-5-ASA to unknown substances, which are 
not detected with the presently applied method 
of analysis. 
We conclude that during accelerated intestinal 
transit the disposition of 5-ASA from Salofalk 
and Pentasa is more favourable than that from 
sulphasalazine and olsalazine, with Asacol in an 
intermediate position. As compared with normal 
intestinal transit, the disposition of all 5-ASA-
delivenng drugs is impaired, especially from the 
azo compounds. Salofalk and Pentasa are there­
fore to be preferred when intestinal transit is 
clearly accelerated. 
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SUMMARY 
The disposition of 5-aminosalicylic acid (5-ASA; mesalazine) from the azo-
compounds sulphasalazine and olsalazine (DipentumR), and from the slow-release 
mesalazine drugs PentasaR, AsacolR and SalofalkR, was studied in 20 patients with 
inflammatory bowel disease. Ten of them had diarrhoea and 10 had normal 
stools. On the last two days of a seven-day maintenance treatment with each of 
the study drugs urine and faeces were collected for determination of 5-ASA, 
acetyl-5-ASA and unsplit azo-compound. A large proportion of acetyl-5-ASA in 
urine, and especially in faeces, was considered an indicator of timely release of 5-
ASA in the bowel. The median intestinal transit time was 20.6 hours in patients 
with diarrhoea and 39.1 hours in patients without diarrhoea. In patients with and 
without diarrhoea the urinary and the faecal excretion of acetyl-5-ASA was lowest 
during treatment with olsalazine. The proportion of acetyl-5-ASA in faeces was 
highest during treatment with Pentasa" in both groups. The presence of diarrhoea 
was associated with a decrease of the proportion of acetyl-5-ASA in faeces during 
treatment with all drugs, not significant only for PentasaR. The proportion of 
unsplit azo-compound in faeces increased in case of diarrhoea to almost 50%. 
It is concluded that in patients with inflammatory bowel disease diarrhoea 
substantially influences the disposition from all these drugs, except PentasaR. 
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INTRODUCTION 
Sulphapyridine-free alternatives for sulphasalazine are now widely used in the 
treatment of patients with inflammatory bowel disease. 
PentasaR, AsacolR and Salofalk" contain mesalazine (5-aminosalicylic acid, 5-ASA) 
in a sustained release or slow-release formulation, and DipentumR contains 
olsalazine, consisting of two 5-ASA molecules linked together by an azo bond. 
The slow-release formulations are necessary to prevent premature absorption of 
5-ASA in the proximal part of the small intestine, resulting in insufficient 
availability of 5-ASA in the more distal parts, where the inflammation is often the 
most severe. Intact olsalazine is hardly absorbed in the small bowel (1), but the 
azo bond is split by intestinal bacteria in the terminal ileum and colon, resulting 
in the release of 5-ASA at these sites. 
The disposition of 5-ASA delivering drugs has been studied and compared rather 
extensively in healthy volunteers (2-6), sometimes after induction of diarrhoea (7-
9), far less often however in patients with inflammatory bowel disease (IBD) 
(10,11). It has been demonstrated in healthy volunteers that the disposition is 
markedly influenced by a change in intestinal transit time (7-9). 
When 5-ASA is released in 
Table 1 Clinical characteristics of patients m the two groups 1 ^ ε c o l o n ^ ¡s Subject to 
acetylation, partly by 
no diarrhoea diarrhoea 
, _
 10. intestinal bacteria (12), partly 
by the intestinal mucosa (13). 
33 (23-67) The proportion of acetylated 
5-ASA in the faeces is 
6 :4 
therefore an indicator of the 
9 availability of 5-ASA to the 
3 (3) distal intestine. When 5-ASA 
3
 is released too late, or not at 
all, little or no acetyl-5-ASA 
1 
is found in faeces. When it is 
median age (range) 
male : female 
Crohn's disease 
ileitis (resected) 
ileocolitis 
colitis 
Ulcerative colitis 
37.5 (28-75) 
6 : 4 
6 
4(3) 
1 
1 
4 
105 
released too early in the proximal small intestine, it is rapidly absorbed, acetylated 
and excreted into the urine, resulting in a large amount of acetyl-5-ASA in urine 
and little (acetyl)-5-ASA recovered in faeces (6,14,15). 
Starting from these principles, the disposition of 5-ASA from 5-ASA delivering 
drugs was compared in ten patients with IBD and a normal stool frequency, and 
in ten different patients with IBD and diarrhoea. 
PATIENTS AND METHODS 
Twenty patients with inflammatory bowel disease agreed to take part in the study 
and gave their informed consent in accordance with the Declaration of Helsinki. 
Ten patients reported three or less bowel motions per day and are referred to as 
patients without diarrhoea. The ten patients who reported four or more bowel 
motions per day were called patients with diarrhoea. The main characteristics of 
both patient groups are listed in Table 1. All patients without diarrhoea had 
clinically quiescent disease, characterized by a normal ESR and serum albumin 
levels and the absence of blood in the stools. Of the patients with diarrhoea the 
patient with ulcerative colitis had moderately severe disease according to the 
criteria of Truelove and Witts (16). The nine patients with Crohn's disease had 
quiescent or at most moderately severe disease with a Van Hees Activity index 
(17) at most 167 (values of less than 100 denote quiescent disease, of 100 to 150 
indicate mild disease, of 150 to 210 indicate moderately severe disease, and of 
more than 210 indicate very severe disease). In two of them the diarrhoea was 
attributed mainly to bile acid overflow after ileocoecal resection. All patients were 
treated on an out-patient basis. 
Before the start of the study, all patients were treated with sulphasalazine or 
another 5-ASA containing drug. At entry, the pre-study drug was withdrawn and 
medication according to the study protocol was immediately started. None of the 
patients received corticosteroids or intrarectal medication. 
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Study protocol 
During five consecutive weeks the patients received a daily dose of 3000 mg of 
sulphasalazine (Salazopyrin"), 1500 mg of olsalazine (DipentumR), 1500 mg of 
PentasaR, 1200 mg of AsacolR and 1500 mg of SalofalkR, divided in three gifts, 
each during one week, in a random order. In the mornings of the last three days 
of each week a capsule with 20 radio-opaque rings, of a different size for each 
day, was taken by mouth. On the last two days of each week urine and faeces 
were collected. 
Processing of urine and stool specimens 
Urine was collected in plastic containers and immediately after voiding placed on 
dry ice. Stools were collected separately in plastic containers with HgClj 1% to 
prevent further breakdown and acetylation of 5-ASA (18), and after thorough 
shaking also immediately placed on dry ice. The time of each defaecation was 
noted. Urine and faeces were later stored at -20oC until analysis. After 
radiographing of the separate stools, faeces of each 48-hour collection period 
were pooled and subsequently thoroughly homogenized and mixed. Samples were 
taken for duplicate analysis. Urine and stool specimens were analyzed for 5-ASA, 
acetylated 5-ASA and unsplit SASP and olsalazine by means of HPLC, combined 
with fluorescence spectrophotometry (18). The values obtained were divided by 
two to obtain the amounts excreted per 24 hours. 
Calculation of the intestinal transit time 
All stool specimens were radiographed separately to determine the number and 
size of the radio-opaque rings. Initially it was intended to calculate the intestinal 
transit time (111) according to the single stool method of Cummings (19). This 
requires the presence of at least two different forms of radio-opaque rings in one 
stool. Especially when the ITT was short, this condition was often not met. 
Therefore the ITT was considered to be the time at which 80% of one of the 
forms of rings was recovered, as proposed by Hinton (20). In some instances the 
ITT could be determined both according to Cummings and to Hinton. From these 
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cases a regression equation was calculated, allowing for transformation of the ITT 
according to Cummings to an ITT according to Hinton on those occasions where 
only the 111' according to Cummings was available. 
Statistical analysis 
The daily amounts of excreted 5-ASA, acetyl-5-ASA and unsplit parent drug were 
obtained by dividing the amounts, excreted in 48 hours, by two, and expressed as 
proportions of the daily ingested dose. The urinary excretions of acetylated 5-
ASA, unacetylated 5-ASA and unsplit parent molecule are not mentioned 
separately, as the last two constitute only a very small part of 5-ASA excreted in 
urine (less than 2%). Therefore only the total amount of urinary excretion of 5-
ASA is presented, and referred to as acetyl-5-ASA. Data within one group of 
patients (with normal stools or diarrhoea) were tested with the Wilcoxon's signed 
rank test, and comparisons between the two groups were tested with the rank 
sum test. For correlations Spearman's rank correlation was used. Only two-sided 
results were used. P-values of 0.05 or less were considered significant. 
RESULTS 
The disposition of 5-ASA from the 5-ASA delivering drugs in patients without 
diarrhoea is shown in Figures 1 (daily urinary excretion) and 2 (daily faecal 
excretion). The urinary disposition of 5-ASA from olsalazine was significantly 
lower than that from SASP, Pentasa" and SalofalkR, and the urinary excretion of 
acetyl-5-ASA from SalofalkR was significantly higher than that from olsalazine, 
AsacolR and PentasaR. The faecal excretion of acetylated 5-ASA from olsalazine 
and AsacolR was significantly lower than that from SalofalkR and PentasaR. The 
faecal excretion of unacetylated 5-ASA was highest after ingestion of AsacolR. A 
significantly larger part of olsalazine was recovered unsplit in faeces, as compared 
with SASP. 
The results from the group of patients with diarrhoea are presented in Figures 
3 and 4. In this group of patients the urinary excretion of acetyl-5-ASA from 
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olsalazine was significantly lower than that from all other drugs. The faecal 
excretion of acetyl-5-ASA was significantly higher during treatment with PentasaR 
than during treatment with all other drugs, while the faecal excretion of acetyl-5-
ASA from olsalazine was significantly lower than that from all other drugs, except 
AsacolR. 
In Table 2 the data from the two groups of patients are compared. In patients 
with diarrhoea the proportion of unsplit SASP and olsalazine in faeces was 
significantly higher, and the urinary excretion of acetyl-5-ASA from SASP and 
olsalazine was significantly less than in patients without diarrhoea. The faecal 
excretion of acetylated 5-ASA after intake of olsalazine, AsacolR and SalofalkR 
was significantly less in patients with diarrhoea than in patients without diarrhoea. 
All patients during all study periods had at least one bowel motion per 48 hours. 
The ITTs in both groups of patients are listed in Table 3. The correlation 
between the ITT according to Cummings and the ITT according to Hinton was 
derived from simultaneously available data in 35 cases and could be described by 
the formula y = 0 85x + 11.6 in which y = ITT according to Hinton and χ = 
ITT according to Cummings (r = 0.73, ρ < 0.001) . In patients without diarrhoea, 
the ITT according to Hinton was available in 30 of 50 cases and could be derived 
from the ITT according to Cummings in 10 cases, leaving 10 cases in which no 
sufficient data at all were present. In the group of patients with diarrhoea these 
numbers were 33, 8 and 9 respectively. 
Within one group of patients no significant differences in ITT occurred. The ITT 
in the group of patients with diarrhoea was shorter than in patients without 
diarrhoea during intake of all five drugs, not significant only for SASP and nearly 
significant for AsacolR. 
Regression of the proportion of excreted metabolites of 5-ASA versus the I l l ' s 
showed significant correlations between the proportions of acetyl-5-ASA excreted 
in faeces and the Π Τ for all drugs except for PentasaR (Table 4). The correlation 
between the unsplit sulphasalazine in faeces and the ITT failed to reach 
significance (r = -0.47, η = 16, ρ = 0.07), but the correlation between unsplit 
olsalazine and the ITT was very significant (r = -0.69, η = 16, ρ = 0 003). 
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Table 2. Disposition of 5-ASA during maintenance treatment with 5-ASA delivering drugs m IBD 
patients without and with diarrhoea Figures are the daily excretions, calculated by dividing the 
amounts excreted on two consecutive collection days by two, and are expressed as the proportion of 
the ingested dose, with SEM m parentheses 
Sulphasalazinc 
Olsalazine 
Pentasa" 
Asacol" 
Salofalk" 
Sulphasalazinc 
Olsalazine 
PentasaR 
Asacol" 
Salofalk* 
Sulphasalazinc 
Olsalazine 
Pentasa11 
Asacol" 
Salofalk* 
Sulphasalazinc 
Olsalazine 
Sulphasalazinc 
Olsalazine 
Ретава* 
Asacol* 
Salofalk* 
patients without 
diarrhoea 
(n = 10) 
Urmary excretion of 5-ASA 
26 2 (4 3) 
12 9 (19) 
25 1 (3 2) 
24 3 (5 7) 
34 7 (3 2) 
patients with 
diarrhoea 
(n = 10) 
(acetylated + unacetylated) 
118 (2 4) 
5 4 ( 2 1) 
22 7 ( 4 2) 
16 2 (3 4) 
22 8 (5 1) 
Faecal excretion of 5-ASA 
24 3 (4 5) 
22.3 (2 2) 
162 (3 2) 
34 2 (67) 
2 0 9 ( 3 9) 
Faecal excretion 
2 9 6 ( 8 7) 
16 7 (28) 
39 5 (3 5) 
18 4 (2 8) 
27 9 (7 8) 
2 2 3 ( 5 2) 
131 ( 4 0 ) 
29 2 ( 2 8) 
50 7 (112) 
2 7 0 ( 5 0 ) 
of acetyl-5-ASA 
119 (3 7) 
4 3 ( 1 5 ) 
27 4 (2 5) 
9 0 (2 6) 
13 7 (3 2) 
Faecal excretion of unsplit parent molecule 
5 3 ( 1 6 ) 
15 2 ( 3 7) 
Total recovery 
819 (14 2) 
670 ( 56) 
80 9 (118) 
769 ( 6 4 ) 
835 ( 82) 
42 9 (12 2) 
47 2 ( 1 0 0) 
of ingested drug 
888 ( 9 6 ) 
70 1 ( 5 9) 
794 ( 6 5 ) 
75 9 (13 8) 
632 ( 9 2 ) 
Ρ 
0009 
003 
0 73 
0 27 
016 
062 
002 
002 
047 
052 
009 
0003 
0 38 
002 
0 01 
0004 
003 
0 47 
0 79 
097 
097 
0 79 
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% oí ingested dose (mean SD) % ol ingested dose (mean SEM) 
iiìJ li il 
sulpfieaalezlne olsalazlne Pentasa" A3acolR Salofalkq 
sulphasalaz rm olsalazine PentesaR AsecolR З ІоГаІкя I 5 ASA [ ] acetyl 6 ASA sunapfll paranl drug 
Figure 1. Urmary excretion of acetyl-5-ASA 
from 5-ASA delivering drugs m ten patients with 
inflammatory bowel disease without diarrhoea. 
Bars represent the amounts excreted on day 6 
and 7 of a seven-day treatment period, divided 
by two, and expressed as the proportion of the 
daily ingested dose 
Figure 2 Faecal excretion of 5-ASA, acetyl-5-
ASA and unsplit parent drug from 5-ASA 
delivering drugs m ten patients with 
inflammatory bowel disease without diarrhoea 
Bars represent the amounts excreted on day 6 
and 7 of a seven-day treatment period, divided 
by two, and expressed as the proportion of the 
daily ingested dose 
% of ingested dose (mean SEM) 95 ot ingested dose (mean SEM) 
sulpnasaiazlne olaalezine PentaseR А8асоІя Salolalk" 
Figure 3. Urinary excretion of acetyl-5-ASA 
from 5-ASA delivering drugs m ten patients with 
inflammatory bowel disease and diarrhoea. Bars 
represent the amounts excreted on day 6 and 7 
of a seven-day treatment period, divided by two, 
and expressed as the proportion of the daily 
ingested dose 
sulphasalazlne olaalazlne Pentasa 
H б ASA [ZZI acetyl 6 ASA 
Asecol Salotalk 
!S unapllt parent drug 
Figure 4. Faecal excretion of 5-ASA, acelyl-5-
ASA and unspla parent drug from 5-ASA 
delivering drugs m ten patients with 
inflammatory bowel disease and diarrhoea Ban 
represent the amounts excreted on day 6 and 7 
of a seven-day treatment period, divided by two, 
and expressed as the proportion of the daily 
ingested dose 
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DISCUSSION 
From previous studies in healthy volunteers it is known that a marked accelerati­
on of the ITT profoundly influences the disposition of 5-ASA from 5-ASA 
delivering drugs (7-9). This is confirmed in the present study. In the group of 
patients with diarrhoea, with median I l l s ranging from 15.1 (olsalazine) to 23.8 
hours (Saiofalk") there were marked differences in disposition between the study 
drugs, and also marked differences in comparison with the non-diarrhoea group. 
In the first place azo compounds are far less completely split in case of 
diarrhoea. This has a marked unfavourable effect on the availability of 5-ASA in 
the bowel lumen, reflected in a decrease of both the proportion of 5-ASA 
excreted in urine and of acetyl-5-ASA in faeces. The disposition of olsalazine 
appears to be impaired somewhat more than the disposition of SASP. 
The disposition of Asacol" in patients with diarrhoea is characterized by a high 
proportion of 5-ASA excreted in faeces, but little in the acetylated form, 
indicating that release must have taken place distally, if at all. 
Although the disposition from SalofalkR and PentasaR is also impaired in case of 
diarrhoea, the changes are far less substantial and the disposition remains rather 
favourable. Specifically the faecal excretion of acetyl-5-ASA from PentasaR is 
Table 3. Intestinal transit time according to Hinton in patients with and without diarrhoea. 
Figures are median values (hours), with the range in parentheses. 
Sulphasalazine 
Olsalazine 
PentasaR 
Asacol" 
Saiofalk* 
All treatments 
patients without 
diarrhoea 
38.2 (16.3-66.0) 
39.7 (15.0-54.5) 
34.6 (13.0-75.5) 
38.8 (11.8-65.5) 
45.8 (26.5-53.2) 
39.1 (11.8-75.5) 
patients with 
diarrhoea 
21.7 (13.7-59.8) 
15.1 ( 6.8-30.6) 
15.6 ( 6.4-28.4) 
23.1 ( 6.0-30.6) 
23.8 ( 4.6-33.0) 
20.6 ( 4.6-59.8) 
Ρ 
0.17 
0.006 
0.02 
0.057 
0.02 
<0.0001 
No significarli internal differences in either group of patients 
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Table 4. Coefficients of correUuion between the proportion 
of acelyl-5-ASA in faeces and the intestinal transit time. 
Sulphasalazine 
Olsalazine 
Pentasa 
Asacol 
Salofalk 
• 
r 
0.54 
0.90 
0.16 
0.86 
0.73 
π 
16 
16 
15 
16 
18 
Ρ 
0.032 
«cO.OOl 
0.58 
<0.001 
0.001 
* Spearman rank correlation 
significantly higher than from 
all other drugs under 
conditions with an accelera­
ted intestinal transit. This 
also finds expression in the 
fact that PentasaR was the 
only drug without a signifi­
cant correlation between the 
proportion of acetyl-5-ASA 
in faeces and the ITT. 
These results are in full agreement with those obtained in healthy volunteers after 
administration of a single dose of these 5-ASA delivering drugs, with and without 
induction of diarrhoea with bisacodyl (6,9). 
The proportion of acetyl-5-ASA that is excreted in urine of patients with 
quiescent disease is almost identical to that of normal volunteers (6), with the 
exception of olsalazine, which has a lower urinary recovery in patients (mean 12.9 
vs 24.8%). 
The faecal excretion of acetyl-5-ASA in patients without diarrhoea was about 
identical to the data of healthy volunteers as far as Salofalk" and Pentasa" are 
concerned, but lower for SASP, olsalazine and AsacolR (9). Also, the proportion 
of unsplit olsalazine was higher in patients without diarrhoea than in volunteers 
(mean 15.2 and 4.1% respectively). The cause of these differences might be the 
fact that even in patients without diarrhoea the ITT was shorter than in normal 
persons. Indeed, we found in a previous study in normal persons a mean 111 
according to Hinton of 53.2 hours (9), and in the present study mean ITTs 
ranging from 36.4 to 42.0 hours. Obviously, olsalazine is influenced most by this 
slight acceleration of 111, while the disposition of Salofalk" and Pentasa" is not 
substantially altered. 
Our results are also in agreement with the study of van Hees (7), who measured 
the disposition of sulphasalazine in volunteers during normal and accelerated 
intestinal transit and found the proportion of unsplit drug in faeces to increase 
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from 0.5 to 45.4%, and the proportion of 5-ASA in urine to decrease from 18.5 
to 5.9%. 
In the study of Christensen et al. (8) concerning the disposition of Pentasa" 
during normal and accelerated ITT the differences in urinary excretion of 5-ASA 
were larger than in our study, probably due to a five-fold speeding up of the ITT 
by bisacodyl. Their figures for faecal excretion are almost identical to ours. 
Staerk Laursen et al (21) investigated the disposition of olsalazine, PentasaR, 
AsacolR and SalofalkR in 14 patients with ulcerative colitis in remission (less than 
two bowel motions per day). As in our study they found that the urinary excretion 
of acetyl-5-ASA and faecal excretion of acetyl-5-ASA were highest after ingestion 
of PentasaR and SalofalkR. The intraluminal colonic concentrations of 5-ASA, as 
measured by equilibrium in vivo dialysis, was highest after intake of olsalazine and 
AsacolR, which is consistent with predominantly colonic release of 5-ASA by these 
drugs in the absence of diarrhoea. 
With the method of processing the faeces used in the present study it was not 
possible to distinguish released 5-ASA from 5-ASA still captured in a slow-release 
tablet (SalofalkR and AsacolR) or in ethylcellulose vesicles (Pentasa"). It is 
possible that some tablets were excreted with an intact coat, which was not 
broken until the homogenization of the faeces. If this happens to most tablets, 
only low proportions of acetyl-5-ASA in urine and faeces can be expected. After 
homogenizing a dispersed PentasaR tablet and an AsacolR tablet with faeces we 
measured a recovery of 5-ASA of more than 80% for both tablets, indicating that 
the homogenization procedure was vigorous enough to disrupt the majority of the 
small ethylcellulose vesicles of PentasaR and the resin coat of AsacolR. This means 
that we cannot distinguish released 5-ASA from still captured 5-ASA and that 
the measurement of acetyl-5-ASA in faeces is indispensable to estimate timely 
release in the colon. 
Although it was initially suggested that acetyl-5-ASA was also effective in the 
treatment of ulcerative colitis (22), this could not be confirmed by others (23, 24), 
and at present only 5-ASA is considered to have important anti-inflammatory 
properties. So, although a high proportion of acetyl-5-ASA is an indicator of 
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timely release in the gut, it is inactive in itself, and a very high ratio of acetylated 
to unacetylated 5-ASA in faeces is therefore not desirable for patients with 
inflammation in the distal colon. 
The results of the present study entail important consequences for the choice of 
5-ASA delivering drugs under specific clinical circumstances. In patients without 
diarrhoea, too late release of 5-ASA does not appear to be a major problem, as 
the proportion of acetyl-5-ASA in faeces is considerable, olsalazine being on the 
low side with 16%. The fact that the mean faecal excretion of acetyl-5-ASA after 
ingestion of PentasaR is as high as 39.5% and the proportion of unacetylated 5-
ASA in faeces only 16.2% might even indicate that 5-ASA is released too early 
for patients with inflammation in the distal colon, without diarrhoea. This is 
confirmed by the presence of low colonic intraluminal concentrations of 5-ASA 
during intake of PentasaR by patients with quiescent ulcerative colitis (21). On the 
other hand, PentasaR has been proven to possess relapse preventing properties 
equal to sulphasalazine in patients with quiescent ulcerative colitis (25). 
Therefore, it is hard to express a preference for one drug to the other when no 
frank diarrhoea is present. However, when a patient does suffer from diarrhoea 
and ITT is substantially shortened, important differences in disposition become 
apparent. Under these circumstances, olsalazine clearly has the least favourable, 
and PentasaR, and to a somewhat lesser extent SalofalkR, the most favourable 
disposition profile. This should be taken into account when prescription of a 5-
ASA delivering drug is considered. 
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SUMMARY 
Fifty-five patients with active ulcerative colitis were treated at random in a 
prospective, double-blind, multicentre trial with sulphasalazine 6 g/d or olsalazine 
3 g/d for six weeks, to be continued for another six weeks if no remission had 
been achieved. Clinical and laboratory evaluation was performed every two weeks, 
and endoscopic evaluation at 0, 6 and 12 weeks. After 6 weeks 6 of 27 évaluable 
patients (22.2%) on sulphasalazine and 9 of 28 patients (32.1%) on olsalazine had 
achieved a remission (95% CI of the difference -33.3 to 13.4%). After 12 weeks 
11 of 27 patients (40.7%) on sulphasalazine and 14 of 26 patients (53.8%) on 
olsalazme were in remission (95% CI of the difference -39.8 to 13.6%). 
Substantial endoscopic improvement was eventually achieved in 48.2% of patients 
on sulphasalazine and 65.4% of patients on olsalazine (95% CI of the difference -
43.4 to 9.0%). Six patients from each group were withdrawn because of adverse 
effects or increasing severity of disease. By means of a newly developed numerical 
Ulcerative Colitis Activity Index no significant difference as to the effect of 
treatment between both groups could be demonstrated. Olsalazine is at least as 
effective and as well tolerated as sulphasalazine in patients with active ulcerative 
colitis. 
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INTRODUCTION 
Since it is recognized that 5-aminosalicylic acid (mesalazine) is the active part of 
sulphasalazine (1,2), whereas sulphapyrídine is the cause of the majority of 
adverse effects (3), sulphapyridine-free drugs have been developed for the 
treatment of patients with inflammatory bowel disease. As plain mesalazine is 
rapidly absorbed in the proximal small bowel (4), measures have been taken to 
delay release by enveloping mesalazine with a special coating, or by binding it to 
another molecule that greatly reduces absorption in the small bowel. Olsalazine 
(DipentumR) consists of two mesalazine molecules, linked together with an azo 
bond, and is hardly absorbed in the small bowel (5). On the analogy of sul-
phasalazine (6) it is split by intestinal bacteria in terminal ileum and colon, 
resulting in the release of two mesalazine molecules at that site (7). Olsalazine is 
more effective than placebo in active ulcerative colitis (8). We compared the 
efficacy and safety of olsalazine and sulphasalazine in patients with active 
ulcerative colitis. 
PATIENTS AND METHODS 
The study was prospectively carried out in a double-blind, randomized, 
multicentre fashion. 
Patient selection 
Fourteen Dutch hospitals participated in this study. From October 1985 to april 
1989 patients with active ulcerative colitis, extending 25 cms or more from the 
anal verge, and with an Ulcerative Colitis Activity Index (see next section) of 120 
or more, were considered eligible for the trial. The diagnosis of ulcerative colitis 
was made on the basis of typical clinical, endoscopic and histological appearances, 
and the absence of positive stool cultures for Salmonella, Shigella, Campylobacter 
jejuni and Yersinia enterocolica. Patients with a first attack as well as patients 
with a relapse were eligible. Criteria for exclusion are listed in Table 1. 
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Table 1. Cnterta for exclusion of patients 
1. Uncooperativeness. 
2. Colitis wiih a specific cause (infectious colitis, pseudomembranous colitis, radiation-
induced colitis). 
3 Presence of features of Crohn's disease. 
4. Colitis extending less than 25 cm from the anal verge. 
5. Use of prednisone, prednisolone or more than 3 g of sulphasalazine daily in the last 
two weeks 
6. Proven hypersensitivity to sulpha drugs or salicylates. 
7. Pregnancy or desire to become pregnant. 
8. Only slightly active colitis (UCAI <120). 
9. Temperature of 39°C or more due to ulcerative colitis. 
10. Severe illness, i.e. 
a. severe blood loss requiring transfusions, 
b. severe diarrhoea (>10 motions/day), 
с any other condition that makes, in the opinion of the attending physician, the nsk 
involved in the participation in the trial unacceptable (eg toxic megacolon) 
11. Need (for whatever reason) for antibiotics or corticosteroids. 
12 Presence of colostomy or ileo-rectal anastomosis. 
13. Two or more abnormal liver function tests (bilirubin, alkaline phosphatase, ALAT or 
ASAT more than twice the upper limit of normal), or signs of cirrhosis of the liver. 
14. Clearly impaired kidney function (endogenous creatinine clearance <30 ml/mm). 
15. Acute intermittent porphyria. 
Protocol review 
The study protocol was reviewed and approved by the ethics committee of the 
University Hospital Nijmegen, and by the local ethics committees of the 
participating hospitals. Patients were fully informed and their wntten consent was 
obtained in accordance with the declarations of Helsinki and Tokyo. 
Study design and randomization 
Patients who satisfied the diagnostic criteria, lacked the exclusion entena and gave 
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their written informed consent were assigned to receive either sulphasalazine or 
olsalazine. Patients were allocated to treatment groups with a modification of the 
standardized variance allocation method as described by Begg and Iglewicz (9), in 
order to ensure equal distribution of prognostic factors among both treatments. 
The modification consisted of standardization of the variance method. The factors 
taken into account were age (less than 40 years; 40 years and older), sex, 
duration of disease (less than 2 months; 2 months to 2 years; more than 2 years), 
extent of colitis (distal to splenic flexure, beyond splenic flexure). Ulcerative 
Colitis Activity Index (see below) and attending physician. 
The duration of treatment was six weeks, to be continued for another six 
weeks if no clinical remission according to Truelove and Witts, and endoscopic 
remission was achieved. The dose of sulphasalazine was 6 g daily and of 
olsalazine 3 g daily, divided in three doses, to be taken on top of a meal, and to 
be reduced to 4 and 2 g daily respectively when adverse effects occurred. 
Sulphasalazine and olsalazine were given in externally indistinguishable capsules, 
containing 333 mg of sulphasalazine or 167 mg of olsalazine, provided by 
Pharmacia AB, Uppsala, Sweden, in sealed plastic containers. On day 1 and 2 the 
dosage was one-third, and on day 3 and 4 three two-thirds of the full dose. 
Control visits were performed every two weeks. At the inclusion visit and each 
control visit a medical history was taken, patients were questioned about the 
intake of capsules and the occurrence of possible adverse effects, and a physical 
examination was made with emphasis on the findings necessary for the calculation 
of the Truelove-Witts catagoiy and the UCAI. Blood was drawn for determination 
of the laboratory data included in these activity indices and, in order to recognize 
possible adverse effects, also of leucocytes, platelets, glucose, creatinine, liver 
function parameters (bilirubin, alkaline phosphatase, ALAT, ASAT and lactate 
dehydrogenase) and haptoglobin. Urine was analyzed for the presence of protein 
and glucose. Before entry, faeces were cultured for Salmonella, Shigella, Cam-
pylobacter jejuni and Yersinia enterocolitica. 
All patients recorded their complaints on a diary card during the whole treatment 
period. 
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Criteria for premature discontinuation of treatment 
Treatment was stopped prematurely, and cases were consequently considered a 
treatment failure, if on account of the severity of the disease continuation of the 
"blind" therapy was not longer regarded as warranted in the opinion of the 
attending physician, or if adverse effects neccessitated a decrease of the dose of 
the study drug to less than two-thirds of the full dose. Patients withdrawn for 
these reasons were included in the evaluation and considered a treatment failure. 
Assessment of inflammatory activity 
The inflammatory activity was assessed by means of two clinical activity indices, 
an endoscopic index and a histological score. 
Clinical assessments 
First, the severity index as described by Truelove and Witts (10) was used. 
Because it is not clear from their description in which grade of severity a patient 
has to be classified when a patients meets criteria of different catagories of 
illness, we devised a modification as shown in Table 2. 
Secondly, we devised an Ulcerative Colitis Activity Index (UCAI) because it was 
supposed that the three-grade Truelove-Witts classification would limit the 
statistical processing of data and would offer insufficient opportunity to assess 
minor changes of disease activity. 
The UCAI was developed in a similar way as has been done for Crohn's disease 
(11). From the files of 89 patients with ulcerative colitis, treated in the period 
1956-1984 in the University Hospital Nijmegen, 112 sets of simultaneous 
observations of the following 15 variables were obtained: sex, Quetelet index 
(weight divided by height squared), stool frequency, well-being, abdominal pain, 
cramps, megacolon, loss of blood in stools, body temperature, ESR, haemoglobin 
concentration, leucocytes and serum albumin. The maximum number of sets of 
observations of the same patient was three. These 112 sets of observations were 
duplicated. In a random order the resulting 224 sets were rated by five 
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Table 2. Modified Tmelove-Witts classification for the severity of ulcerative colitis. 
Mild colitis: at least 3 of the 4 criteria ad I and 1 of the 2 criteria ad II are fulfilled. 
I. - mean frequency of defaecation < 4/day 
- small amounts of macroscopic blood in stools 
- no fever (evening temperature <37.50C) 
- no tachycardia (pulse rate <90/min) 
II. - haemoglobin male >8.0 mmol/1; female >7.4 mmol/l 
- ESR <20 mm 
Severe colitis: at least 3 of the 4 criteria ad III and 1 of the 2 criteria ad IV are fulfilled. 
III. - mean frequency of defaecation > 7/day 
- always substantial amounts of macroscopic blood in stools 
- evening temperature 38.0Χ on at least 3 out of 5 consecutive days 
- tachycardia (pulse rate >90/min) 
IV. - haemoglobin male <6.5 mmol/1; female < 6.0 mmol/1 
- ESR >30 mm 
Moderately severe colitis: neither the criteria for the mild nor for the severe modality are 
fulfilled. 
Colitis in remission: 
- mean frequency of defaecation < 3/day 
- no blood in stools 
- no fever 
- no tachycardia 
- haemoglobin normal or returning towards normal 
- ESR normal or returning towards normal 
gastroenterologists with the scores 1, 2, 3 and 4, denoting no, mild, moderate and 
severe activity of the colitis respectively. Comparing the scores awarded to the 
duplicate sets never more than a difference of 1 point (in 18% of the cases) was 
found. Pearson correlation coefficients between the sum of duplicate scores of the 
physicians two and two were at least 0.90. Having established in this way a 
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sufficient intra- and interrater consistency the 10 ratings of the five physicians 
were added. The sum of these ratings now can be considered a reliable measure 
of the severity of colitis according to the common judgement of the five 
physicians. 
By stepwise multiple linear regression a function of 6 of the 15 variables has been 
constructed predicting the sum score of a patient with sufficient accuracy. We 
refrained from adding another variable because the multiple correlation 
coefficient exceeded 0.95 after inclusion of the sixth variable. The activity index 
is this function multiplied by 6 in order to obtain a similar scale as in the activity 
index for Crohn's disease mentioned before. The ulcerative colitis activity index 
(UCAI) is defined as follows: 
UCAI = 24.6T - 1.86Alb + 24.9B1 - 5.54HB + 15.6MC + 0.205ESR - 746. 
Where Τ =body temperature (0C) 
Alb = serum albumin (g/1) 
Bl = blood loss in stools (1 = no, 2 = mild (not always present or 
only blood streaks), 3= always clearly present). 
Hb = haemoglobin concentration (mmol/1) 
MC = megacolon (l=absent, 2=present, 3=severe) 
ESR = erythrocyte sedimentation rate (mm in 1 h) 
The maximum difference between the index and the sum of the ten original 
ratings multiplied by 6 is 37, that is 0.62 in the 1,2,3,4 scale of the original ratings. 
The residual standard deviation is 18.4 or 0.31 in the 1,2,3,4 rating scale. 
The fractional contribution of a variable to the UCAI is taken as the standard 
deviation of that variable times the absolute value of its coefficient in the UCAI 
and devided by the sum of such products for all variables. These fractions are 
32.4% (T), 21.4% (Alb), 22.5% (Bl), 9.7% (HB), 6.9% (MC) and 7.1% (ESR) 
respectively. 
Endoscopic assessment 
Patients underwent a flexible sigmoidoscopy or colonoscopy before entry in the 
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study, after 6 and, if suitable, after 12 weeks of treatment. 
In order to obtain reproducible judgements of the endoscopic severity of 
inflammation a standardized five-parameter assessment, with maximally four levels 
for each parameter, was used. The assessment was always performed 20-30 cm 
from the anal verge. Parameters and the resulting grading of severity are shown 
in Table 3. 
Histological score 
Biopsies for histological examination were taken in the 20-30 cm region, and, if 
no macroscopically recognizable inflammation was present at that site, also at 5 
cm from the anal verge. The biopsies were judged by the local pathologist and 
scored for the absence or presence of inflammation. 
Assessment of response to therapy and statistical analysis 
The following end-points were used to measure the response to treatment. 
1. The number of patients achieving endoscopic and clinical (according to the 
modified Truelove-Witts criteria) remission. 
2. The number of patients achieving a "success" as assessed with the Truelove-
Witts classification. Success is defined as the achievement of remission (grade 
0) or a decrease of severity by two grades or more. 
3. The number of patients achieving a "success" as assessed with endoscopy. 
Success is defined as the achievement of remission (grade 0) or a decrease of 
severity by two grades or more. 
4. The number of patients achieving histological remission. 
5. The relative value of the UCAI (expressed as the proportion of the initial 
value) after 6 and twelve weeks of treatment. 
If a patient left the trial after 6 weeks because of achievement of remission, he 
was also counted as a remission and a success at 12 weeks. 
In case of premature withdrawal due to treatment failure or adverse effects the 
exact values of the above mentioned parameters were set on an arbitrary value 
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higher than the values of any other patient. As this results in a non-normal 
distribution medians and quartiles are presented instead of mean and standard 
deviation. The Wilcoxon two-sample test was used to test differences in the 
proportional UCAI, and Fisher's exact test for differences in success rates. Only 
two-sided test results were used, and p-values of less than 0.05 were considered 
signiflcant. 
Reflections about the size of the treatment groups 
The null-hypothesis in this study was that no difference in therapeutic effect and 
in incidence of adverse effects between the two groups would exist. It was 
calculated that 75 patients in each treatment group would be needed in order to 
obtain a probability of 80% to find a significant test result at the 5% level for a 
28% difference between both treatment groups. However, due to lower than 
expected enrollment this number was not reached in reasonable time, and it was 
decided to stop the trial after inclusion of 55 évaluable patients. All treatment 
results are now presented with their 95% confidence intervals. 
RESULTS 
During the entire study period 65 patients were randomized. Ten of them 
dropped out in the first 6 weeks for reasons other than treatment failure or 
adverse effects: four because of uncooperativeness, two because of a major 
protocol violation (visit at 6 weeks postponed for more than 7 days), two because 
of too severe disease at the intended starting day, one because of prolonged need 
for antibiotics in relation with a pneumonia, and one patient because he soon 
appeared to suffer from Crohn's disease. These patients were not included in the 
analysis. Of the remaining 55 patients, 27 were assigned to sulphasalazine and 28 
to olsalazdne. The characteristics of both treatment groups are shown in Table 4. 
Two more patients dropped off after 6 weeks because of uncooperativeness. They 
were included in the analysis at 6 weeks, but excluded from the analysis at 12 
weeks. 
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Table 4. Main characteristics of both treatment groups. In the first 6 weeks of 
treatment 6 patients 
assigned to sulphasala-
zine, and 6 assigned to 
olsalazine were with-
drawn for the reasons 
mentioned in Table 5, 
and consequently added 
to the évaluable 
patients as treatment 
failures. Patients were 
defined as having 
increasing diarrhoea if 
an increasing frequency 
of loose stools was the 
only event observed. If 
patients also experien-
ced increasing fever, if 
laboratory parameters 
of inflammation 
(haemoglobin and ESR) 
clearly deteriorated or 
the endoscopic appear-
ance substantially worsened, the patients were considered having an increasing 
severity of disease. 
The results after 6 and 12 weeks of treatment are mentioned in Table 6. 
Although every end point with the exception of clinical improvement after 6 
weeks showed a trend in favour of olsalazine, due to wide confidence limits at 
neither point of time significant differences occurred in the rates of achievement 
of clinical and endoscopic remission, clinical or endoscopic success, or in the 
relative value of the UCAI. The achievement of remission was not dependent on 
median age (range) 
male : female 
duration of disease 
<2 months 
2 months - 2 years 
>2 years 
extent of colitis 
not beyond splenic flexure 
beyond splenic flexure 
unknown* 
Ulcerative Colitis Activity Index 
120 - 139 
140 - 179 
>180 
Patients treated with 
sulphasalazine 
(n = 27) 
36 (12-78) 
1 8 : 9 
7 
13 
7 
14 
11 
2 
16 
10 
1 
severity according to Truelove and Witts 
mild 
moderately severe 
severe 
10 
10 
2 
olsalazine 
(n = 28) 
33 (13-76) 
18: 10 
9 
11 
8 
14 
13 
1 
14 
13 
1 
8 
13 
0 
* splenic flexure not reached at endoscopy 
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Table 5. Reasons for patient withdrawal 
sulphasalazine group olsalazine group 
upper abdominal complaints 4* increasing severity of colitis 3 
rash 1 increasing diarrhoea (>10/day) 2 
depression, insomnia 1 pancreatitis 1 
* one of the four patients also had headache 
the severity according to Truelove-Witts at entry, as 9 of 18 patients with mild 
disease came into remission after 12 weeks, 15 of 35 patients with moderately 
severe disease and 1 of the 2 patients with severe disease. 
Biopsies were not available from all patients évaluable at 6 and 12 weeks. 
Some patients, withdrawn shortly after entry or being severely ill, refused 
endoscopy. Thus, after 6 weeks judgeable biopsies were available in 41 patients, 
and after 12 weeks in 25 patients. At 6 weeks, no histologically active 
inflammation was found in 4 out of 21 patients treated with sulphasalazine and in 
3 out of 20 patients treated with olsalazine. At 12 weeks, inflammation was 
absent in 3 out of 14 and 4 out of 11 patients respectively. All together, six 
patients from the sulphasalazine group had no histologically active inflammation 
any more at the time they left the trial, and seven patients from the olsalazine 
group. None of the differences in histological outcome between the two 
treatments was significant. On 19 occasions histological signs of inflammation were 
still present whilst the endoscopic appearance was quiet, and in one patient with 
clinical and endoscopic signs of inflammation the histological appearance was 
normal. 
Minor adverse effects that disappeared spontaneously or after dose-reduction 
by less than one-third occurred in 11 patients (40.7%) treated with sulphasalazine 
and 6 patients (21.4%) treated with olsalazine, as shown in Table 7. Some 
patients experienced more than one adverse effect. The 95%-confîdence intervals 
of the difference are -5 and 43%. No major abnormalities in laboratory tests 
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Table 6. Results of therapy: remission and success rates with 95%-confidence intervals, and course of UCAI. 
After 6 weeks of treatment 
treatment group 
sulphasalazine olsalazine 
95% CI of 
difference 
After 12 weeks of treatment 
treatment group 
sulphasalazine olsalazine 
95% CI of 
difference 
endoscopic and clinical remission 6/27 (22.2%) 
endoscopic success* 9/27 (33.3%) 
clinical (Truelove-Witts) success* 12/27 (44.4%) 
median relative UCAI**· 65.0 (56.8-79.1) 
9/28 (32.1%) -33.3 - 13.4% 11/27 (40.7%) 
11/28 (39.3%) -31.3 - 19.4% 13/27 (48.2%) 
11/28 (39.3%) -20.8 - 31.2% 15/26 (57.7%)** 
72.2 (62.0-83.1) 73.1 (59.2 -112.6) 
14/26 (53.8%) -39.7 - 13.6% 
17/26 (65.4%) -43.5 - 9.0% 
16/26 (61.5%) -30.5 - 22.8% 
71.3 (60.8-129.9) 
* success defined as remission or decrease of severity by two grades or more. 
·* in one patient insufficient laboratory data were collected after 12 weeks for determination of the Truelove-Witts category. 
*** expressed as the proportion of the initial dose [%], with quartile range in parentheses. 
For patients in remission after 6 weeks, values of UCAI at 6 weeks were used to calculate the 12 weeks median and quartile range. 
None of the differences between the treatment groups were significant 
occurred in both groups. In one patient of each treatment group mild, transient 
leucopenia to a minimal count of 3.4xl09/l (on sulphasalazine) and 2.9 109/1 (on 
olsalazine) was encountered. In four patients treated with sulphasalazine and one 
treated with olsalazine haptoglobin decreased to levels under the normal range, 
indicating low grade haemolysis. 
The daily intake of the study drugs was similar in both treatment groups. Sixteen 
of the 27 patients assigned to sulphasalazine and 14 of the 28 assigned to 
olsalazine were able to take the full dose throughout the study, as derived from 
the diaries. In the sulphasalazine group the mean intake was 5.4 g (90% of the 
full dose) after 6 weeks, and 5.0 g (83%) after 12 weeks. In the olsalazine group 
these figures were 2.6 g (87%) and 2.8 g (94%), respectively. 
Validation of the UCAI 
The mean value of the UCAI increased from low to high Truelove-Witts 
catagories. At entry, the initial UCAI was 131 ± 12 (mean ± SD) in patients in 
Truelove-Witts catagory 1, 145 ± 19 in catagoiy 2, and the two patients in 
Truelove-Witts catagoiy 3 had a UCAI of 151 and 153. This trend was significant 
Table 7. Minor adverse effects, not necessitating withdrawal. 
sulphasalazine (n = 27) 
upper abdominal complaints 
headache 
dizziness 
tinnitus 
feeling of tension 
burning retrosternal pain 
number of patients with 
adverse effects 
6 
3 
2 
1 
1 
1 
11* 
olsalazine (n = 28) 
upper abdominal complaints 
increasing diarrhoea (>10/day) 
lower abdominal pain 
3 
2 
1 
6 
* some patients had more than one adverse effect 
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(ρ = 0.0004, trend-test). The UCAI-values in catagory 1 differed significantly from 
the values in catagory 2 and 3. The Spearman correlation coefficient between the 
Truelove-Witts catagories and the UCAI at entry was 0.47 (n = 55, ρ = 0.0002). 
Also, the change of UCAI after 6 weeks correlated significantly with the change 
in Truelove-Witts catagory (r = 0.51, η =39, ρ = 0.0008) 
DISCUSSION 
In this study, sulphasalazine and olsalazine were equally effective, as measured 
by the number of patients achieving clinical, endoscopic and histological remission, 
and by the decrease of the Ulcerative Colitis Activity Index. This is in accordance 
with other studies in patients with active ulcerative colitis, where olsalazine was as 
effective as sulphasalazine (12), or more effective than placebo (6,13). The 
present study differs from these previous studies as to the choice of its major 
end-points (clinical and sigmoidoscopic remission instead of improvement), the 
additional use of an Ulcerative Colitis Activity Index with continuous scale, the 
longer duration (6 to 12 weeks instead of 2 to 4 weeks), and the higher dosages 
of olsalazine and sulphasalazine. The choice of remission as major end-point is 
logical, because this is the goal one is aiming at when treating patients with active 
colitis. As it is well known from clinical experience that it takes usually longer 
than four weeks to achieve remission by sulphasalazine alone, we chose for a 
treatment duration up to 12 weeks. The dosage of 3 g olsalazine, and especially 
of 6 g sulphasalazine per day, is higher than used elsewhere. Notwithstanding the 
high incidence of adverse effects, reported in the littérature with such high or 
even lower dosages of sulphasalazine (12), our personal impression is that a 
reasonable part of patients with active disease tolerate this dosage well. 
Meanwhile, it has been demonstrated for olsalazine (13) and it is reasonable to 
expect from sulphasalazine that the efficacy is dose-related. Feurle et al, 
comparing olsalazine with placebo suggested that the lack of a significant 
difference as to clinical and histological parameters was a consequence of the low 
dose of 2 g olsalazine per day (14). In our study, using daily dosages of 6 g of 
135 
sulphasalazine or 3 g of olsalazine about half of the patients were able to take 
the full dose throughout the study, and the mean intake in both study groups was 
about 90% of the full dose. With this regimen, 40.7% of patients treated with 
sulphasalazine and 53.8% treated with olsalazine had achieved clinical and 
endoscopic remission after 12 weeks. As other studies on olsalazine do not 
mention remission rates, the figures are not well comparable. In studies on slow-
release mesalazine drugs divergent remission rates are reported. Habal and 
Greenberg treated patients with active ulcerative colitis in an open study with 3.2 
g daily of AsacolR (slow-release mesalazine), equivalent to the dosages used in 
this study, and found a remission rate after 3 months of 29% (15). They pointed 
out that the success rate was strongly dependent of the severity of disease at 
entry. Sixty-four percent of patients with mild or moderate disease, and none of 
the patients with severe disease (according to a self-devised grading) achieved 
remission. In the present study the remission rate was independent of the 
Truelove-Witts catagory or the height of the UCAI, probably because severely ill 
patients were hardly admitted. 
In another trial with even higher dosages of 4.8 g AsacolR only 24% of patients 
with mildly and moderately active ulcerative colitis had achieved remission after 
six weeks (16). In a multicentre study reported by Rachmilewitz, 49% of patients 
taking 1.5 g Mesasal (coated mesalazine) and 47% of patients taking 3 g 
sulphasalazine were in endoscopic remission after eight weeks (17). These figures 
are comparable with those from the present study. 
In addition to achievement of remission, an all or nothing criterium, and decrease 
of severity according to Truelove-Witts or to endoscopic aspect, that allows only a 
limited number of grades, we used an Ulcerative Colitis Activity Index with a 
continuous scale in order to detect more subtle differences between the treatment 
groups. Also with this activity index we were unable to find significant differences 
between the effects of sulphasalazine and olsalazine. Although the UCAI consist 
of partly different factors, its correlation with the Truelove-Witts catagories is 
significant, as is the correlation between the changes of both indices during 
treatment. This corroborates the idea that the UCAI might be a useful 
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instrument. 
The use of high dosages in the present study was accompanied by a withdrawal of 
six patients in both treatment groups (22.2% for sulphasalazine and 21.4% for 
olsalazine). These figures are higher than from some studies with lower doses of 
olsalazine (12-14), but comparable with the withdrawal rate in both arms of the 
Mesasal-sulphasalazine trial (17). In a study to the relapse preventing effect of 2 
g olsalazine in patients with quiescent ulcerative colitis the withdrawal rate for 
side effects was 24% (18). 
It is interesting that the reasons for withdrawal were different for both treatment 
groups. Most withdrawals from the sulphasalazine group took place because of 
upper gastrointestinal complaints, whereas increasing severity of the colitis and 
increasing frequency of loose stools were the most frequent reasons for 
withdrawal from olsalazine. Increasing severity of the colitis can stand for a treat-
ment failure, but also for an adverse effect of 5-aminosalicylic containing drugs 
(19,20). Increasing numbers of loose stools is a known side-effect of olsalazine, as 
a result of impaired absorption of water and electrolytes in the small intestines 
(21,22). The frequency reported in other studies ranges from 2.2 to 12.5% (12-
14,23,24). In the present study two patients were withdrawn for this reason, and 
one other had only transient complaints. So, in this study loose stools caused by 
olsalazine are not a major problem. The case of pancreatitis during treatment 
with olsalazine deserves some elaboration. It is not absolutely sure that olsalazine 
was the cause of this event, as the patient had already some abdominal 
discomfort a few days before the start of treatment. On the 13th day of 
treatment, however, she developed a frank pancreatitis. No predisposing factors 
such as gallstones, alcohol abuse, hypercalcaemia or hyperlipidaemia were present. 
After withdrawal of the drug she recovered completely, and two years later she 
was treated with olsalazine 1.5 g daily without problems. Interestingly, some cases 
of pancreatits caused by olsalazine (25) and coated mesalazine (26) are reported 
in the literature. 
In the present study less patients treated with olsalazine experienced minor 
adverse effects, as compared with sulphasalazine (21.7 vs 40.7%). The incidence is 
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especially high for sulphasalazine, but it is reassuring that all these adverse effect 
disappeared spontaneously or after dose reduction to two-thirds. The comparison 
of the incidence of adverse effects is the more in favour of olsalazine when it is 
realized that most patients entering this study had taken sulphasalazine before, so 
that the study group is more or less selected for its tolerance of sulphasalazine. 
The adverse effects of sulphasalazine are similar as reported in the littérature. 
It is concluded that olsalazine is as effective as sulphasalazine in patients with 
mildly and moderately active colitis, that it is accompanied by the same 
withdrawal rate, and by a lower mcidence of minor adverse effects. Both 
olsalazine and sulphasalazine are reasonably well tolerated in higher dosages than 
usually administered (3 and 6 g daily respectively). In patients intolerant of sulpha 
drugs olsalazine deserves the preference over sulphasalazine. This also counts for 
males at reproductive age, desiring to father children, as the seminal 
abnormalities induced by sulphasalazine (27,28) disappear on olsalazine (21). 
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CHAPTER 9 
THE RELAPSE PREVENTING EFFECT AND SAFETY 
OF SULPHASALAZINE AND OLSALAZINE 
IN PATIENTS WITH ULCERATIVE COLITIS IN REMISSION. 
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SUMMARY 
Fourty-nine patients with ulcerative colitis in remission were entered into a 
prospective, double-blind, multicentre trial comparing the relapse preventing effect 
and safety of 4 g sulphasalazine and 2 g olsalazine daily during 48 weeks. Of the 
46 évaluable patients 23 were assigned to sulphasalazine and 23 to olsalazine. 
Seven of 23 patients (30.4%) relapsed on sulphasalazine and six of 23 patients 
(26.1%) on olsalazine (95% confidence interval of the difference -22.0% to 
30.3%). The relapse-free survival curves did not differ significantly at any time 
during the trial period. In both treatment groups three patients dropped out 
because of adverse effects. Four patients on sulphasalazine and six patients on 
olsalazine experienced minor adverse effects. One patient on sulphasalazine had 
mild leucopenia, and four patients on sulphasalazine and one patient on 
olsalazine had decreased levels of haptoglobin. 
Thus, sulphasalazine and olsalazine are equally effective in maintaining remission 
of ulcerative colitis and are accompanied by a similar incidence of adverse effects. 
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INTRODUCTION 
Sulphasalazine has been the mainstay of treatment for patients with ulcerative 
colitis in remission, as it was the first drug that proved to be more effective than 
placebo in maintaining remission (1). Its relapse preventing effect is dose-
dependent, but unfortunately adverse effects become more frequent when higher 
dosages are used (2). For this reason, the dosage during remission is usually 
limited to 2 or 3 g per day. Since it has become evident that the sulphapyridine 
part of sulphasalazine is responsible for the majority of adverse effects (3), and 
that 5-aminosalicylic acid (mesalazine) is the active moiety (4,5), sulphapyridine-
free, mesalazine containing alternatives have been developed. As plain mesalazine 
is rapidly absorbed in the proximal part of the small intestine and the effect of 
mesalazine is dependent on its local concentration, measures must be taken to 
delay release, in order to deliver mesalazine more distally. Therefore, slow-release 
forms of mesalazine have been developed. Olsalazine (DipentumR) consists of two 
mesalazine molecules, linked together via an azo bond, and is hardly absorbed in 
the small bowel (6). On the analogy of sulphasalazine (7), the azo bond in 
olsalazine is split by bacteria in the distal ileum and colon, resulting in the release 
of two mesalazine molecules distally in the gut (8) with avoidance of superfluous 
and potentially harmful substances. 
Olsalazine is more effective than placebo in the prevention of relapses in patients 
with quiescent ulcerative colitis, and is tolerated by most patients intolerant of 
sulphasalazine (9). In the present paper we report a prospective, double-blind, 
randomized multicentre trial in which the relapse preventing properties and the 
safety of sulphasalazine and olsalazine in patients with ulcerative colitis in 
remission are compared. 
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PATIENTS AND METHODS 
Patient selection 
Thirteen physicians from 10 Dutch hospitals, listed in the Appendix, participated 
in this study. Inclusion lasted from december 1985 until January 1989. Patients 
with active ulcerative colitis in the past, proven by endoscopy with biopsies, being 
in remission for not longer than two years, were elegible. Remission was defined 
as the absence of clinical signs of inflammation, i.e. three stools or less per day 
without blood and a normal mucous membrane on sigmoidoscopy. Patients with a 
normal endoscopic appearance but histological signs of inflammation were 
included. Patients were recruited from two groups. The first group consisted of 
patients who had participated in a trial comparing sulphasalazine and olsalazine in 
active colitis and had achieved a remission after 6 or 12 weeks of treatment. 
Patients from the second group had not participated in this trial but met the 
inclusion criteria. Exclusion criteria are mentioned in Table 1. 
Protocol review 
The study protocol was reviewed and approved by the ethics committee of the 
Table 1. Criteria for occlusion of patients. 
1. Uncooperativeness. 
2. Colitis with a specific cause (infectious colitis, pseudomembranous colitis, radiation-
induced colitis). 
3. Presence of features of Crohn's disease. 
4. Proven hypersensitivity to sulpha drugs or salicylates. 
5. Pregnancy or desire to become pregnant. 
6. Need (for whatever reason) for antibiotics or corticosteroids. 
7. Presence of colostomy or ileo-rectal anastomosis. 
8. Two or more abnormal liver function tests (bilirubin, alkaline phosphatase, ALAT or 
ASAT more than twice the upper limit of normal), or signs of cirrhosis of the liver. 
9. Clearly impaired kidney function (endogenous creatinine clearance <30 ml/min). 
10. Acute intermittent porphyria. 
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University Hospital Nijmegen, and by the local ethics committees of the 
participating hospitals. Patients were fully informed and their written consent was 
obtained in accordance with the declarations of Helsinki and Tokyo. 
Study design and randomization 
Patients meeting the inclusion criteria, lacking the exclusion criteria and having 
given their written informed consent were randomly assigned to receive either 
sulphasalazine or olsalazine daily. Patients were allocated to treatment groups 
with a modification of the standardized variance allocation method as described 
by Begg and Iglewicz (10), in order to ensure equal distribution of prognostic 
factors among both treatments. The modification consisted of standardazation of 
the variance method. The following factors were taken into account: duration of 
disease (two years or less, more than two years), sex, age (40 years or less, more 
than 40 years), extent of last exacerbation (not beyond splenic flexure, beyond 
splenic flexure, unknown), attending physician, and, if the patient had participated 
in the active disease trial: time to achieve remission (6 or 12 weeks) and 
medication in that trial (sulphasalazine or olsalazine). 
The treatment lasted 48 weeks, or until the time of relapse. The 
dose of sulphasalazine was 4 g daily and of olsalazine 2 g daily, divided in two 
doses, to be taken on top of a meal. In case of adverse effects dose reduction to 
3 and 1.5 g daily respectively was allowed. Sulphasalazine and olsalazine were 
given in externally indistinguishable capsules, containing 333 mg of sulfasalazine or 
167 mg of olsalazine, provided by Pharmacia AB, Uppsala, Sweden, in sealed 
plastic containers. On day 1 and 2 the dosage was one-third, and on day 3 and 4 
two-thirds of the full dose. 
Control visits were performed after 4, 12, 24, 36 and 48 weeks. At the 
inclusion visit and each control visit a medical history was taken, patients were 
questioned about the intake of capsules and the occurrence of possible adverse 
effects, and a physical examination was made. Blood was drawn for the 
determination of haemoglobin, leucocytes, platelets, glucose, creatinine, liver 
function parameters (bilirubin, alkaline phosphatase, ALAT, ASAT and lactate 
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dehydrogenase) and haptoglobin, in order to recognize possible adverse effects. 
Urine was analyzed for the presence of protein and glucose. 
All patients recorded their complaints on a diary card during each week 
preceeding a control visit. At the inclusion visit and the 48 week visit a 
sigmoidoscopy with biopsies was performed to check whether the colitis was in 
remission indeed. 
Criteria for premature discontinuation of treatment 
Patients were withdrawn from the trial if a relapse occurred before the end of the 
48 weeks period. A relapse was defined as a recurrence of colitis symptoms 
(blood in stools, with or without diarrhea) and signs of inflammation at 
endoscopy. A patient was also regarded as having a relapse if he had only 
endoscopic signs of inflammation at the 48 week assessment, without the presence 
of complaints. 
Patients dropped out if they were uncooperative or wished to discontinue the trial 
for any reason, if pregnancy occurred, if hypersensitivity to the study drug 
occurred and if the dosage was lowered to less than 75% for more than 4 weeks, 
due to adverse effects or other reasons. These patients were not counted a 
relapse in the statistical evaluation. 
Statistical analysis 
Both the overall relapse rate and the relapse-free survival in the two treatment 
groups were compared. Differences between overall relapse rates (numbers of 
relapses at any time during treatment) and between incidence rates of adverse 
effects were tested with Fisher's exact test. Relapse-free survival curves were 
constructed according to the Kaplan-Meier method and differences between the 
two curves were tested with the log-rank test. When a patient had dropped out 
for other reasons than a relapse, he or she was deducted from the number of 
patients at risk. Only two-sided test results were used, and p-values of less than 
0.05 were considered significant. 
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RESULTS 
Fourty-nine patients were randomized for the trial. Three of them appeared 
uncooperative from the very beginning and were not included in the analysis. Of 
the 46 remaining patients 23 were assigned to sulphasalazine and 23 to olsalazine. 
The main characteristics of both groups are shown in Table 2. 
In the sulphasalazine group 7 patients (30.4%) relapsed and in the olsalazine 
group 6 patients (26.1%). The 95% confidence interval for the difference in 
overall relapse rate is 
Table 2. Main characteristics of both treatment groups. " 22.2 to 30.3%. Four 
patients assigned to 
sulphasalazine and eight 
assigned to olsalazine 
dropped out for other 
reasons than a relapse, as 
mentioned in Table 3. 
The relapse-free survival 
in both treatment groups 
is shown in Figure 1. 
Their was no significant 
difference at any time 
during the trial. After 24 
weeks of treatment the 
survival was 81.8% in the 
sulphasalazine group and 
73.7% in the olsalazine 
group, with a 95% 
confidence interval of the 
differerence of -19 to 
35%, and after 48 weeks 
the survival rate was 
median age and range (years) 
male : female 
duration of disease 
less than 2 years 
2 years or more 
Patients treated with 
sulfasalazine 
(n = 
44(22 
13 : 
extent of colitis at last exacerbation 
not beyond splenic flexure 
beyond splenic flexure 
unknown* 
Patients coming from 
active disease trial 
remission achieved in 6 weeks 
remission achieved in 12 weeks 
23) 
-78) 
10 
9 
14 
9 
9 
5 
12 
7 
5 
olsalazine 
(n = 23) 
36 (16 - 76) 
14 : 9 
10 
13 
10 
9 
4 
12 
9 
3 
* splenic flexure not reached at endoscopy 
None of the differences between the two treatment groups 
was significant. 
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Tabic 3. Reasons for drop out of patients. 
sulphasalazine group 
adverse effects: 
upper abdominal complaints 
rash 
uncooperativeness 
2 
1 
1 
olsalazine group 
adverse effects: 
loose stools 
uncooperativeness 
shipwrecked 
3 
4 
1 
69.7% and and 65.5% respectively, 95% confidence interval -28 to 36%. The 
minus sign denotes a difference in favour of olsalazine. 
No patient had endoscopic signs of inflammation at entry, but in in the biopsies 
of 4 patients treated with sulphasalazine and 7 patients treated with olsalazine 
active inflammation was present. There was a trend towards a higher relapse rate 
in patients with histological evidence of inflammation at entry (5 relapses in 11 
patients, and 8 relapses in 35 patients without histological inflammation), but the 
level of significance was not reached (p = 0.15). At the end of the study 
histological inflammation was present in 9 of 17 assessable biopsies from the 
sulphasalazine group and in 10 of 18 biopsies from the olsalazine group (p = 
1.0). 
Relapse-rree survival 
sulphasalazine 
Of the 24 patients who had achieved a 
remission just before entry six 
1 
relapsed, as opposed to seven of 22 
ο,β 
patients with a longer lasting 
0i4 remission. 
cw Eight patients treated with 
0
 sulphasalazine (34.8%) reported an 
adverse effect and nine patients 
Figure 1. Relapse-free survival rate in patients with treated with olsalazine (39.1%). The 
ulcerative colitis in remission, treated with sulphasalazine 
(n = 23) or olsalazine (n = 23) adverse effects resulting in a drop out 
Ί2 К 20 2* 2B 32 36 40 44 46 
WEEKS 
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are included in Table 3 and the minor adverse effects disappearing spontaneously 
or after lowering the dose by less than 25% are mentioned in Table 4. 
In one patient mild leucopenia (2.8 109/1) developed on sulphasalazine. In four 
patients treated with sulphasalazine and two patients treated with olsalazine 
serum haptoglobin levels dropped below the lower limit of normal, probably 
indicating low grade haemolysis. 
The drug intake was not significantly different at any time during treatment. The 
mean intake of sulphasalazine and olsalazine was 97% and 89% of the full dose 
after 24 weeks and 90% and 84% respectivly after 48 weeks. 
DISCUSSION 
We found no significant difference between the relapse preventing potentials of 
sulphasalazine and olsalazine. While the present study was in progress, Ireland et 
al reported a trial comparing 1 g olsalazine and 2 g sulphasalazine daily for six 
months in 164 patients with ulcerative colitis in remission (11). They found no 
difference in relapse rate, being 12.2% for sulphasalazine and 19.5% for 
olsalazine. Also in the trial of Ireland et al there was a trend to have a higher 
relapse rate for patients with histological evidence of disease. 
In studies comparing controlled release mesalazine with sulphasalazine in 
quiescent ulcerative colitis relapse rates higher than or comparable to ours were 
encountered. In one study 54% of patients taking 1.5 g PentasaR daily and 46% 
of patients taking 3 g sulphasalazine daily were in remission after 12 months (12), 
Table 4. Incidence of minor adverse effects. 
sulphasalazine group olsalazine group 
upper abdominal complaints 3 upper abdominal complaints 2 
mild, transient rash 1 fatigue 2 
loose stools 1 
mild itching 1 
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and in another trial, comparing 0.8-1.6 g AsacolR with 2-4 g sulphasalazine, 37.5% 
of patients on AsacolR and 38.6% of patients on sulphasalazine had suffered a 
relapse (13). These figures are roughly comparable with the results from the 
present study. 
Adverse effects were not absent in patients taking olsalazine. Upper abdominal 
discomfort was more common during sulphasalazine treatment, but the occurrence 
of loose stools were the most, frequent side effect of olsalazine in this study. Four 
out of 23 patients (17.3%) suffered from this untoward effect, and on three 
occasions it was a reason to stop the medication. The same problem has been 
encountered in other studies, where incidence rates of loose stools range from 2.2 
to 12.5% (9,14-17). Whereas it was mentioned initially that its incidence was 
related to the extent of inflammation (9), others were not able to confirm this 
(11). In patients with active colitis we found an incidence of 7%, lower than in 
the present remission-phase study. 
In accordance with the study of Ireland et al we found no significant difference 
between the total numbers of adverse effects in both treatments groups. It has to 
be borne in mind that the majority of patients in the present trial had taken 
sulphasalazine in the past, so a part of the study population is selected on its 
tolerance of sulphasalazine. 
We did not pay attention to a "hidden" but important adverse effect of 
sulphasalazine, being infertility in man at reproductive age, due to impaired 
seminal quality (18,19). It has been demonstrated that this effect is reversible 
after withdrawal of the sulphapyridine part and that men remain fertile after 
institution of mesalazine (20) or olsalazine (9). It is therefore a good reason not 
to start sulphasalazine in this catagory of patients. 
It is concluded that sulphasalazine and olsalazine are equally 
effective in maintaining remission in patients with ulcerative colitis and that both 
treatments are accompanied by a similar incidence of adverse effects, that are 
different of character. 
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SUMMARY 
As mentioned in Chapter 1, the aim of this study was to investigate some 
unexplored areas in the medical treatment of chronic inflammatory bowel disease, 
in particular the advantage, if any, of the addition of prednisone to sulphasalazine 
in the treatment of patients with active Crohn's disease, the disposition of 
sulphasalazine, olsalazine and slow release mesalazine formulations and finally the 
efficacy and safety of sulphasalazine and olsalazine in patients with active 
ulcerative colitis and their relapse preventing effect and safety in patients with 
quiescent ulcerative colitis. 
In Chapter 2 a survey of the present knowledge of the epidemiology, etiology, 
and prognosis of ulcerative colitis and Crohn's disease is presented, the modes of 
measurement of disease activity are discussed and available data on 
pharmacokinetics and the therapeutic effect of drugs used in the treatment of 
inflammatory bowel diseases are brought together. 
In the study decribed in Chapter 3 the effects of sulphasalazine plus prednisone 
and sulphasalazine plus placebo are compared in 60 patients with active Crohn's 
disease. In the first six weeks of a 16-week study period the Van Hees Activity 
Index decreased significantly more in the 30 patients treated with sulphasalazine 
plus prednisone (to a median of 70% of the initial value, interquartile range 57 -
84%) than in the 30 patients treated with sulphasalazine plus placebo (median 
87%, interquartile range 70 - 94%; ρ = 0.001). In the last four weeks of 
treatment the difference appeared still in favour of the combination of 
sulphasalazine plus prednisone but failed to reach the level of significance. By 
means of the Crohn's Disease Activity Index no statistical difference at all 
between the two treatment groups could be demonstrated, although the trends 
had the same direction as the Van Hees Activity Index. The combination of 
sulphasalazine and prednisone appeared to be especially beneficial in the initial 
phase of treatment in patients with disease located in the colon, with or without 
involvement of the small bowel. In the end phase of treatment the only significant 
difference between both treatment regimens was found in patients with a high 
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initial Van Hees Activity Index. In patients assigned to treatment with 
sulphasalazine and placebo, the therapeutic effect was negatively correlated with 
the severity of diarrhea. Response to treatment did not correlate with the severity 
of diarrhea in patients who received sulphasalazine and prednisone. The main 
conclusion of this study is that addition of prednisone to sulphasalazine, in the 
dosages prescribed in this study, results in a faster initial improvement but not in 
a significantly better result in the end. In patients with a high initial Van Hees 
Activity Index or with diarrhea, or both, treatment with sulphasalazine plus 
prednisone is definitely preferable. 
In Chapter 4 the possible value of the measurement of serum levels of the acute 
phase proteins orosomucoid and C-reactive protein, as an adjunct to or a 
substitute for the clinical activity indices, is described. For this purpose, data 
obtained in patients participating in the study described in Chapter 3 and in 
patients excluded from that study, mainly because of a too low Van Hees Activity 
Index, were analyzed. The correlations between the levels of the acute phase 
reactants on the one hand and the clinical activity indices on the other hand 
appeared to be rather poor, as none of the r-values exceeded 0.57. Patients with 
a high initial orosomucoid level (>175mg/100 ml) showed a better response with 
regard to the van Hees Activity Index to treatment with sulphasalazine and 
prednisone (median 40.8% of initial value, interquartile range 34.9-66.2%) as 
compared with sulphasalazine alone (median 62.6%, interquartile range 47.1-
85.7%; p=0.07). The changes of the acute phase reactants after 2 and 4 weeks of 
treatment did not distinguish patients with a good or a bad response. It was 
concluded from this study that the acute phase reactants cannot serve as a 
substitute for clinical activity indices and that they are of limited value in 
predicting the response to therapy. 
In Chapters 5, б and 7 the disposition of the 5-aminosalicylic acid delivering drugs 
sulphasalazine (SalazopyrinR), olsalazine (DipentumR) and mesalazine (PentasaR, 
AsacolR and Salofalk") is compared in healthy volunteers, in healthy volunteers 
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with induced diarrhoea, and in patients with inflammatory bowel disease with and 
without diarrhoea. In all these studies two basic assumptions were made, based 
on our former findings and on those of other investigators. First it was assumed 
that 5-aminosalicylic acid, early released in the proximal part of the intestine is 
rapidly absorbed and excreted into the urine. The second assumption was that 5-
aminosalicylic acid released in the colon is acetylated by intestinal bacteria and 
mucosa. As opposed to unacetylated 5-aminosalicylic acid, acetyl-5-aminosalicylic 
acid is poorly absorbed from the bowel lumen. Therefore, a large amount of 5-
aminosalicylic acid excreted in urine early after ingestion correlates with early 
release, and the proportion of acetylated 5-aminosalicylic acid in faeces is a 
measure of with exposure of 5-aminosalicylic acid to the colon. 
A study comparing the disposition of 5-aminosalicylic acid from a single dose of 
the S-aminosaUcylic acid delivering drugs in eight healthy volunteers is described 
in Chapter 5. In these subjects, the early urinary excretion (in the first eight hours 
after ingestion) of 5-aminosalicylic acid was significantly lower after intake of the 
azo-compounds sulphasalazine and olsalazine (mean 2.6%) than after intake of 
the slow-release compounds Pentasa", AsacolR and SalofalkR (mean 7.3%). The 
proportion of acetylated 5-aminosalicylic acid in the faeces was significantly higher 
after ingestion of the azo-compounds (42.3 ± 2.7%, mean ± SEM) as compared 
with the slow-release compounds (34.6 ± 2.1%). The proportion of unacetylated 
5-aminosalicylic acid in faeces was rather small, varying from 5.2 ± 1.3% for 
SalofalkR to 12.8 ± 2.2% for sulphasalazine. Little azo-compound was recovered 
unsplit in faeces: 6.6 ± 1.8% after ingestion of sulphasalazine and 4.1 ± 1.1% 
after ingestion of olsalazine. It was concluded that in healthy subjects the azo-
compounds have the most favourable disposition release profile for disposition in 
the colon. Individual drugs, however, have different properties and cannot be 
simply lumped together in an azo-group and a slow-release group. An additional 
analysis was performed on data obtained for each drug separately, showing that 
sulphasalazine and olsalazine are preferentially released in the colon, that 
PentasaR and SalofalkR have a considerably larger proportion released in the small 
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bowel and that AsacolR takes an intermediate position. 
The presence of diarrhoea is one of the differences between patients with active 
inflammatory bowel disease and healthy volunteers. In order to obtain a situation 
resembling that in patients with active disease, a study similar to the one 
described in Chapter 5 was performed in healthy subjects after induction of 
diarrhoea with bisacodyl, the results of which are presented in Chapter 6. In the 
eight subjects participating in this study the use of bisacodyl resulted in a two to 
threefold reduction of the intestinal transit time. Under these circumstances, the 
urinary excretion of acetyl-5-ASA was 4.5 ± 1.5% (mean ± SEM) after ingestion 
of sulphasalazine and 4.9 ± 1.5% after ingestion of olsalazine. The proportions of 
acetylated 5-aminosalicylic acid in faeces were 6.6 ± 2.1% and 8.4 ± 2.7%, 
respectively. These very low figures indicate poor disposition of 5-aminosalicylic 
acid to both small bowel and colon. This appeared to be the result of impaired 
splitting of the azo-bond in these drugs, as approximately half of the ingested 
dose was recovered unsplit in the faeces. Ingestion of PentasaR and SalofalkR was 
associated with the largest proportion of acetylated 5-aminosalicylic acid in faeces 
(21.2 ± 3.4% and 18.6 ± 6.0%, respectively) and in urine (14.5 ± 2.5% and 26.7 
± 4.9%, respectively), indicating more favourable release patterns. The figures for 
Asacol" were intermediate. When the results of this study are compared with the 
results of the study described in Chapter 5, the disposition of 5-aminosalicylic acid 
from all drugs is impaired during accelerated intestinal transit time, but most 
pronounced so in the case of sulphasalazine, olsalazine and AsacolR. 
In Chapter 7 the disposition of 5-aminosalicylic acid from the 5-aminosalicylic acid 
delivering drugs is studied during maintenance treatment in 20 patients with 
inflammatory bowel disease, 10 of whom suffered from diarrhoea. The figures 
obtained appeared very well comparable to the figures in healthy volunteers with 
and without induced diarrhoea. The presence of diarrhoea was associated with a 
less favourable release pattern of all drugs, as the proportion of acetylated 5-
aminosalicylic acid in faeces and of acetylated 5-aminosalicylic acid in urine 
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decreased substantially. The disposition from PentasaR was the less influenced. 
Similar to the findings in healthy volunteers, diarrhoea resulted in a very 
substantial decrease of the splitting of the azo-bond. In patients with diarrhoea, 
42.9 ± 12.2% of sulphasalazine and 47.2 ± 10.0% of olsalazine was recovered 
unsplit in the faeces. 
On the basis of the findings in Chapters 5, 6 and 7 it is concluded that in the 
absence of diarrhoea the differences in the disposition patterns of the drugs 
studied are slightly in favour of the azo-compounds if the colon is the intended 
site of drug delivery. PentasaR and SalofalkR are more fit for delivery of 5-
aminosalicylic acid to the small bowel. In case of diarrhoea, however, the timely 
release of 5-aminosalicylic acid from sulphasalazine, olsalazine and AsacolR is 
substantially impaired. In patients with diarrhoea PentasaR appears to be the best, 
and SalofalkR the second best choice, also for patients with only colonic involve-
ment. 
The definite proof of the validity of the conclusions drawn above can only be 
given in controlled therapeutic trials, comparing the efficacy and safety of the 
available 5-aminosalicylic acid delivering drugs in patients with quiescent and 
active inflammatory bowel disease. 
In Chapter 8 the efficacy and safety of sulphasalazine and olsalazine is compared 
in 55 patients with active ulcerative colitis who were treated in a prospective, 
double-blind, multicentre trial with 6 g sulphasalazine or 3 g olsalazine daily for 
six weeks, to be continued for another six weeks if no remission had been 
achieved. After 6 weeks 6 of 27 évaluable patients (22.2%) had achieved a 
remission on sulphasalazine, and 9 of 28 patients (32.1%) on olsalazine. The 95% 
confidence limits are -33.3 and 13.4%. After 12 weeks 11 of 27 patients (40.7%) 
on sulphasalazine and 14 of 26 still évaluable patients (53.8%) on olsalazine were 
in remission, the 95% confidence interval of the difference being -39.8 and 13.6%. 
Substantial endoscopic improvement was eventually achieved in 48.2% of patients 
on sulphasalazine and 65.4% of patients on olsalazine (95% confidence interval of 
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the difference -43.4 to 9.0%). Six patients from each group were withdrawn 
because of adverse effects or increasing severity of disease. By means of a newly 
developed numerical Ulcerative Colitis Activity Index no significant difference 
between both treatment groups could be demonstrated. Eleven patients on 
sulphasalazine (40.7%) and six on olsalazine (21.4%) experienced minor side 
effects (95%- confidence interval of the difference -5 to 43%). It is concluded 
that olsalazine is at least as effective and at least as well tolerated as sulpha-
salazine in patients with active ulcerative colitis. 
In the study described in Chapter 9, 49 patients with ulcerative colitis in remission 
entered a prospective, double-blind, multicentre trial comparing the relapse 
preventing effect and safety of 4 g sulphasalazine and 2 g olsalazine daily during 
48 weeks. Of the 46 évaluable patients 23 were assigned to sulphasalazine and 23 
to olsalazine. Seven of 23 patients (30.4%) relapsed on sulphasalazine and six of 
23 patients (26.1%) on olsalazine (95% confidence limits of the difference -22.0% 
and 30.3%). The relapse-free survival curves did not differ significantly at any 
time during the trial period. Three patients assigned to treatment with 
sulphasalazine dropped out because of adverse effects; two patients because of 
upper abdominal complaints and one patient because of a skin rash. The 
occurence of loose stools was an adverse effect leading to the drop out of three 
patients treated with olsalazine. Four patients on sulphasalazine and six patients 
on olsalazine experienced minor adverse effects. Moreover, one patient on sul-
phasalazine had mild leucopenia, and four patients on sulphasalazine and one 
patient on olsalazine had decreased levels of haptoglobin. Thus, sulphasalazine 
and olsalazine are equally effective in maintaining remission of ulcerative colitis 
and are accompanied by a similar incidence of adverse effects. 
On the basis of the results obtained in the studies described in the Chapters 8 
and 9 it is concluded that olsalazine and sulphasalazine are equally effective and 
safe, both in patients with active and with quiescent ulcerative colitis. Olsalazine is 
therefore a good alternative for patients intolerant of sulphasalazine. Starting 
from the results of the pharmacokinetic studies described in the Chapters 5, 6 
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and 7 it can be speculated that other 5-aminosalicylic acid delivering drugs, 
especially PentasaR, are preferable to olsalazine and sulphasalazine in patients 
with active disease and diarrhoea. Up to the present this remains to be proven in 
a controlled clinical trial. 
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SAMENVATTING 
Het doel van deze studie was, zoals vermeld in hoofdstuk 1, het onderzoeken 
van enkele 'Svitte vlekken" op het gebied van de behandeling van chronische 
idiopathische darmontstekingen. Met name werd onderzoek verricht naar het 
mogelijke voordeel van het toevoegen van prednison aan salazosulfapyridine bij 
patiënten met een actieve ziekte van Crohn, naar de beschikbaarheid van 5-
aminosalicylzuur (mesalazine) uit salazosulfapyridine, olsalazine en slow-release 
mesalazine preparaten, en tenslotte werden de effectiviteit en veiligheid van 
salazosulfapyridine en olsalazine vergeleken bij patiënten met een actieve colitis 
ulcerosa en bij patiënten met colitis ulcerosa in remissie. 
In hoofdstuk 2 wordt een overzicht gegeven van de huidige kennis op het gebied 
van epidemiologie, etiologie en prognose van colitis ulcerosa en de ziekte van 
Crohn en worden de methoden voor het meten van de ziekteactiviteit besproken. 
Verder wordt een overzicht gegeven van de op dit moment beschikbare gegevens 
over de farmacokinetiek en het therapeutisch effect van de geneesmiddelen, die 
gebruikt worden bij de behandeling van deze ziekten. 
In het onderzoek dat beschreven wordt in hoofdstuk 3 wordt het therapeutisch 
effect van salazosulfapyridine plus prednison vergeleken met dat van 
salazosulfapyridien plus placebo bij 60 patiënten met een actieve ziekte van 
Crohn. In de eerste 6 weken van een 16 weken durende onderzoeksperiode 
daalde de activiteitsindex volgens van Hees significant meer bij de 30 patiënten 
die behandeld werden met salazosulfapyridine plus prednison (tot een mediane 
waarde van 70% van de uitgangswaarde, met een interquartiel bereik van 57 tot 
84%) dan bij de 30 patiënten die behandeld werden met salazosulfapyridine plus 
placebo (tot een mediane waarde van 87%, interquartiel bereik 70 tot 94%; ρ = 
0,001). In de laatste 4 weken van de behandeling was het verschil tussen beide 
groepen patiënten nog steeds in het voordeel van de combinatie salazosulfapyri-
dine plus prednison, zij het niet significant. Door middel van de Crohn's Disease 
Activity Index kon geen enkel significant verschil tussen beide behandelings-
groepen worden aangetoond, al tendeerden de verschillen in dezelfde richting als 
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gemeten met de activiteitsindex volgens van Hees. De combinatie van salazo-
sulfapyridine met prednison bleek met name van voordeel in de beginfase van de 
behandeling bij patiënten met de ziekte van Crohn in het colon, al dan niet met 
gelijktijdige localisaties in de dunne darm. In de eindfase van de behandeling 
werd het enige significante verschil tussen beide behandelingen gevonden bij die 
patiënten, die een hoge uitgangswaarde hadden van de activiteitsindex volgens van 
Hees. Bij patiënten die aan behandeling met salazosulfapyridine en placebo waren 
toegewezen was het therapeutisch effect negatief gecorreleeerd met de ernst van 
de diarree. De reactie op de behandeling hing niet samen met de ernst van de 
diarree bij patiënten die behandeld werden met salazosulfapyridine en prednison. 
De belangrijkste conclusie van dit onderzoek is dat het toevoegen van prednison 
aan salazosulfapyridine, althans in de doseringen zoals in deze studie gebruikt, 
leidt tot een snellere verbetering in het begin van de behandeling, maar niet tot 
een significant beter uiteindelijk resultaat. Bij patiënten met een hoge uitgangs-
waarde van de activiteitsindex volgens van Hees of met ernstige diarree, of met 
beide, moet zeker de voorkeur gegeven worden aan behandeling met salazosulfa-
pyridine plus prednison. 
In hoofdstuk 4 wordt de mogelijke waarde van het meten van de serum spiegels 
van de acute fase eiwitten orosomucoid en C-reactive protein, als aanvulling op of 
vervanging van de activiteitsindices beschreven. Hiertoe werden gegevens 
geanalyseerd die verkregen werden bij de patiënten die beschreven zijn in 
hoofdstuk 3, en bovendien bij patiënten met de ziekte van Crohn die van dat 
onderzoek waren uitgesloten, meestal vanwege een te lage activiteitsindex volgens 
van Hees. De correlaties tussen de serum spiegels van de acute fase eiwitten 
enerzijds en de hoogte van de activiteitsindices anderzijds bleken nogal mager te 
zijn, waarbij geen van de correlatie coëfficiënten hoger was dan 0,57. Patienten 
met een hoge uitgangswaarde van het serum orosomucoid gehalte (>175 mg/100 
ml) reageerden beter op behandeling met salazosulfapyridine plus prednison, 
althans gemeten met de activiteitsindex volgens van Hees (die bij hen daalde tot 
mediaan 40,8% van de uitgangswaarde in de laatste 4 weken van de 
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behandelingsperiode, interquartiel bereik 34,9 tot 66,2%) dan patiënten die met 
alleen salazosulfapyridine behandeld werden (daling tot mediaan 62,6%, 
interquartiel bereik 47,1 tot 85,7%; ρ = 0,07). Op grond van de veranderingen 
van de acute fase eiwitten na 2 en 4 weken behandeling was het niet mogelijk 
een onderscheid te maken tussen patiënten met een goede of minder goede 
reactie op de therapie op het einde van de behandelingsperiode. Op grond van 
deze resultaten wordt geconcludeerd dat acute fase eiwitten de activiteitsindices 
niet kunnen vervangen en dat hun voorspellende waarde wat betreft de reactie op 
de behandeling beperkt is. 
In de hoofdstukken 5, б en 7 worden vergelijkende onderzoeken beschreven naar 
de beschikbaarheid van de S-aminosalicylzuur bevattende geneesmiddelen 
salazosulfapyridine (SalazopyrineR), olsalazine (Dipentum") en slow-release 
mesalazdne (PentasaR, AsacolR en Salofalk") bij gezonde vrijwilligers, bij gezonde 
vrijwilligers bij wie diarree is opgewekt en bij patiënten met chronische 
darmontstekingen, met en zonder diarree. Bij al deze onderzoeken werd 
uitgegaan van twee vooronderstellingen, gebaseerd op eerder onderzoek van 
onszelf en van andere onderzoekers. Op de eerste plaats werd aangenomen dat 5-
aminosalicylzuur dat proximaal in de dunne darm vrijkomt snel wordt opgenomen 
en in de urine wordt uitgescheiden. Een grote hoeveelheid in de urine 
uitgescheiden 5-aminosalicylzuur betekent dan een vroege afgifte van 5-
aminosalicylzuur uit het betreffende geneesmiddel en een geringere 
beschikbaarheid voor het distale deel van de darm. De tweede aanname was dat 
5-aminosalicylzuur, dat vrijkomt in het colon, geacetyleerd wordt door 
darmbacteriën en darmslijmvlies. In tegenstelling tot ongeacetyleerd 5-
aminosalicylzuur wordt geacetyleerd 5-aminosalicylzuur slecht uit het darmlumen 
opgenomen. De hoeveelheid geacetyleerd 5-aminosalicylzuur in de feces is dus 
een maat voor de beschikbaarheid in het colon. 
Een vergelijkend onderzoek naar de beschikbaarheid van 5-aminosalicylzuur na 
een éénmalige toediening van de S-aminosalicylzuur bevattende geneesmiddelen 
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bij gezonde vrijwilligers wordt beschreven in hoofdstuk 5. Bij deze personen was 
de vroege uitscheiding (in de eerste 8 uur na inname) van 5-aminosalicylzuur in 
urine significant minder na inname van de azo-verbindingen salazosulfapyridine en 
olsalazine (gemiddeld 2,6% van de ingenomen dosis) dan na inname van de slow-
release preparaten PentasaR, AsacolR en SalofalkR (gemiddeld 7,3%). Het 
percentage geacetyleerd 5-aminosalicylzuur in de feces was significant hoger na 
inname van de azo-verbindingen (42,4% ± 2,7%, gemiddelde ± S.E.M.) dan na 
inname van de slow-release preparaten (34,6 ± 2,1%). Het percentage 
ongeacetetyleerd 5-aminosalicylzuur in de feces was vrij gering, variërend van 5,2 
± 1,3% voor SalofalkR tot 12,8 ± 2,2% voor salicylazosulfapyridine. Slechts een 
klein gedeelte van de azo-verbindingen werd ongesplitst in de feces 
teruggevonden: 6,6 ± 1,8% na inname van salicylazosulfapyridine en 4,1 ± 1,1 % 
na inname van olsalazine. De conclusie luidde dat bij gezonde proefpersonen de 
azo-verbindingen het meest gunstige afgifte profiel hebben met betrekking tot 
beschikbaarheid in het colon. Ieder geneesmiddel op zich heeft echter eigen 
kenmerken, en een indeling in azo-verbindingen en slow-release preparaten is 
daarom niet zonder meer gerechtvaardigd. Daarom werden nog aanvullende 
analyses verricht met de gegevens die voor elk geneesmiddel apart waren 
verkregen. Hieruit bleek dat de afgifte van 5-aminosalicylzuur uit salicylazosulfa-
pyridine en olsalazine met name in het colon plaatsvond, uit PentasaR en 
Salofa]kR in aanzienlijke mate in de dunne darm, en dat AsacolR een tussenpositie 
innam. 
Eén van de aspecten waarin patiënten met een actieve darmontsteking vaak van 
gezonde vrijwilligers verschillen is de aanwezigheid van diarree. Teneinde de 
situatie bij patiënten met een actieve ziekte na te bootsen werd een onderzoek 
als beschreven in hoofdstuk 4 uitgevoerd bij vrijwilligers, bij wie diarree was 
opgewekt door middel van bisacodyl. De resultaten hiervan zijn beschreven in 
hoofdstuk 6. Bij de acht deelnemers aan deze studie resulteerde de toediening 
van bisacodyl in een twee- tot drievoudige afname van de darmpassagetijd. Onder 
deze omstandigheden bedroeg de uitscheiding van acetyl-5-aminosalicylzuur in de 
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urine 4,5 ± 1,5% (gemiddelde ± S.E.M.) van de ingenomen dosis na inname van 
salicylazosulfapyridine en 4,9 ± 1,5% na inname van olsalazine. De percentages in 
de feces uitgescheiden acetyl-5-aminosalicylzuur na inname van deze 
geneesmiddelen waren respecievelijk 6,6 ±2,1 % en 8,4 ± 2,7%. Deze zeer lage 
percentages zijn een aanwijzing voor geringe beschikbaarheid van 5-
aminosalicylzuur uit deze twee geneesmiddelen voor dunne en dikke darm onder 
deze omstandigheden. Dit bleek veroorzaakt te worden door een verminderde 
splitsing van de azo-binding in beide stoffen, aangezien ongeveer de helft van de 
ingenomen hoeveelheid ongesplitst werd teruggevonden in de feces. Gebruik van 
PentasaR en SalofalkR gaf het grootste percentage geacetyleerd 5-aminosalicylzuur 
in de feces (respectievelijk 21.2 ± 3,4 en 18,6 ± 6,0%) en in urine 
(respectievelijk 14,5 ± 2,5% en 26,7 ± 4,9%), hetgeen wijst op een gunstiger 
afgifte profiel. AsacolR nam wederom een tussenpositie in. Bij vergelijking van de 
resultaten van deze studie met de resultaten van de studie die beschreven is in 
hoofdstuk 5 blijkt de beschikbaarheid van 5-aminosalicylzuur uit alle 
geneesmiddelen te zijn afgenomen tijdens versnelde darmpassage, maar het meest 
uitgesproken in het geval van salicylazosulfapyridine, olsalazine en AsacolR. 
In hoofdstuk 7 wordt de beschikbaarheid van 5-aminosalicylzuur uit de 5-
aminosalicylzuur bevattende geneesmiddelen beschreven tijdens een 
onderhoudsbehandeling bij 20 patiënten met chronische darmontstekingen, van 
wie er 10 diarree hadden. De uitkomsten die hierbij werden verkregen bleken 
zeer goed vergelijkbaar met de gegevens afkomstig van gezonde vrijwilligers, met 
of zonder geïnduceerde diarree. De aanwezigheid van diarree ging gepaard met 
een minder gunstig afgifte patroon van alle geneesmiddelen, blijkens een 
aanzienlijke afname van de hoeveelheid geacetyleerd 5-aminosalicylzuur in feces 
en in urine. De beschikbaarheid van 5-aminosalicylzuur uit PentasaR werd het 
minst beïnvloed. Zoals het geval was bij gezonde proefpersonen had diarree tot 
gevolg dat de splitsing van de azo-binding in salicylazosulfapyridine en olsalazine 
aanzienlijk verminderde. Bij patiënten met diarree werd 42,9 ± 12,2% van 
salicylazosulfapyridine en 47,2 ± 10,0% van olsalazine ongesplitst in de feces 
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teruggevonden. 
Op grond van de gegevens uit de hoofdstukken 5, 6 en 7 wordt geconcludeerd 
dat bij afwezigheid van diarree de verschillen in het afgifte patroon van 5-
aminosalicylzuur uit de verschillende geneesmiddelen enigszins in het voordeel van 
de azo-verbindingen zijn, wanneer het gaat om de afgifte van 5-aminosalicylzuur 
in het colon. PentasaR en Salofalk* hebben meer afgifte in de dunne darm. 
Echter, een tijdige afgifte van 5-aminosalicylzuur uit salicylazosulfapyridine, 
olsalazine, en AsacolR neemt duidelijk af wanneer er sprake is van diarree. Voor 
patiënten met diarree lijken PentasaR en Salofalk" de beste keus, ook wanneer 
alleen het colon is aangedaan. Het definitieve bewijs van de geldigheid van de 
hierboven getrokken conclusies kan alleen geleverd worden in gecontroleerde 
onderzoeken, waarbij de werkzaamheid en veiligheid van de beschikbare 5-amino-
salicylzuur bevattende geneesmiddelen worden vergeleken bij patiënten met 
chronische darmontstekingen, zowel in de actieve als in de rustige fase. 
In hoofdstuk 8 worden de werkzaamheid en veiligheid van salicylazosulfapyridine 
en olsalazine vergeleken bij 55 patiënten met een actieve colitis ulcerosa, die in 
een prospectief, dubbelblind multicenter onderzoek werden behandeld met 6 gram 
salicylazosulfapyridine of 3 gram olsalazine per dag gedurende 6 weken. Dit werd 
nog eens 6 weken voortgezet indien na de eerste 6 weken de ziekte nog niet in 
remissie was gekomen. Na 6 weken hadden 6 van de 27 met salicylazosulfapyri-
dine behandelde patiënten (22,2%) een remissie bereikt, en 9 van de 28 met 
olsalazine behandelde patiënten (32,1%). De 95% betrouwbaarheidsgrenzen van 
het verschil waren -33,3 en 13,4%. Na 12 weken waren 11 van de 27 met 
salicylazosulfapyridine behandelde patiënten (40,7%) in remissie en 14 van de 26 
op dat moment nog evalueerbare patiënten (53,8%) die met olsalazine waren 
behandeld. Het 95% betrouwbaarheidsinterval van het verschil was -39,8 tot 
13,6%. Een aanzienlijke endoscopische verbetering op het einde van de 
behandelingsperiode werd gezien bij 48,2% van de met salicylazosulfapyridine 
behandelde patiënten en bij 65,4% van de met olsalazine behandelde patiënten 
169 
(95% betrouwbaarheidsinterval van het verschil -43,4 tot 9,0%). Bij zes patiënten 
uit beide groepen werd de behandeling gestaakt wegens bijwerkingen of toename 
van de ernst van de ontsteking. Door middel van een nieuw ontwikkelde 
numerieke activiteitsindex voor colitis ulcerosa kon geen significant verschil tussen 
beide behandelingen worden aangetoond. Bij elf patiënten die met 
salicylazosulfapyridine behandeld werden (40,7%) en zes patiënten die met 
olsalazine behandeld werden (21,4%) traden minder ernstige bijwerkingen op 
(95% betrouwbaarheidsinteval van het verschil -5 tot 43%). De conclusie van dit 
onderzoek is dat olsalzine minstens even effectief is en minstens even goed 
verdragen wordt als salicylazosulfapyridine bij patiënten met een actieve colitis 
ulcerosa. 
In de studie die in hoofdstuk 9 wordt beschreven namen 49 patiënten met colitis 
ulcerosa in remissie deel aan een prospectief, dubbelblind multicenter onderzoek, 
waarin het effect op het voorkómen van recidieven en de veiligheid van een 
dagelijkse dosis van 4 gram salicylazosulfapyridine of 2 gram olsalazine gedurende 
48 weken worden vergeleken. Van de 46 evalueerbare patiënten werden er 23 
behandeld met salicylazosulfapyridine en 23 met olsalazine. Zeven van de 23 met 
salicylazosulfapyridine behandelde patiënten (30,4%) kregen een recidief 
tegenover 6 van de 23 met olsalazine behandelde patiënten (26,1%). De 95% 
betrouwbaarheidsgrenzen van het verschil waren -22,0 en 30,3%. De recidiefvrije 
overlevingscurven verschilden op geen enkel moment tijdens de behandeling 
significant van elkaar. Drie patiënten, die behandeld werden met 
salicylazosulfapyridine, vielen uit vanwege bijwerkingen: twee wegens 
bovenbuiksklachten en één wegens huiduitslag. Het ontstaan van dunne ontlasting 
was een bijwerking die het uitvallen van drie met olsalazine behandelde patiënten 
tot gevolg had. Vier patiënten hadden geringe bijwerkingen van salicylazosulfapyri-
dine, en zes van olsalazine. Bovendien trad bij één patient op salicylazosulfapyri-
dine een geringe leucopenie op, en zes met salicylazosulfapyridine behandelde 
patiënten en één met olsalazine behandelde patient hadden verlaagde 
serumspiegels van haptoglobine, hetgeen wijst op enige hémolyse. 
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Salicylazosulfapyridine en olsalazine zijn dus even effectief voor het handhaven 
van een remissie en gaan in vergelijkbare mate gepaard met het optreden van 
bijwerkingen. 
Op grond van de in de hoofdstukken 8 en 9 verkregen uitkomsten wordt 
geconcludeerd dat olsalazine en salicylazosulfapyridine gelijkwaardig aan elkaar 
zijn wat betreft werkzaamheid en veiligheid, zowel bij patiënten met een actieve 
als met een inactieve colitis ulcerosa. Olsalazine is daarom een goed alternatief 
voor patiënten die salicylazosulfapyridine niet goed kunnen verdragen. Uitgaande 
van de pharmacokinetische studies die beschreven zijn in de hoofdstukken 5, 6 en 
7 zou men kunnen stellen dat andere 5-aminosalicylzuur bevattende preparaten, 
met name PentasaR, en in wat mindere mate Salofa]kR, de voorkeur verdienen 
boven olsalazine bij patiënten met een actieve ontsteking en diarree. Dit dient 
echter in een gecontroleerd klinisch onderzoek nog bewezen te worden. 
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WOORDEN VAN DANK 
Het schrijven van dit proefschrift is, zoals meestal, slechts mogelijk geweest 
dankzij de hulp en steun van velen. 
Mijn dank gaat in de eerste plaats uit naar alle patiënten die enthousiast en 
nauwgezet aan de verschillende onderzoeken hebben meegewerkt. 
De vele collega's in het Sint Radboudziekenhuis en elders in den lande die 
patiënten hebben aangemeld en behandeld in het kader van de "multi centre 
studies" ben ik zeer erkentelijk. Met name dr. W.M.M. Driessen uit het Sint 
Josephziekenhuis te Eindhoven (inmiddels Veldhoven) heeft hiervoor zich steeds 
bijzonder ingespannen. 
Dr. R.A. van Hogezand, nu gastroenteroloog in het Medisch Spectrum Twente te 
Enschede, heeft aan de basis gestaan van de onderzoeken beschreven in de 
hoofdstukken 3 en 4 en ook een aanzienlijk deel van de praktische uitvoering 
ervan voor zijn rekening genomen. 
Zonder de hulp van de Medisch Statistische Adviesafdeling was dit werk zeker 
niet tot stand gekomen. Drs. Ph. van Eiteren en Ir. H.J.J. van Lier hebben veel 
energie gestoken in het ontwerpen en uitvoeren van de meeste studies en nog 
meer energie in het analyseren en publicatie-rijp maken van de resultaten. 
Dr. P.A.M. van Hees, gastroenteroloog in het Sint Antoniusziekenhuis te 
Nieuwegein heeft meegedacht bij de opzet en uitvoering van enkele in dit 
proefschrift beschreven onderzoeken. 
Annie van Schaik, laborante op het laboratorium voor maag-, darm- en 
leverziekten was een immer vriendelijke en enthousiaste steunpilaar die zeer 
accuraat de vele bepalingen van 5-aminosalicylzuur en zijn derivaten uitvoerde en 
ook behulpzaam was bij de nodige distributie- en inzamelingswerkzaamheden. 
De firma Kabi Pharmacia stelde gedurende drie jaar een volledige beurs ter 
beschikking en leverde ook uitgebreide logistieke steun voor de onderzoeken, 
beschreven in de hoofdstukken 8 en 9. Met name de heer S. Ljungberg van Kabi 
Pharmacia Sweden en de heren H. Krommendam, drs. H. Looman en P. 
Ooijevaar van Kabi Pharmacia Nederland ben ik veel dank verschuldigd. 
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Mijn collega's op de afdeling maag-, darm- en leverziekten ben ik dankbaar voor 
al het meedenken, de morele steun en de zeer prettige en collegiale sfeer waarin 
het werk verricht kon worden dat tot dit proefschrift heeft geleid. 
Ik ben mijn voorganger in Breda, T.M.J. Ottenhoff, internist, zeer erkentelijk voor 
het feit dat hij zijn praktijk nog drie maanden langer dan gepland heeft 
voortgezet waardoor ik in staat was het proefschrift vóór mijn komst naar Breda 
vrijwel af te ronden. 
Herlin, je voelde je vaak als de atleet die steeds vlak voor de finish opnieuw de 
bel voor de laatste ronde hoorde. Ik dank je voor je uithoudingsvermogen. Bij 
alle transpiratie waren jij en Martijn mijn inspiratie. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd op 26 januari 1953 geboren te Eindhoven. 
Na het behalen van het diploma gymnasium ß aan het Lyceum Augustinianum in 
Eindhoven in 1971 werd begonnen met de studie geneeskunde aan de Katholieke 
Universiteit te Nijmegen. Het doctoraalexamen werd in 1976 en het artsexamen in 
1979 afgelegd. 
Na vervulling van de militaire dienstplicht werd in september 1980 begonnen met 
de opleiding tot internist in het ziekenhuis De Stadsmaten te Enschede (opleiders: 
dr. S.G. Hulst en R.J.Th.M. Ypma), hetgeen vanaf maart 1982 werd voortgezet 
aan de Universiteitskliniek voor Inwendige Ziekten van het Sint 
Radboudziekenhuis te Nijmegen (opleider: Prof. dr. A. van 't Laar). Op 1 
september 1985 werd hij ingeschreven als internist in het register van erkende 
medische specialisten. 
Aansluitend was hij werkzaam op de afdeling maag-, darm- en leverziekten van 
bovengenoemd ziekenhuis (hoofd: dr. J.H.M, van Tongeren) waar hij werd 
opgeleid tot gastroenteroloog en de onderzoeken verrichtte die tot dit proefschrift 
hebben geleid. 
Vanaf 1 juli 1990 is hij gevestigd als internist met als speciaal aandachtsgebied de 
maag-, darm- en leverziekten in het Interconfessioneel Ziekenhuis de Baronie te 
Breda, in associatie met de internisten mevrouw A.M. van Gent, B.J.V Horák, 
J.A.M. Hoskam, dr. P.J. Stijnen en G.P. Verburg. 
Hij is getrouwd met Herlin Woldberg. Zij hebben een zoon: Martijn. 
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STELLINGEN 
I 
Bij patiënten met een actieve ziekte van Crohn leidt het toevoegen van prednison 
aan salazosulfapyridine tot een snellere verbetering in het begin van de behandeling, 
maar niet tot een duidelijk beter uiteindelijk resultaat, behalve bij patiënten met een 
ernstige activiteit van de ziekte en/of ernstige diarree. 
- dit proefschrift -
II 
Een versnelde darmpassage heeft een aanzienlijke invloed op de beschikbaarheid 
van 5-aminosalicylzuur uit zowel azo-verbindigen als preparaten met vertraagde of 
uitgestelde afgifte, het minst echter op PentasaR. 
- dit proefschrift -
III 
Olsalazine is even effectief als salazosulfapyridine bij de behandeling van patiënten 
met een actieve colitis ulcerosa en bij het voorkomen van recidieven bij patiënten 
met colitis ulcerosa in remissie. 
- dit proefschrift -
IV 
Bijwerkingen treden niet significant minder op tijdens behandeling met olsalazine 
dan tijdens behandeling met salazosulfapyridine maar zijn anders van karakter, zodat 
olsalazine toch een goed alternatief kan zijn bij voor salazosulfapyridine 
overgevoelige patiënten. 
- dit proefschrift -
V 
Bij oudere patiënten met een nog aanwezige galblaas, bij wie langs endoscopische 
weg een Papillotomie van de papil van Vater en extractie van choledochusstenen 
heeft plaatsgevonden, dient niet routinematig later alsnog een cholecystectomie 
uitgevoerd te worden. 
Rijk MCM en Yap SH. Ned Tijdschr Geneeskd 1989; 133: 1919-1922. 
VI 
Bij de behandeling van patiënten met de ziekte van Wegener is intermitterend 
intraveneuze toediening van cyclofosfamide minder effectief dan dagelijkse orale 
toediening. 
Hoffmann et al. Am J Med 1990; 89: 403-411. 
VII 
Bij patiënten met ernstige, door kanker veroorzaakte pijn heeft continue subcutane 
toediening van morfine de voorkeur boven continue intraveneuze toediening, omdat 
het technisch eenvoudiger is en even effectief. 
Moulin DE et al. Lancet 1991; 337: 465-468. 
Vili 
Bij een gram-negatieve sepsis kan toediening van HA-IA humane monoclonale 
antistoffen tegen endotoxine een effectieve aanvullende behandeling zijn. 
Ziegler JE et al. New Engl J Med 1991; 324: 429-436. 
IX 
Zoals blijkt uit de levenskansen van de deelnemers aan de Elfstedentourtocht van 
1956 hebben mannen met een goede lichamelijke conditie een grotere kans op het 
bereiken van een hoge leeftijd. 
JLCM van Saase et al. Br Med J 1990; 301: 1409-1411. 
X 
Het enthousiasme waarmee trialformulieren worden ontworpen wordt zelden gedeeld 
door degenen die ze moeten invullen. 
- eigen waarneming -
XI 
Bij de jacht op statistische significantie wordt te vaak vergeten dat het verschil tussen 
net wel en net niet statistisch significant niet gelijk staat aan het verschil tussen waar 
en onwaar, of tussen wel en niet relevant. 
XII 
Het in het buitenland lezen van nederlandse weerberichten kan ook wel eens tot 
zware depressies leiden. 
Breda, 17 maart 1991 Mamo Rijk 
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